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PDK	  REGULATED	  WARBURG	  EFFECT	  PROTECTS	  DIFFERENTIATED	  ADIPOCYTES	  AGAINST	  
ROS	  
	  
Literature	  has	  demonstrated	  the	  ability	  of	  human	  adipose	  tissue	  to	  generate	  large	  
amounts	  of	  lactate.	  	  However,	  it	  is	  not	  understood	  why	  adipose	  tissue	  produces	  lactate,	  
how	  the	  production	  of	  lactate	  is	  regulated,	  and	  what	  potential	  benefit	  this	  has	  to	  the	  
adipocyte	  or	  the	  organism.	  	  We	  first	  characterized	  a	  human	  model	  of	  adipogenic	  
differentiation	  with	  minimal	  donor	  to	  donor	  variability	  to	  assess	  metabolic	  changes	  
associated	  with	  mature	  adipocytes	  compared	  to	  their	  precursors.	  	  Indeed,	  similar	  to	  
what	  was	  observed	  in	  human	  clinical	  studies,	  the	  differentiated	  adipocytes	  
demonstrated	  increased	  lactate	  production.	  	  However,	  the	  differentiated	  adipocytes	  
compared	  to	  their	  precursors	  (preadipocytes	  or	  ASCs)	  demonstrate	  an	  aerobic	  
glycolysis-­‐like	  (also	  called	  Warburg	  effect-­‐like)	  increase	  in	  glycolysis	  characterized	  by	  a	  
5.2	  fold	  increase	  in	  lactate	  production	  in	  normoxic	  conditions	  (atmospheric	  oxygen	  
tension).	  	  Remarkably,	  this	  increase	  in	  lactate	  occurred	  even	  though	  the	  differentiated	  
adipocytes	  simultaneously	  demonstrate	  an	  increase	  in	  oxidative	  capacity.	  	  This	  low	  
fraction	  of	  oxidative	  capacity	  coupled	  with	  increased	  lactate	  production	  indicated	  
regulation	  of	  oxidative	  rates	  most	  likely	  at	  the	  point	  of	  pyruvate	  conversion	  to	  either	  
acetyl-­‐CoA	  (oxidative	  metabolism)	  or	  lactate	  (glycolytic	  metabolism).	  	  To	  investigate	  the	  
potential	  regulation	  of	  this	  metabolic	  phenotype,	  PDK	  isoform	  expression	  was	  assessed	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and	  we	  found	  PDK	  1	  and	  4	  transcript	  and	  protein	  elevated	  in	  the	  differentiated	  cells.	  	  
Non-­‐selective	  pharmacologic	  inhibition	  of	  the	  PDKs	  resulted	  in	  decreased	  lactate	  
production,	  supporting	  a	  regulatory	  role	  for	  PDK	  in	  modulation	  of	  the	  observed	  Warburg	  
effect.	  	  PDK	  inhibition	  also	  resulted	  in	  increased	  ROS	  production	  in	  the	  adipocytes	  after	  
several	  hours	  of	  treatment	  and	  a	  decrease	  in	  cell	  viability	  when	  PDK	  inhibition	  was	  
carried	  out	  over	  36	  hours.	  	  The	  resulting	  loss	  in	  viability	  could	  be	  rescued	  by	  antioxidant	  
(Tempol)	  treatment,	  indicating	  the	  decrease	  in	  viability	  was	  ROS	  mediated.	  	  Similar	  to	  
what	  is	  seen	  in	  cancer	  cells,	  our	  data	  demonstrate	  that	  differentiation	  of	  human	  
adipocytes	  is	  accompanied	  by	  a	  PDK-­‐dependent	  increase	  in	  glycolytic	  metabolism	  
(Warburg	  effect)	  that	  not	  only	  leads	  to	  lactate	  production,	  but	  also	  seems	  to	  protect	  the	  
cells	  from	  increased	  and	  detrimental	  generation	  of	  ROS.	  
	  
Keith	  L	  March,	  MD,	  Ph.D.,	  Chair	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A.	  	  	  Obesity	  
A.1	  Introduction	  
Obesity,	  defined	  generally	  as	  an	  excess	  in	  adipose	  tissue,	  has	  rapidly	  become	  one	  
of	  the	  most	  prevalent	  healthcare	  issues	  facing	  the	  world.	  	  There	  are	  a	  number	  of	  
comorbidities	  affecting	  quality	  and	  duration	  of	  life	  associated	  with	  obesity.	  	  Its	  
prevalence	  has	  expanded	  to	  the	  point	  where	  it	  has	  achieved	  epidemic	  levels	  and	  has	  
become	  one	  of	  the	  leading	  causes	  of	  healthcare	  expense	  in	  the	  United	  States.	  	  	  
A.2	  Pathophysiologies	  associated	  with	  obesity	  
There	  is	  much	  literature	  demonstrating	  the	  association	  of	  cardiovascular	  disease	  
and	  type	  2	  diabetes	  with	  obesity.	  	  These	  are	  summed	  up	  very	  well	  in	  several	  
comprehensive	  reviews	  that	  demonstrate	  obesity	  (and	  pathogenic	  fat	  or	  adiposopathy	  
often	  associated	  with	  hypertrophied	  adipocytes)	  is	  a	  significant	  comorbidity	  with	  CVD,	  
type	  2	  diabetes,	  hypertension,	  and	  kidney	  disease	  [1-­‐11].	  	  Further	  demonstrating	  the	  
association	  of	  excess	  adiposity	  with	  these	  comorbidities,	  weight	  loss	  demonstrates	  a	  	  
positive	  effect	  in	  prevention	  of	  certain	  aspects	  of	  metabolic	  syndrome	  and	  obesity	  
related	  comorbidities	  and	  can	  even	  reverse	  some	  of	  the	  effects	  [12,	  13].	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In	  addition	  to	  the	  comorbidities	  often	  associated	  with	  obesity	  and	  the	  metabolic	  
syndrome	  listed	  above,	  a	  number	  of	  other	  pathophysiologies	  are	  associated	  with	  
obesity	  such	  as	  sleep	  apnea	  [14-­‐19]	  and	  gastroesophageal	  reflux	  disease	  (GERD)	  [20,	  
21].	  	  Non-­‐alcoholic	  steatohepatitis	  (NASH)	  and	  non-­‐alcoholic	  fatty	  liver	  disease	  (NAFLD)	  
are	  more	  prevalent	  in	  obese	  populations	  and	  directly	  correlate	  with	  increased	  adiposity	  
in	  individuals	  [22-­‐26].	  	  A	  number	  of	  cancers	  demonstrate	  high	  degrees	  of	  correlation	  
with	  obesity	  including	  breast	  cancer	  [27-­‐29],	  endometrial	  cancer	  [30-­‐32],	  colorectal	  
cancer	  [33-­‐37],	  renal	  cell	  carcinoma	  [38-­‐40],	  ovarian	  cancer	  [41-­‐43],	  and	  prostate	  cancer	  
[44-­‐49].	  	  Adiposity	  also	  contributes	  to	  musculoskeletal	  pathologies	  including	  joint	  pain	  
[50-­‐52]	  and	  osteoarthritis	  (OA)	  [51,	  53-­‐58].	  	  	  
A.3	  Costs	  associated	  with	  obesity	  
Obesity	  correlates	  with	  a	  reduction	  in	  life	  expectancy	  largely	  due	  to	  the	  
comorbidities	  previously	  mentioned.	  	  	  A	  body	  mass	  index	  (BMI)	  greater	  than	  or	  equal	  to	  
30	  is	  considered	  obese.	  	  BMIs	  of	  30-­‐35	  and	  40-­‐50	  reduce	  life	  span	  by	  3	  years	  and	  10	  
years	  respectively	  [59].	  	  Such	  effects	  on	  lifespan	  are	  similar	  to	  the	  effects	  of	  smoking.	  	  
Often	  not	  explored	  however	  are	  the	  costs	  associated	  with	  obesity	  though	  the	  total	  cost	  
for	  obesity	  related	  medical	  expenditures	  is	  high	  [60].	  	  	  A	  near	  linear	  correlation	  exists	  
between	  increase	  in	  healthcare	  costs	  and	  BMI	  that	  increases	  from	  20-­‐40	  [61].	  	  Medical	  
resources	  allocated	  per	  obese	  individual	  is	  estimated	  to	  be	  one	  third	  higher	  than	  




A.4	  Measuring	  adipose	  tissue	  mass	  and	  obesity	  
Considering	  the	  important	  physiologic	  role	  of	  adipose	  tissue	  and	  
pathophysiologic	  impact	  of	  excess	  adiposity	  in	  humans,	  many	  methods	  have	  been	  
developed	  for	  assessing	  adipose	  tissue	  mass	  and	  classify	  obesity.	  	  Obesity	  is	  most	  often	  
clinically	  defined	  by	  BMI.	  	  BMI	  is	  an	  attempt	  to	  estimate	  (more	  accurately	  qualify)	  
adipose	  tissue	  mass	  in	  humans	  using	  indirect	  measures.	  	  It	  is	  calculated	  as	  weight	  
(pounds)	  multiplied	  by	  703	  divided	  by	  height	  (inches)	  squared,	  or	  as	  weight	  (kilograms)	  
divided	  by	  height	  (meters)	  squared.	  	  Severe	  thinness	  is	  considered	  a	  BMI	  of	  less	  than	  16,	  
moderate	  thinness	  is	  16-­‐16.9,	  mild	  thinness	  is	  17-­‐18.49,	  normal	  is	  18.5-­‐24.9,	  overweight	  
is	  25-­‐29.9	  and	  obese	  is	  greater	  than	  or	  equal	  to	  30.	  	  There	  are	  three	  to	  four	  (depending	  
on	  reference)	  subcategories	  of	  obesity:	  	  class	  I	  is	  BMI	  30-­‐34.9,	  class	  II	  is	  35-­‐39.9,	  and	  
class	  III	  is	  greater	  than	  or	  equal	  to	  40	  [63]	  
While	  BMI	  is	  widely	  used,	  alternative	  measurements	  for	  classification	  of	  obesity	  
and	  their	  	  	  	  ability	  to	  correlate	  with	  obesities	  comorbidities	  can	  be	  used.	  	  These	  are	  
valuable	  since	  BMI	  can	  be	  misleading	  as	  an	  indirect	  measure	  of	  obesity	  that	  does	  not	  
take	  into	  account	  fat	  vs	  lean	  mass.	  	  For	  example,	  BMI	  does	  not	  reflect	  the	  increase	  in	  fat	  
mass	  and	  decrease	  in	  muscle	  mass	  that	  occurs	  in	  the	  elderly.	  	  As	  a	  result,	  portly	  elderly	  
persons	  with	  low	  muscle	  mass	  often	  have	  underestimated	  body	  fat	  with	  low	  reported	  
BMIs	  [64].	  	  Conversely,	  individuals	  with	  high	  muscle	  mass	  such	  as	  professional	  athletes	  
tend	  to	  have	  overestimation	  of	  obesity.	  	  For	  example,	  in	  the	  National	  Football	  League,	  
one	  in	  four	  athletes	  are	  considered	  extremely	  obese	  (BMI	  ≥	  35)	  [65],	  however,	  their	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mean	  body	  fat	  percentage	  when	  directly	  measured	  is	  14%,	  well	  within	  very	  healthy	  
ranges	  [66].	  	  The	  relationship	  between	  actual	  body	  fat	  percentage	  and	  BMI	  is	  non-­‐linear	  
[67]	  and	  the	  fact	  that	  much	  of	  the	  data	  has	  been	  accrued	  using	  BMI	  as	  an	  index	  for	  
obesity	  has	  caused	  improper	  classifications	  [68].	  
Other	  measurements	  exist	  as	  alternatives	  to	  BMI	  that	  often	  demonstrate	  
increased	  correlation	  with	  the	  incidence	  of	  obesity	  comorbidities.	  	  Abdominal	  indicators	  
have	  been	  identified	  as	  potentially	  more	  accurate	  discriminators	  of	  cardiovascular	  risk	  
[69].	  	  Waist	  circumference	  demonstrates	  positive	  correlation	  for	  predicting	  Type	  II	  
Diabetes	  in	  obese	  populations	  [70];	  waist	  to	  height	  ratio	  has	  a	  better	  correlation	  than	  
BMI	  for	  the	  obesity	  related	  comorbidities	  hypertension,	  lipidemia,	  and	  Type	  II	  Diabetes	  
[71];	  waist	  to	  hip	  ratio	  has	  demonstrated	  better	  correlation	  than	  BMI	  for	  cardiovascular	  
risk	  factors	  associated	  with	  obesity	  in	  some	  studies	  [72].	  	  Beyond	  abdominal	  and	  other	  
anthropomorphic	  	  indices,	  other	  measurements	  such	  as	  impedance	  has	  been	  suggested	  
as	  a	  more	  accurate	  classification	  tool	  for	  adipocity	  [73].	  	  Nevertheless,	  BMI	  is	  still	  most	  
commonly	  used	  since	  it	  is	  easily	  obtained	  and	  large	  amounts	  of	  data	  have	  already	  been	  
accrued	  using	  this	  method.	  	  	  
A.5	  Obesity	  prevalence	  
Regardless	  of	  method	  for	  assessing	  obesity,	  it	  affects	  an	  alarming	  number	  of	  
individuals	  Using	  the	  NHANES	  data,	  trends	  in	  the	  frequency	  of	  obesity	  have	  been	  
tracked	  by	  collecting	  height	  and	  weight	  data	  for	  which	  BMI	  is	  calculated.	  	  Data	  from	  
1988-­‐1994	  showed	  an	  increase	  in	  obesity	  of	  8	  percent	  over	  data	  from	  1977-­‐1980	  with	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prior	  data	  collection	  from	  1960-­‐1980	  levels	  of	  obesity	  remaining	  level	  [74,	  75].	  	  Looking	  
further,	  data	  from	  1999-­‐2000	  demonstrated	  increased	  obesity	  as	  well	  [76].	  	  Data	  from	  
2001-­‐2002	  and	  2003-­‐2004	  demonstrated	  increasing	  trends	  among	  men	  but	  not	  women	  
compared	  to	  1999-­‐2000	  data	  [77,	  78].	  	  The	  2003-­‐2004	  data	  from	  the	  2005-­‐2006	  and	  
2007-­‐2008	  data	  showed	  no	  real	  increase	  in	  prevalence	  of	  obesity	  [21].	  	  	  
While	  there	  has	  not	  been	  a	  dramatic	  increase	  in	  obesity	  within	  the	  past	  several	  
years,	  the	  overweight	  and	  obese	  population	  in	  the	  United	  States	  is	  alarmingly	  high.	  	  
Specifically,	  from	  the	  most	  recent	  NHANEs	  data	  (2009-­‐2010)	  on	  overweight	  and	  obesity	  
prevalence	  in	  the	  US,	  the	  prevalence	  of	  obesity	  adjusted	  for	  age	  was	  35.7%.	  	  For	  adult	  
men	  prevalence	  was	  35.5%	  	  overall.	  	  For	  women,	  prevalence	  was	  35.8%.	  	  No	  significant	  
difference	  existed	  among	  age	  adjusted	  prevalence	  of	  obesity	  between	  men	  and	  women	  
(P	  =	  0.86).	  	  Combining	  both	  overweight	  (BMI	  ≥	  25)	  and	  obese	  (BMI	  ≥	  30),	  age	  adjusted	  
prevalence	  among	  adults	  was	  68.8%	  	  with	  73.9%	  	  of	  men	  and	  63.7%	  of	  women	  meeting	  
that	  criteria.	  	  Numbers	  are	  similarly	  high	  among	  various	  ethnicities	  within	  the	  United	  
States.	  	  Among	  men	  and	  women	  tested,	  34.3%	  	  of	  non-­‐Hispanic	  white,	  49.5%	  of	  non-­‐
Hispanic	  black,	  39.1%	  of	  Hispanic,	  and	  40.4%	  	  of	  Mexican	  Americans	  were	  obese.	  	  
Overweight	  and	  obese	  populations	  combined	  again	  demonstrated	  alarmingly	  high	  rates:	  	  
66.7%	  of	  non-­‐Hispanic	  white,	  76.7%	  of	  non-­‐Hispanic	  black,	  78.8%	  of	  Hispanic,	  and	  81.2%	  
of	  Mexican	  American	  individuals	  demonstrated	  this	  phenotype.	  	  All	  of	  this	  data	  was	  
obtained	  from	  summaries	  by	  Flegal	  et	  al	  [79].	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Perhaps	  even	  more	  alarming	  is	  the	  high	  degree	  of	  obesity	  among	  children	  and	  
adolescents	  in	  the	  US.	  	  Clinical	  trends	  identify	  obese	  children	  at	  higher	  risk	  for	  
development	  of	  adult	  obesity	  and	  morbid	  obesity	  placing	  obese	  youth	  at	  risk	  for	  the	  
same	  comorbidities	  later	  life	  [80,	  81].	  	  This	  trend	  in	  obesity	  leads	  to	  increased	  risk	  
factors	  in	  adults.	  	  One	  study	  demonstrates	  being	  overweight	  during	  adolescence	  
associates	  with	  an	  increase	  of	  2.4-­‐3	  fold	  in	  high	  total	  cholesterol	  and	  LDL,	  an	  8.5-­‐fold	  
increase	  in	  hypertension,	  and	  an	  8-­‐fold	  increase	  in	  reduced	  high-­‐density	  lipoprotein	  
cholesterol	  in	  adults[82].	  	  Another	  study	  found	  that	  increasing	  BMI	  during	  the	  age	  range	  
of	  7-­‐13	  correlates	  with	  increasing	  prevalence	  of	  coronary	  events	  later	  in	  life	  [83].	  	  
Current	  childhood	  obesity	  trends	  from	  1999-­‐2010	  are	  well	  characterized	  by	  Ogen	  et	  al	  
[84].	  	  Briefly,	  in	  youth	  through	  age	  19,	  obesity	  prevalence	  was	  16.9%	  and	  overweight	  
prevalence	  was	  31.8%.	  Of	  these	  data,	  males	  demonstrated	  a	  higher	  percentage	  of	  
obesity	  compared	  to	  females,	  18.6	  vs.	  15.0%	  respectively	  (P	  =	  0.01).	  	  While	  childhood	  
obesity	  growth	  rates	  have	  somewhat	  plateaued	  [85];	  the	  overall	  prevalence	  of	  obesity	  
across	  all	  ages	  is	  alarmingly	  elevated.	  	  
A.6	  Obesity	  summary	  
With	  multiple	  comorbidities	  affecting	  mortality	  and	  quality	  of	  life,	  the	  prevalence	  
of	  and	  costs	  associated	  with	  obesity	  have	  become	  a	  major	  health	  concern	  worldwide	  
and	  especially	  in	  the	  United	  States.	  	  This	  has	  increased	  the	  need	  for	  research	  into	  
obesity.	  	  Physiologically,	  these	  research	  studies	  focus	  on	  adipose	  tissue	  and	  more	  
specifically	  on	  adipocyte	  biology,	  its	  normal	  and	  pathophysiologic	  function.	  	  By	  studying	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this	  particular	  cell	  type,	  adipose	  tissue	  function	  is	  better	  defined	  which	  leads	  to	  a	  better	  
understanding	  of	  the	  biology	  at	  the	  center	  of	  the	  obesity	  epidemic.	  	  This	  dissertation	  
falls	  into	  this	  important	  research	  category	  and	  provides	  a	  better	  understanding	  of	  
human	  adipocyte	  biology	  with	  respect	  to	  its	  differentiation	  and	  metabolic	  phenotype.	  	  	  
	  
B.	  	  	  Adipose	  Tissue	  
B.1	  Introduction	  	  
In	  the	  previous	  section,	  a	  number	  of	  ways	  have	  been	  introduced	  that	  are	  used	  to	  
categorize	  and	  quantify	  obesity,	  however	  all	  of	  them	  attempt	  to	  estimate	  lean	  vs.	  fat	  
mass.	  	  Fat	  mass	  is	  almost	  entirely	  adipose	  tissue.	  	  Some	  extra	  adipose	  tissues/organs	  
such	  as	  brain,	  marrow	  and	  liver/skeletal	  muscle	  (when	  fatty)	  can	  contribute	  to	  more	  
sensitive	  quantitative	  methods	  (such	  as	  QMR),	  however,	  contribution	  of	  extra-­‐adipose	  
lipid	  to	  whole	  animal	  or	  human	  fat/lean	  measurements	  is	  negligible	  compared	  to	  
adipose	  tissue	  itself.	  	  This	  said,	  clinical	  obesity	  is	  qualitatively	  described	  as	  an	  increased	  
body	  mass	  particularly	  in	  adipose	  tissue	  sufficiently	  large	  enough	  to	  produce	  adverse	  
health	  consequences[86].	  	  This	  increase	  in	  adipose	  tissue	  is	  primarily	  due	  adipogenic	  
differentiation	  of	  adipocyte	  precursors	  as	  well	  as	  hypertrophy	  of.	  	  These	  processes	  are	  
driven	  by	  energy	  imbalance	  (net	  positive	  caloric	  balance)	  and	  hormonal	  regulation	  but	  




B.2	  Genetic	  component	  of	  adipose	  tissue	  formation	  and	  obesity	  
Through	  clinical	  studies	  in	  humans	  where	  genetic	  abnormalities	  contribute	  to	  
changes	  in	  adipose	  tissue	  mass,	  genetic	  components	  that	  contribute	  to	  regulation	  of	  
adipose	  tissue	  mass	  have	  been	  identified.	  	  This	  is	  challenging	  however,	  since	  a	  series	  of	  
molecular	  mechanisms	  have	  been	  cloned	  and	  defined	  that	  regulate	  energy	  homeostasis	  
[87],	  even	  though	  in	  animal	  studies,	  body	  size	  is	  polygenic	  with	  no	  Mendelian	  pattern	  as	  
it	  is	  controlled	  by	  multiple	  loci.	  	  In	  humans,	  identifying	  a	  genetic	  component	  of	  obesity	  is	  
even	  more	  daunting	  as	  environmental	  variables	  contribute	  to	  feeding	  behavior	  and	  
energy	  expenditure.	  	  However,	  evidence	  exists	  that	  variance	  of	  BMI	  within	  a	  population	  
can	  be	  genetically	  determined	  [87,	  88]	  with	  some	  estimates	  of	  heritability	  ranging	  
between	  40-­‐70%	  [89]	  though	  such	  studies	  are	  difficult	  to	  account	  for	  similar	  
environmental	  factors	  affecting	  parents/offspring.	  	  Association,	  linkage,	  and	  candidate	  
gene	  studies	  have	  identified	  a	  number	  of	  human	  obesity	  associated	  genes.	  	  These	  
include	  LEP	  (leptin	  deficiency)	  [90-­‐92],	  LEPR	  (leptin	  receptor	  deficiency)	  [93,	  94],	  POMC	  
(proopiomelanocortin	  deficiency)	  [95,	  96],	  PCSK1	  (proprotein	  convertase	  1/3	  deficiency)	  
[97,	  98],	  MC4R	  (melanocortin	  4	  receptor	  deficiency)	  [99-­‐102],	  BDNF	  (brain	  derived	  
neurotrophic	  factor	  deficiency)	  [103,	  104],	  NTRK2	  (neurotrophic	  tyrosine	  receptor	  
kinase	  2	  deficiency)	  [105],	  SIM1	  (single	  minded	  homolog	  1	  deficiency)	  [106],	  BBS1-­‐16,	  
(Bardet	  Biedl	  Syndrome)	  [107],	  ALMS1	  (Alstrom	  Syndrome)	  [108],	  GNAS	  (Albright	  
Hereditary	  Osteodystrophy)	  [109],	  with	  new	  genes	  still	  being	  identified.	  	  While	  these	  
studies	  indicate	  a	  clear	  genetic	  component	  to	  obesity,	  most	  are	  rare	  genetic	  
abnormalities	  and	  do	  not	  largely	  contribute	  to	  population	  obesity	  in	  a	  major	  way.	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B.3	  Energy	  imbalance	  and	  formation	  of	  adipose	  tissue	  
As	  informative	  as	  the	  genetic	  association	  studies	  have	  been,	  the	  increased	  
prevalence	  of	  obesity	  over	  the	  last	  several	  decades	  especially	  in	  the	  United	  States	  is	  
most	  likely	  not	  due	  to	  a	  sudden	  change	  in	  Western	  World	  genetics.	  	  It	  is	  more	  likely	  due	  
to	  change	  in	  lifestyle	  and	  availability/composition	  of	  food	  consumed.	  	  Whether	  genetic,	  
environmental,	  and/or	  behavioral,	  an	  increase	  in	  fat	  mass	  is	  essentially	  a	  shift	  in	  energy	  
balance.	  	  Assuming	  that	  physiologic	  nutrient	  absorption	  and	  storage	  of	  energy	  is	  
functioning	  within	  normal	  parameters,	  stored	  energy	  only	  increases	  when	  energy	  intake	  
exceeds	  energy	  expenditure.	  	  In	  this	  positive	  caloric	  state,	  excess	  energy	  storage	  is	  most	  
optimally	  stored	  in	  new	  adipocytes	  created	  by	  adipogenic	  differentiation	  of	  existing	  
adipocyte	  precursors	  (discussed	  in	  more	  detail	  later)	  [86,	  110-­‐113].	  	  Hypertrophy	  of	  
existing	  adipocytes	  is	  also	  involved	  in	  storage	  of	  excess	  energy	  in	  positive	  caloric	  
balance.	  	  Initially,	  when	  in	  a	  state	  of	  excess	  energy,	  hypertrophy	  of	  existing	  adipocytes	  
triggers	  adipose	  tissue	  paracrine	  signaling	  resulting	  in	  differentiation	  of	  new	  adipocytes	  
[114-­‐116].	  	  	  
B.4	  Adipocyte	  number	  and	  hypertrophy	  
Historically,	  a	  prevailing	  hypothesis	  was	  that	  human	  have	  a	  fixed	  number	  of	  
adipocytes	  determined	  early	  on	  and	  kept	  constant	  regardless	  of	  
environmental/physiologic	  conditions	  throughout	  life.	  	  Thus	  an	  increase	  in	  adipose	  
tissue	  mass	  was	  thought	  to	  be	  entirely	  due	  to	  hypertrophy	  of	  existing	  adipocytes	  and	  
that	  this	  this	  fixed	  number	  of	  adipocytes	  (in	  excess	  or	  insufficiency)	  might	  predispose	  to	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obesity	  and	  its	  comorbidities	  [117].	  	  This	  has	  been	  shown	  to	  not	  be	  the	  case.	  	  Increase	  in	  
fat	  mass	  also	  occurs	  by	  recruitment/proliferation	  of	  preadipocytes	  which	  undergo	  
adipogenic	  differentiation	  increasing	  energy	  storage	  capacity	  in	  adipose	  tissue	  [114,	  
118-­‐122].	  	  Thus,	  expansion	  of	  fat	  mass	  is	  a	  balance	  of	  hypertrophy	  of	  existing	  adipocytes	  
and	  differentiation	  of	  new	  adipocytes.	  	  It	  is	  important	  to	  note	  however	  that	  when	  
hypertrophy	  exceeds	  normal	  physiologic	  parameters	  (resulting	  from	  insufficient	  new	  
adipocyte	  differentiation	  leading	  to	  increased	  adipocyte	  size)	  a	  pathologic	  state	  often	  
exists	  in	  adipose	  tissue	  that	  drives	  many	  of	  the	  pathophysiologies	  previously	  described	  
associated	  with	  obesity	  [1-­‐4,	  110,	  123-­‐132].	  	  Differentiation	  of	  new	  adipocytes,	  thereby	  
expanding	  the	  capacity	  of	  adipose	  tissue	  to	  store	  energy	  without	  over-­‐hypertrophy	  of	  
existing	  adipocytes,	  is	  critical	  for	  normal	  adipose	  tissue	  function.	  
B.5	  Adipose	  tissue	  as	  an	  endocrine	  organ	  
While	  classically	  described	  as	  an	  energy	  storage	  depot,	  additionally	  adipose	  
tissue	  has	  more	  recently	  been	  characterized	  as	  having	  an	  endocrine	  role	  with	  extensive	  
hormone	  production	  [133-­‐135].	  	  As	  early	  as	  1987	  sex	  steroid	  metabolism	  [136]	  and	  
adipsin	  production	  [137]	  were	  described	  in	  adipose	  tissue.	  	  Since	  then,	  a	  number	  of	  
adipokines	  have	  been	  identified	  with	  endocrine	  and	  paracrine	  action	  regulating	  multiple	  
in	  vivo	  systems.	  	  These	  include	  but	  are	  not	  limited	  to…	  leptin	  [138-­‐140],	  adiponectin	  
[141-­‐145],	  resistin	  [146-­‐150],	  chemerin	  [151-­‐153],	  omentin	  [154],	  retinol	  binding	  protein	  
4	  (RBP4)	  [155-­‐157],TNFα	  [138,	  139,	  158,	  159],	  IL-­‐6	  [138,	  139,	  160,	  161],	  MCP-­‐1[162-­‐
164],	  plasminogen	  activator	  inhibitor	  (PAI)-­‐1	  [165],	  and	  multiple	  components	  of	  the	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rennin	  angiotensin	  system	  (RAS)	  [166,	  167].	  	  Adipokine	  production	  and	  regulation	  is	  
critical	  for	  normal	  physiologic	  function	  both	  systemically	  and	  within	  adipose	  tissue,	  
regulating	  multiple	  functions	  contributing	  to	  several	  pathophysiologies	  when	  
dysregulated	  [86,	  110,	  113,	  168-­‐170].	  	  	  	  
B.6	  Adipocyte	  differentiation	  
During	  adipocyte	  differentiation,	  preadipocytes	  with	  no	  lipid	  droplets	  
differentiate	  into	  mature	  adipocytes	  filled	  with	  perlipin	  coated	  lipid	  vesicles.	  	  This	  
involves	  several	  stages.	  	  Adipose	  tissue	  contains	  mesenchymal	  precursors	  with	  
proliferative	  capacity	  and	  plasticity	  to	  differentiate.	  	  Under	  adipogenic	  conditions,	  these	  
cells	  then	  go	  on	  to	  become	  committed	  preadipocytes	  that	  still	  have	  the	  ability	  to	  
proliferate.	  	  These	  further	  go	  on	  to	  growth	  arrest	  and	  differentiation	  into	  mature	  
adipocytes[112,	  171].	  	  	  
B.7	  Intracellular	  regulation	  of	  adipocyte	  differentiation	  
A	  number	  of	  transcription	  factors	  have	  been	  identified	  that	  regulate	  adipogenic	  
differentiation,	  with	  two	  emerging	  as	  the	  most	  critical	  for	  this	  process:	  	  PPARγ	  and	  
C/EBPα.	  	  Peroxisome	  proliferator-­‐activated	  receptor	  gamma,	  or	  PPARγ,	  is	  considered	  to	  
be	  the	  master	  regulator	  of	  adipocyte	  differentiation.	  	  PPARγ	  forms	  a	  heterodimer	  with	  
RXR	  to	  bind	  DNA.	  	  	  	  The	  target	  of	  this	  heterodimer	  is	  the	  DR-­‐1	  sequence,	  characterized	  
by	  repeats	  of	  ‘AGGTCA’	  with	  a	  random	  nucleotide	  between	  them	  [172].	  	  PPARγ	  is	  critical	  
for	  adipogenic	  induction	  and	  sufficient	  to	  induce	  adipogenesis	  [173,	  174].	  	  Both	  PPARγ1	  
and	  2	  have	  been	  shown	  to	  contribute	  to	  adipocyte	  differentiation	  [175-­‐178].	  	  PPAR	  
12	  
	  
gamma	  ligand	  is	  upregulated	  by	  C/EBPβ	  and	  SREBP1C	  [179,	  180].	  	  Specific	  endogenous	  
PPARγ	  ligands	  remain	  elusive	  though	  lipid	  metabolites	  such	  as	  polyunsaturated	  fatty	  
acids	  and	  eicosanoids	  have	  been	  implicated	  as	  potential	  candidates	  [181];	  Prostaglandin	  
15-­‐deoxy-­‐Δ12,	  and	  14-­‐prostaglandin	  J2	  have	  been	  considered	  potential	  endogenous	  
ligands	  although	  their	  expression	  is	  low	  in	  adipocytes	  [182,	  183].	  	  cAMP-­‐dependent	  	  
ligand	  activity	  is	  temporarily	  elevated	  early	  in	  differentiation	  though	  PPARγ	  expression	  
remains	  elevated	  throughout	  differentiation	  [184]	  indicating	  that	  continued	  receptor	  
agonism	  is	  not	  necessary	  for	  PPARγ	  expression.	  	  Further,	  inducible	  PPARγ	  knockout	  in	  
vivo	  [185]	  and	  introduction	  of	  a	  dominant	  negative	  PPARγ	  in	  vitro	  [186]	  have	  
demonstrated	  that	  continued	  expression	  of	  PPARγ	  is	  critical	  for	  adipogenic	  
differentiation	  and	  mature	  adipocyte	  function.	  	  	  
Also	  critical	  for	  adipose	  tissue	  differentiation	  is	  CCAAT-­‐enhancer-­‐binding-­‐protein	  
alpha	  (C/EBPα).	  	  This	  directly	  induces	  many	  adipocyte	  genes	  and	  is	  itself	  induced	  by	  
C/EBPβ	  and	  C/EBPδ	  [187-­‐189].	  	  Other	  members	  of	  the	  C/EBP	  family	  suppress	  
adipogenesis	  potentially	  through	  heterodimerization	  and	  inactivation	  of	  C/EBPβ	  [187].	  	  
Though	  important	  for	  differentiation,	  C/EBP	  can	  not	  function	  apart	  from	  PPARγ	  [190,	  
191].	  	  C/EBPs	  continue	  to	  play	  a	  role	  in	  mature	  adipocytes	  to	  maintain	  insulin	  sensitivity	  
[192,	  193].	  	  	  
While	  PPARγ	  and	  C/EBPα	  are	  considered	  the	  most	  critical	  regulators	  of	  
adipogenesis,	  a	  number	  of	  other	  intracellular	  factors	  have	  been	  identified	  as	  regulating	  
different	  aspects	  of	  adipogenic	  differentiation	  both	  downstream	  of	  PPARγ	  and	  C/EBPα	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and/or	  contributing	  to	  their	  elevation.	  	  These	  include	  but	  are	  not	  limited	  to	  KLF2,	  5,	  7,	  
15	  [194-­‐198],	  LXRs	  (α	  and	  β)	  [199-­‐201],	  STAT5a	  [202,	  203],	  CREB	  [204],	  Krox-­‐20	  [205],	  
early	  beta	  cell	  factor	  (EBF)	  [206],	  and	  SREBP1	  [180,	  207,	  208].	  	  	  
B.8	  Extracellular	  signal	  regulation	  of	  adipocyte	  differentiation	  
Wnts	  are	  a	  family	  of	  highly	  conserved	  secreted	  glycoproteins	  that	  influence	  cell	  
fate	  and	  development	  by	  either	  paracrine	  and/or	  autocrine	  action	  with	  affecting	  
multiple	  organs	  and	  tissues	  such	  as	  bone,	  intestine,	  hematopoiesis	  of	  multiple	  white	  
blood	  cells[209].	  	  Wnt	  signaling	  occurs	  through	  both	  β-­‐catenin	  driven	  pathways	  
(canonical)	  and	  other	  non-­‐canonical	  pathways	  [209,	  210]	  that	  regulate	  adipogenic	  
differentiation.	  	  Wnt	  signaling	  inhibits	  in	  vitro	  adipogenic	  differentiation	  by	  blocking	  
PPARγ	  and	  C/EBPα	  expression	  [200,	  211-­‐213].	  	  Selective	  deletion	  studies	  during	  
embryogenesis	  suggest	  that	  Wnt	  proteins	  serve	  a	  similar	  regulatory	  role	  of	  adipogenic	  
differentiation	  in	  vivo	  [214].	  	  Along	  with	  Wnts,	  a	  number	  of	  other	  extracellular	  signaling	  
proteins	  have	  been	  identified	  as	  playing	  a	  role	  in	  regulating	  adipogenic	  differentiation.	  	  
The	  transforming	  growth	  factor	  β	  (TGFβ)	  family	  members	  have	  demonstrated	  various	  
regulatory	  roles	  on	  adipogenesis;	  these	  includeTGFβ	  [215-­‐220],	  myostatin	  [221-­‐226],	  
and	  bone	  morphogenic	  proteins	  (BMPs)	  [227-­‐232].	  	  Notch	  signaling	  has	  also	  been	  
implicated	  in	  adipocyte	  differentiation	  and	  is	  regulated	  by	  a	  number	  of	  factors	  including	  
jagged	  and	  γ-­‐secretase	  [233-­‐238].	  	  DLK1/PREF1	  signaling	  represses	  adipogenic	  
differentiation	  [239-­‐244].	  	  Fibroblast	  growth	  factors	  (FGFs)	  are	  generally	  pro-­‐adipogenic	  
signaling	  [245-­‐249].	  	  These	  factors	  have	  been	  identified	  in	  controlled	  experiments	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attempting	  to	  identify	  the	  role	  of	  individual	  factors.	  	  The	  net	  regulation	  of	  adipogenesis	  
in	  vivo	  is	  a	  concert	  of	  all	  these	  factors	  and	  others	  as	  is	  the	  case	  with	  most	  differentiation	  
events.	  	  	  
B.9	  Modeling	  adipogenesis	  in	  vitro	  
Most	  of	  what	  has	  been	  learned	  about	  adipocyte	  differentiation	  has	  come	  from	  in	  
vitro	  models	  of	  adipocyte	  differentiation.	  	  A	  number	  of	  cell-­‐based	  models	  exist,	  the	  
most	  commonly	  used	  are	  3T3-­‐L1	  and	  3T3-­‐F442A	  cells.	  	  These	  have	  been	  used	  in	  an	  
impressive	  body	  of	  literature	  that	  has	  greatly	  aided	  in	  our	  understanding	  of	  adipocyte	  
differentiation	  and	  adipocyte	  function.	  	  These	  clonal	  lines	  of	  fibroblasts	  were	  initially	  
isolated	  from	  Swiss	  3T3	  mouse	  embryos	  [250-­‐252].	  	  	  
While	  these	  embryonic	  mouse	  fibroblast	  lines	  have	  contributed	  to	  the	  
understanding	  of	  adipogenesis,	  human	  models	  using	  human	  adipocyte	  precursors	  may	  
be	  preferable	  to	  more	  appropriately	  model	  human	  adipogenic	  differentiation.	  	  This	  can	  
be	  done	  using	  the	  stromal	  vascular	  fraction	  of	  adipose	  tissue,	  containing	  adipose-­‐
derived	  stromal	  cells	  (ASCs),	  which	  can	  be	  readily	  obtained	  through	  minimally	  invasive	  
lipoaspiration	  as	  well	  as	  abdominoplasty.	  	  This	  adipose	  stromal	  cell	  population	  is	  largely	  
composed	  of	  adipocyte	  precursors	  and	  the	  MSCs	  that	  give	  rise	  to	  adipocyte	  precursors	  
[253].	  	  While	  the	  stromal	  vascular	  population	  out	  of	  processed	  lipoaspirate	  contains	  
ASCs	  it	  also	  contains	  a	  large	  number	  of	  endothelial	  and	  leukocytic	  cells	  [254].	  	  Thus,	  this	  
population	  represents	  the	  cells	  that	  contribute	  to	  normal	  adipogenic	  differentiation	  in	  
vivo.	  	  It	  seems	  reasonable	  that	  study	  of	  adipogenic	  differentiation	  of	  these	  cells	  is	  using	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the	  “right	  cell	  from	  the	  right	  tissue,	  in	  the	  right	  species,”	  and	  provides	  a	  more	  
physiologic	  model	  for	  studying	  human	  adipogenic	  differentiation	  than	  the	  previously	  
mentioned	  3T3	  lines.	  	  ASCs	  have	  demonstrated	  multilineage	  potential	  including	  in	  vitro	  
differentiation	  into	  mesenchymal	  cells	  [255-­‐258]	  as	  well	  as	  hepatocytes	  [259],	  neuronal	  
cells	  [260],	  endothelial	  cells	  [261,	  262],	  and	  cardiomyocytes	  [263,	  264].	  	  ASCs	  occupy	  a	  
perivascular	  niche	  and	  support	  vascular	  networks	  [254,	  265,	  266]	  in	  addition	  to	  
contributing	  to	  new	  adipocyte	  formation.	  	  	  
Adipocyte	  differentiation	  is	  achieved	  by	  multiple	  (similar)	  methods	  depending	  on	  
the	  source	  of	  cells	  for	  differentiation	  and	  the	  extent	  of	  differentiation	  desired.	  	  
Differentiation	  is	  most	  commonly	  induced	  by	  treating	  confluent	  cells	  with	  a	  cocktail	  of	  
insulin,	  dexamethasone,	  and	  isobutylmethylxanthine	  (IBMX).	  	  This	  cocktail	  was	  originally	  
defined	  for	  3T3-­‐L1	  cells	  and	  was	  then	  translated	  into	  use	  for	  human	  adipocyte	  precursor	  
differentiation	  [267-­‐269].	  	  For	  cell	  types	  in	  a	  more	  undifferentiated	  state	  (not	  
committed	  preadipocytes),	  commitment	  and	  progression	  through	  differentiation	  can	  be	  
enhanced	  with	  addition	  of	  PPARγ	  agonists	  such	  as	  Pioglitazone	  and	  Rosiglitazone	  to	  the	  
differentiation	  medium.	  	  This	  is	  important	  for	  the	  stromal	  vascular	  populations	  of	  
adipose	  tissue	  which	  contain	  mesenchymal	  stem	  cells	  and	  preadipocytes	  at	  various	  
stages	  of	  adipogenic	  commitment.	  	  For	  cells	  already	  committed,	  PPARγ	  agonists	  
increase	  PPARγ	  expression.	  	  Thus	  PPARγ	  agonists	  enhance	  adipogenic	  differentiation	  in	  
cell	  lines	  and	  primary	  isolated	  human	  ASCs	  [270-­‐274].	  	  However,	  direct	  comparison	  of	  
the	  effects	  of	  PPARγ	  agonism	  on	  human	  preadipocytes	  from	  different	  depots	  is	  not	  very	  
well	  defined	  and	  is	  explored	  further	  in	  this	  dissertation.	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B.10	  Adipose	  tissue	  summary	  
Human	  ASCs	  provide	  a	  species	  and	  tissue	  appropriate	  physiologic	  model	  for	  
studying	  adipogenic	  differentiation	  and	  even	  a	  method	  for	  providing	  mature	  adipocytes	  
for	  research	  in	  a	  more	  controlled	  manner	  than	  fat	  pad	  culture.	  	  However,	  the	  degree	  of	  
donor-­‐to-­‐donor	  variability	  in	  differentiation	  needs	  to	  be	  assessed	  for	  human	  adipocyte	  
studies.	  	  While	  differentiation	  capacity	  of	  omental	  derived	  ASCs	  is	  reduced	  compared	  to	  
subcutaneous	  with	  respect	  to	  lipid	  	  accumulation,	  percentage	  of	  cells	  differentiating,	  
AP2,	  PPARγ,	  and	  C/EBPα	  expression	  [275],	  enhancing	  commitment	  and	  differentiation	  
procedure	  with	  PPARγ	  agonists	  might	  improve	  differentiation	  studies	  in	  omental	  depots.	  
Differentiation	  from	  a	  pericytic	  niche	  and	  role	  to	  a	  role	  that	  is	  in	  large	  part	  energy	  
storage	  most	  likely	  is	  associated	  with	  a	  drastic	  change	  in	  metabolic	  phenotype.	  	  This	  
dissertation	  research	  aims	  primarily	  at	  exploring	  the	  changes	  in	  metabolic	  phenotype	  
that	  accompany	  adipogenic	  differentiation.	  	  	  
	  
C.	  	  Lactate	  Production	  in	  Adipose	  Tissue	  
C.1	  Introduction	  
Lactate	  production	  primarily	  comes	  from	  the	  conversion	  of	  glycolytically-­‐derived	  
pyruvate	  to	  lactate	  by	  lactate	  dehydrogenase	  under	  hypoxic	  conditions.	  	  This	  was	  
initially	  thought	  to	  primarily	  occur	  in	  skeletal	  muscle	  during	  periods	  of	  intense	  exercise	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where	  oxygen	  delivery	  may	  not	  be	  sufficient	  for	  energy	  utilization.	  	  However,	  adipose	  
tissue	  has	  also	  demonstrated	  lactate	  production	  in	  a	  regulated	  manner.	  	  	  
C.2	  Physiologic	  lactate	  production	  
Lactate	  had	  typically	  been	  thought	  to	  be	  produced	  under	  circumstances	  where	  
conditions	  are	  not	  favorable	  for	  oxidative	  phosphorylation.	  	  Briefly,	  glucose	  is	  
transported	  into	  cells	  and	  phosphorylated	  to	  prevent	  passive	  export.	  	  It	  is	  then	  
catabolized	  by	  a	  series	  of	  enzymes	  into	  two	  three	  carbon	  molecules	  of	  pyruvate.	  	  This	  
pyruvate	  is	  then	  either	  transported	  into	  the	  mitochondria	  to	  be	  oxidized	  or	  it	  is	  
converted	  to	  lactate	  via	  lactic	  acid	  fermentation.	  	  Lactate	  dehydrogenase	  catalyzes	  the	  
conversion	  of	  pyruvate	  to	  lactate	  (and	  the	  reverse	  as	  well).	  	  Essentially	  the	  pyruvate	  
from	  glycolysis	  is	  reduced	  to	  lactate	  by	  NADH	  (which	  is	  oxidized	  to	  NAD+).	  	  When	  
conditions	  are	  not	  permissive	  for	  oxidation	  (hypoxia),	  this	  step	  is	  critical	  to	  replenish	  the	  
NAD+	  necessary	  for	  the	  initial	  glycolytic	  breakdown	  of	  glucose	  entering	  the	  cell.	  	  Lactate	  
can	  passively	  leave	  the	  cell	  which	  can	  enter	  the	  blood	  stream	  for	  uptake	  at	  the	  liver	  
where	  it	  can	  either	  be	  used	  as	  substrate	  for	  glucose	  production	  (gluconeogenesis)	  or	  it	  
can	  be	  taken	  back	  up	  into	  the	  cells	  that	  produced	  it	  and	  converted	  to	  glycogen	  
(primarily	  liver	  and	  skeletal	  muscle)	  .	  	  The	  production	  of	  glucose	  or	  storage	  as	  glycogen	  
from	  systemic	  lactate	  in	  the	  liver	  is	  known	  as	  the	  Cori	  cycle	  [276-­‐278].	  	  This	  is	  considered	  
a	  futile	  cycle	  as	  it	  requires	  additional	  energy	  to	  “reuse”	  the	  carbons	  in	  lactate	  to	  
generate	  glucose	  or	  store	  as	  glycogen.	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Lactate	  production	  has	  classically	  thought	  to	  occur	  in	  tissues	  of	  non-­‐obligate	  
anaerobes	  when	  anaerobic	  metabolism	  is	  necessary	  due	  to	  a	  lack	  of	  sufficient	  oxygen	  to	  
catabolize	  glucose	  by	  oxidative	  phosphorylation.	  	  This	  is	  discussed	  further	  in	  the	  next	  
section	  but	  is	  exemplified	  by	  skeletal	  muscle	  during	  periods	  of	  intense	  contraction	  in	  
which	  oxygen	  is	  not	  sufficient	  to	  provide	  ATP	  through	  oxidative	  phosphorylation	  [279-­‐
281].	  	  Cancer	  cells	  have	  also	  demonstrated	  production	  of	  ATP	  through	  an	  enhanced	  
glycolytic	  phenotype	  resulting	  in	  increased	  lactate	  production	  [282-­‐285]	  which	  will	  be	  
reviewed	  in	  detail	  in	  the	  next	  section.	  	  	  
C.3	  Lactate	  production	  from	  adipose	  tissue	  
Studies	  performed	  nearly	  two	  decades	  ago	  demonstrated	  a	  significant	  
contribution	  to	  systemic	  lactate	  by	  adipose	  tissue	  [286].	  	  Systemic	  lactate	  levels	  change	  
independent	  of	  exercise	  and	  are	  readily	  altered	  by	  feeding	  [287,	  288]	  and	  lactate	  levels	  
rise	  after	  a	  meal	  with	  a	  nearly	  20	  minute	  lag	  time	  in	  relation	  to	  the	  rise	  in	  glucose	  and	  
insulin	  [289,	  290].	  	  Skeletal	  muscle	  and	  splanchnic	  bed,	  the	  common	  sources	  of	  lactate	  
production,	  do	  not	  contribute	  to	  this	  observed	  increase	  in	  systemic	  lactate	  after	  feeding	  
[289,	  291-­‐293]	  suggesting	  a	  non-­‐skeletal	  muscle	  contribution	  to	  blood	  lactate.	  	  Up	  to	  the	  
early	  1980s,	  lactate	  production	  from	  adipose	  tissue	  was	  mentioned	  but	  not	  heavily	  
studied	  [294-­‐298].	  	  Then	  in	  the	  1980s	  and	  1990s,	  glucose	  metabolism	  to	  lactate	  by	  
adipose	  tissue	  and	  focused	  studies	  on	  adipocytes	  began	  to	  demonstrate	  that	  adipose	  
tissue	  is	  a	  significant	  source	  of	  systemic	  lactate	  that	  varies	  with	  experimental	  conditions	  
and	  is	  potentially	  associated	  with	  pathophysiologies	  [299-­‐304].	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A	  number	  of	  factors	  have	  been	  experimentally	  associated	  with	  changes	  in	  lactate	  
production	  by	  adipocytes.	  	  Increased	  adipocyte	  size	  in	  rats	  correlates	  with	  increased	  
conversion	  of	  glucose	  to	  lactate	  [301-­‐305]	  which	  is	  similar	  to	  findings	  in	  humans	  that	  
increased	  lactate	  production	  is	  observed	  in	  adipocytes	  from	  obese	  individuals	  [299,	  300,	  
306].	  	  	  Insulin	  [303]	  and	  epinephrine	  [305]both	  increase	  lactate	  production	  in	  isolated	  
rat	  adipocytes.	  	  Adipocytes	  isolated	  from	  rats	  fed	  a	  high	  fat	  chow	  also	  demonstrated	  
elevated	  glucose	  conversion	  to	  lactate	  as	  compared	  to	  rats	  fed	  normal	  chow	  [294].	  	  Each	  
of	  these	  demonstrate	  that	  adipose	  tissue	  is	  not	  only	  capable	  of	  contributing	  to	  systemic	  
lactate,	  but	  that	  such	  processes	  are	  regulated.	  	  	  
Perhaps	  the	  most	  significant	  characterization	  of	  adipose	  lactate	  production	  
analysis	  was	  achieved	  by	  human	  studies	  of	  adipose	  tissue	  in	  vivo	  by	  direct	  adipose	  tissue	  
microdialysis	  and	  abdominal	  wall	  venous	  drainage	  studies.	  	  A	  small	  number	  of	  human	  
studies	  identified	  elevated	  concentrations	  of	  lactate	  in	  the	  adipose	  tissue	  interstitial	  
space	  compared	  to	  circulating	  plasma	  levels	  during	  fasting,	  and	  an	  even	  greater	  
elevation	  after	  glucose	  load	  [307,	  308].	  	  Similar	  findings	  were	  found	  when	  comparing	  
venous	  and	  arterialized	  plasma	  from	  subcutaneous	  adipose	  tissue	  in	  the	  abdominal	  wall	  
separate	  from	  the	  underlying	  muscle	  [309,	  310].	  	  Microdialysis	  studies	  in	  humans	  also	  
demonstrated	  elevated	  lactate	  production	  in	  obese	  vs.	  lean	  individuals	  [306,	  311].	  	  
Similar	  to	  rodent	  blood	  lactate/adipocyte	  size	  correlation,	  circulating	  lactate	  increases	  in	  
correlation	  with	  adipocyte	  size	  [312]	  and	  in	  obese	  versus	  lean	  humans	  [290,	  313-­‐315],	  
and	  normoglycemic	  first-­‐degree	  relatives	  of	  individuals	  with	  type	  2	  diabetes	  whose	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adipocytes	  have	  demonstrated	  increased	  size	  as	  well	  [316,	  317].	  	  Taken	  together,	  these	  
studies	  clearly	  demonstrate	  adipose	  tissue	  as	  a	  producer	  of	  systemic	  lactate.	  	  	  	  	  	  
As	  far	  as	  two	  decades	  ago	  a	  positive	  correlation	  between	  elevated	  fasting	  lactate	  
and	  a	  reduction	  in	  insulin	  sensitivity	  has	  been	  reported	  [286,	  290,	  318].	  	  However,	  acute	  
increase	  in	  plasma	  lactate	  production	  following	  meal,	  glucose	  challenge,	  or	  euglycemic	  
clamp	  study	  is	  decreased	  with	  a	  progressive	  increase	  in	  insulin	  resistance	  [319-­‐322].	  	  In	  
the	  Atherosclerosis	  Risk	  in	  Communities	  (ARIC)	  study	  examining	  a	  cohort	  of	  over	  8000	  
predominantly	  black	  and	  white	  adults	  ages	  45-­‐64	  over	  two	  decades,	  it	  was	  found	  that	  
baseline	  plasma	  lactate	  (adjusted	  for	  other	  risk	  factors)	  demonstrates	  positive	  
association	  with	  diabetes,	  fasting	  glucose,	  and	  insulin	  [323].	  	  The	  underlying	  mechanism	  
suspected	  to	  be	  driving	  insulin	  resistance	  involves	  gluconeogenic	  response	  to	  elevated	  
lactate	  in	  the	  liver	  resulting	  in	  chronic	  hyperglycemia	  [286,	  324].	  	  While	  this	  has	  been	  
held	  up	  in	  rodent	  clamp/lactate	  infusion	  studies	  [325,	  326],	  acute	  studies	  in	  humans	  
have	  not	  demonstrated	  similar	  elevation	  of	  glucose	  [291,	  327-­‐329]	  though	  the	  effects	  of	  
long	  term	  plasma	  lactate	  elevation	  have	  not	  been	  studied	  requiring	  further	  and	  more	  
rigorous	  experimentation.	  	  	  
C.4	  Lactate	  production	  in	  adipose	  tissue	  summary	  
It	  is	  clear	  from	  literature	  that	  lactate	  is	  produced	  in	  adipose	  tissue	  in	  a	  regulated	  
manner	  and	  correlates	  with	  alterations	  in	  insulin	  sensitivity.	  	  However,	  why	  it	  is	  
produced	  in	  adipose	  tissue	  is	  poorly	  understood.	  	  Further	  discussed	  in	  the	  next	  section,	  
lactate	  production	  as	  a	  result	  of	  glucose	  metabolism	  is	  energy	  inefficient.	  	  Also,	  how	  this	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production	  is	  regulated	  in	  adipocytes	  and	  the	  consequences	  of	  inhibiting	  its	  production	  
in	  these	  cells	  is	  not	  well-­‐understood.	  	  This	  dissertation	  explores	  this	  at	  a	  cellular	  level	  
using	  a	  model	  of	  human	  adipocyte	  differentiation.	  	  	  
	  
D.	  	  Aerobic	  Glycolysis	  (Warburg	  Effect)	  
D.1	  Introduction	  
Cells	  generally	  metabolize	  glucose	  to	  pyruvate	  through	  glycolysis.	  	  Under	  
normoxic	  conditions,	  pyruvate	  is	  further	  metabolized	  to	  CO2	  and	  H2O	  generating	  NADH	  
to	  power	  electron	  transport	  and	  ATP	  generation	  through	  oxidative	  phosphorylation.	  	  
When	  oxygen	  is	  not	  present	  or	  limited,	  pyruvate	  is	  converted	  to	  lactate	  through	  lactic	  
acid	  fermentation.	  	  However,	  in	  some	  unique	  cases,	  lactate	  generation	  occurs	  in	  
normoxic	  conditions,	  this	  is	  generally	  called	  aerobic	  glycolysis	  or	  the	  Warburg	  effect.	  	  	  
D.2	  Glycolysis/pyruvate	  production	  
Glycolysis	  is	  generally	  divided	  into	  two	  phases,	  the	  preparatory	  phase	  which	  
generates	  two	  three-­‐carbon	  sugar	  phosphates	  (glyceraldehydes	  3-­‐phosphate)	  while	  
consuming	  energy	  (2	  ATP)	  followed	  by	  the	  the	  payoff	  phase	  which	  generates	  energy-­‐rich	  
ATP	  and	  NADH.	  	  Each	  reaction	  of	  the	  payoff	  phase	  occurs	  twice	  per	  glucose	  molecule	  
(end	  of	  preparatory	  phase	  generates	  two	  substrate	  for	  the	  payoff	  phase).	  	  The	  net	  
energy	  yield	  of	  glycolysis	  is	  2	  NADH	  and	  2	  ATP	  molecules	  (4	  ATP	  are	  generated	  in	  the	  
payoff	  phase,	  but	  2	  are	  consumed	  in	  the	  preparatory	  phase).	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In	  more	  detail,	  the	  first	  step	  of	  the	  preparatory	  phase	  involves	  the	  
phosphorylation	  of	  glucose	  by	  hexokinases	  forming	  glucose	  6-­‐phosphate	  (G6P).	  	  G6P	  is	  
then	  rearranged	  (isomerized)	  by	  glucose	  phosphate	  isomerase	  to	  form	  fructose	  6-­‐
phosphate	  (F6P).	  	  F6P	  is	  phosphorylated	  by	  phosphofructokinase	  1	  to	  generate	  fructose	  
1,6-­‐bisphosphate	  (F1,6BP).	  	  F1,6BP	  is	  split	  by	  aldolase	  into	  two	  molecules	  forming	  	  
dihydroxyacetone	  phosphate	  (DHAP)	  and	  glyceraldehyde	  3-­‐phosphate	  (GADP).	  	  DHAP	  is	  
then	  interconverted	  by	  triosephosphate	  isomerase	  to	  form	  a	  second	  GADP.	  	  	  
The	  two	  GADPs	  then	  move	  into	  the	  payoff	  phase,	  with	  each	  of	  the	  following	  
reactions	  occuring	  twice.	  	  GADP	  is	  dehydrogenated	  and	  inorganic	  phosphate	  is	  added	  
forming	  1,3-­‐bisphosphoglycerate	  (1,3BPG)	  by	  glyceraldehyde	  phosphate	  dehydrogenase	  
(GAPDH)	  which	  also	  results	  in	  the	  generation	  of	  NADH	  from	  NAD+.	  	  The	  1,3BPG	  
contributes	  one	  phosphate	  to	  ADP	  forming	  ATP	  and	  3-­‐phosphoglycerate	  (3PG)	  by	  
phosphoglycerate	  kinase	  (PGK);	  this	  substrate	  level	  phosphorylation	  producing	  ATP	  (one	  
of	  two	  steps	  generating	  in	  glycolysis).	  	  3PG	  is	  then	  converted	  to	  2-­‐phosphoglycerate	  
(2PG)	  by	  phosphoglycerate	  mutase.	  	  2PG	  then	  becomes	  phosphoenolpyruvate	  (PEP)	  
through	  the	  action	  of	  enolase.	  	  Finally	  PEP	  forms	  pyruvate	  transferring	  one	  more	  
phosphate	  to	  ADP	  through	  the	  action	  of	  pyruvate	  kinase	  (the	  second	  substrate	  level	  
phosphorylation).	  	  This	  results	  in	  the	  formation	  of	  pyruvate	  and	  an	  additional	  ATP	  
completing	  the	  payoff	  phase	  and	  glycolytic	  catabolism	  of	  glucose.	  	  	  
Glycolysis	  can	  ultimately	  be	  written	  as	  the	  following:	  	  glucose	  +	  2	  NAD+	  +	  2	  ADP	  
+2	  Pi	  →	  2	  pyruvate	  +	  2	  NADH	  +	  2	  H+	  +	  2	  ATP	  +2	  H2O.	  	  If	  this	  process	  were	  to	  continue	  for	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ATP	  generation	  with	  no	  additional	  reactions,	  glycolysis	  would	  eventually	  stop	  with	  all	  
the	  cellular	  NAD+	  in	  the	  cell	  being	  used	  and	  not	  replenished.	  	  For	  glycolysis	  continue,	  
cells	  must	  oxidize	  NADH	  back	  to	  NAD+.	  	  Generally,	  under	  conditions	  where	  oxygen	  is	  not	  
present,	  pyruvate	  undergoes	  a	  process	  known	  as	  lactic	  acid	  fermentation,	  generating	  
lactate	  and	  NAD+.	  	  When	  performing	  oxidative	  metabolism,	  NAD+	  for	  glycolysis	  is	  
generally	  replenished	  by	  two	  methods.	  	  	  
Under	  normoxic	  conditions,	  pyruvate	  enters	  into	  TCA	  generating	  even	  more	  
NADH	  with	  oxygen	  used	  as	  the	  final	  electron	  acceptor	  in	  the	  electron	  transport	  chain.	  	  
This	  generates	  the	  needed	  NAD+	  and	  establishes	  the	  proton	  motive	  force	  that	  powering	  
ATP	  synthase.	  	  However,	  due	  to	  their	  semi-­‐permeable	  nature,	  mitochondrial	  
membranes	  inhibit	  transport	  of	  this	  NAD+	  to	  the	  cytosol	  where	  it	  is	  needed	  to	  support	  
further	  glycolysis.	  	  To	  replenish	  NAD+	  in	  the	  cytosol,	  cytosolic	  malate	  dehydrogenase	  
catalyzes	  the	  reaction	  of	  NADH	  with	  oxaloacetate	  producing	  NAD+	  and	  malate.	  	  The	  
NAD+	  can	  be	  used	  in	  glycolysis	  while	  the	  malate	  is	  transported	  into	  the	  mitochondria.	  	  
There,	  mitochondrial	  malate	  dehydrogenase	  converts	  it	  to	  oxaloacetate,	  reducing	  NAD+	  
to	  form	  NADH.	  	  This	  oxaloacetate	  is	  converted	  to	  aspartate	  by	  aspartate	  
aminotransferase	  which	  produces	  alpha-­‐ketoglutarate	  from	  glutamate	  in	  the	  process.	  	  
The	  glutamate	  for	  this	  is	  transported	  into	  the	  mitochondria	  by	  an	  antiporter	  which	  
simultaneously	  transports	  malate	  into	  the	  cytosol.	  	  The	  aspartate	  is	  converted	  back	  to	  
oxaloacetate	  in	  the	  cytosol	  by	  aspartate	  aminotransferase.	  	  This	  is	  generally	  considered	  
the	  malate-­‐aspartate	  shuttle.	  	  Alternatively,	  NAD+	  for	  glycolysis	  can	  be	  restored	  through	  
another	  mechanism	  known	  as	  the	  glycerol	  phosphate	  shuttle.	  	  In	  this	  process,	  NADH	  is	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oxidized	  to	  NAD+	  by	  glycerol-­‐3-­‐phosphate	  dehydrogenase	  as	  it	  converts	  
dihydroxyacetone	  phosphate	  to	  glycerol	  3-­‐phosphate.	  	  The	  NAD+	  produced	  can	  be	  used	  
to	  continue	  glycolysis.	  	  	  
D.3	  Lactic	  acid	  fermentation	  
Lactic	  acid	  fermentation	  is	  considered	  to	  be	  the	  completion	  of	  glycolysis	  when	  
oxygen	  is	  not	  present,	  replenishing	  cellular	  NAD+	  for	  glycolytic	  metabolism	  of	  glucose	  
and	  subsequent	  substrate	  level	  phosphorylation	  generation	  of	  ATP	  to	  occur.	  	  This	  
process	  involves	  the	  conversion	  of	  pyruvate	  to	  lactate	  and	  is	  catalyzed	  by	  lactate	  
dehydrogenase	  (LDH).	  	  The	  overall	  reaction	  is	  as	  follows:	  	  pyruvate	  +	  NADH	  +	  H+	  →	  
lactate	  +	  NAD+.	  	  	  The	  use	  of	  this	  process	  coupled	  with	  glycolysis	  for	  ATP	  production	  is	  
considered	  glycolytic	  metabolism.	  	  	  
D.4	  Oxidative	  metabolism/TCA	  cycle	  
Under	  aerobic	  conditions,	  pyruvate	  is	  converted	  to	  acetyl-­‐CoA	  	  to	  enter	  the	  citric	  
acid	  cycle	  and	  generates	  an	  NADH	  in	  the	  mitochondrial	  matrix	  via	  a	  process	  known	  as	  
pyruvate	  decarboxylation.	  	  This	  is	  achieved	  by	  action	  of	  the	  pyruvate	  dehydrogenase	  
complex	  (PDHC),	  the	  regulation	  of	  which	  will	  be	  discussed	  later	  (see	  section	  on	  PDKs).	  	  
This	  critical	  reaction	  for	  pyruvate’s	  fate	  is	  sometimes	  called	  the	  link	  reaction	  because	  it	  
links	  the	  metabolic	  pathways	  of	  glycolysis	  with	  the	  citric	  acid	  cycle.	  	  	  	  	  
Acetyl-­‐CoA	  under	  aerobic	  conditions	  is	  then	  fed	  into	  the	  citric	  acid	  cycle	  (also	  known	  as	  
the	  tricarboxylic	  acid	  cycle,	  TCA,	  or	  the	  Krebs	  cycle)	  generating	  carbon	  dioxide	  (CO2)	  and	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NADH	  from	  NAD+	  ultimately	  used	  in	  electron	  transport.	  	  TCA	  begins	  with	  consumption	  of	  
acetate	  in	  the	  form	  of	  acetyl-­‐CoA	  along	  with	  oxaloacetate	  to	  form	  citrate	  via	  the	  action	  
of	  citrate	  synthase.	  	  The	  citrate	  is	  then	  converted	  to	  cis-­‐Aconitate	  by	  aconitase	  which	  
also	  catalyzes	  the	  next	  step	  converting	  cis-­‐aconitase	  into	  isocitrate.	  	  This	  is	  then	  turned	  
into	  α-­‐ketoglutarate	  generating	  NADH	  	  by	  isocitrate	  dehydrogenase.	  	  α-­‐Ketoglutarate	  is	  
then	  turned	  into	  succinyl-­‐CoA	  by	  α-­‐ketoglutarate	  dehydrogenase	  generating	  NADH	  in	  
the	  process.	  	  Succinyl-­‐CoA	  is	  then	  converted	  to	  succinate	  by	  succinyl-­‐CoA	  synthetase	  
generating	  GTP	  in	  the	  process.	  	  Succinate	  is	  then	  oxidized	  to	  form	  fumarate	  and	  
ubiquinol	  (QH2)	  by	  succinate	  dehydrogenase.	  	  Fumarate	  is	  then	  hydrated	  to	  generate	  
malate	  via	  fumarase.	  	  Malate	  is	  in	  turn	  converted	  to	  oxaloacetate	  by	  malate	  
dehydrogenase	  generating	  NADH	  in	  the	  process	  and	  also	  providing	  oxaloacetate	  to	  push	  
the	  initial	  step	  of	  TCA	  again	  along	  with	  new	  acetyl-­‐CoA.	  	  The	  overall	  reaction	  for	  TCA	  can	  
be	  described	  as	  acetyl-­‐CoA	  +	  3NAD+	  +	  Q	  (ubiquinone)	  +	  GDP	  +	  Pi	  +	  3H2O	  →	  CoA-­‐SH	  +	  
3NADH	  +	  3H+	  +	  QH2	  +	  GTP	  +	  2CO2.	  	  
D.5	  Metabolic	  yields	  from	  glycolytic	  and	  oxidative	  metabolism	  
NADH	  and	  FADH2	  (from	  TCA)	  are	  then	  used	  as	  electron	  donors	  for	  the	  electron	  
transport	  chain	  generating	  the	  proton	  motive	  force	  across	  mitochondrial	  membrane	  and	  
driving	  ATP	  production	  through	  ATP	  synthase.	  	  Assuming	  3	  ATP	  per	  NADH	  and	  2	  per	  
FADH2,	  the	  maximum	  ATP	  yield	  per	  glucose	  molecule	  under	  aerobic	  conditions	  
(assuming	  complete	  oxidation	  of	  glucose)	  is	  38	  ATP.	  	  However,	  these	  processes	  are	  not	  
entirely	  efficient.	  	  The	  two	  NADH	  generated	  in	  glycolysis	  cost	  ATP	  to	  transport	  into	  the	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mitochondria	  reducing	  the	  total	  ATP	  yield	  per	  glucose	  to	  36.	  	  Furthermore,	  	  the	  
mitochondrial	  membrane	  can	  “leak”	  protons	  reducing	  the	  proton	  motive	  force	  and	  
reducing	  ATP	  production	  per	  NADH/FADH2.	  	  Taking	  this	  into	  consideration,	  the	  net	  ATP	  
yield	  per	  glucose	  is	  theoretically	  approximated	  closer	  to	  30	  ATP.	  	  	  
Comparing	  the	  two	  processes,	  glycolytic	  metabolism	  produces	  a	  maximum	  net	  2	  
ATP	  per	  glucose	  metabolized	  whereas	  oxidative	  metabolism	  produces	  a	  more	  efficient	  
maximum	  of	  38	  ATP	  per	  glucose	  metabolized.	  	  Because	  of	  this	  increased	  efficiency	  cells	  
generally	  produce	  ATP	  through	  oxidative	  metabolism	  in	  permissive	  environments	  
(normoxic	  conditions).	  	  This	  was	  first	  observed	  in	  1857	  when	  Louis	  Pasteur	  
demonstrated	  that	  aerating	  yeast	  broth	  caused	  yeast	  cell	  growth	  to	  increase	  with	  a	  
decrease	  in	  fermentation.	  	  His	  observation	  became	  known	  as	  the	  Pasteur	  effect	  which	  
generally	  suggests	  that	  when	  oxygen	  is	  present,	  metabolism	  will	  generally	  follow	  
oxidative	  processes,	  thus	  describing	  the	  O2	  driven	  suppression	  of	  glycolytic	  
metabolism.	  	  	  
D.6	  Aerobic	  glycolysis	  (Warburg	  effect)	  
The	  Warburg	  effect	  is	  a	  unique	  metabolic	  situation	  where	  the	  Pasteur	  effect	  
does	  not	  hold	  up.	  	  It	  can	  be	  understood	  through	  an	  examination	  of	  the	  historical	  
findings	  by	  which	  it	  was	  discovered	  and	  defined.	  	  In	  the	  first	  half	  of	  the	  1900’s	  Otto	  
Warburg	  observed	  a	  rapid	  increase	  in	  oxygen	  (O2)	  consumption	  accompanying	  cell	  
division	  in	  sea	  urchin	  eggs	  upon	  fertilization[330].	  	  Considering	  the	  rapid	  cell	  division	  
associated	  with	  cancers	  he	  assumed	  he	  would	  find	  similar	  observations	  in	  rapidly	  
27	  
	  
dividing	  tumor	  cells.	  	  However,	  upon	  measuring	  oxygen	  consumption	  rates	  and	  lactate	  
production	  (from	  CO2	  measurements)	  in	  thin	  sections	  of	  Flexner-­‐Jobling	  rat	  liver	  
carcinoma	  with	  rapidly	  dividing	  cells	  he	  found	  that	  they	  did	  not	  demonstrate	  increased	  
oxygen	  consumption	  compared	  to	  normal	  tissue	  but	  rather	  demonstrated	  increased	  
lactate	  production	  in	  the	  presence	  of	  normal	  concentrations	  O2	  [331],	  a	  stark	  
contradiction	  to	  the	  Pasteur	  effect.	  	  Further	  investigation	  found	  that	  approximately	  
tenfold	  more	  glucose	  was	  metabolized	  than	  could	  be	  accounted	  for	  by	  oxidative	  
metabolism	  [332],	  and	  the	  amount	  of	  lactic	  acid	  produced	  by	  cancer	  cells	  (from	  multiple	  
carcinomas	  tested)	  was	  two	  orders	  of	  magnitude	  higher	  than	  that	  produced	  in	  normal	  
tissue	  [333].	  	  Warburg	  hypothesized	  that	  lactate	  production	  in	  normoxic	  conditions	  was	  
due	  to	  some	  defect	  in	  normal	  respiratory	  processes	  making	  it	  unable	  to	  achieve	  the	  
Pasteur	  effect	  and	  inhibit	  glycolytic	  energy	  production	  coupled	  to	  lactic	  acid	  
fermentation	  [333].	  	  	  
It	  was	  later	  found	  (again	  by	  Warburg)	  that	  ascites	  tumor	  cells	  in	  culture	  behaved	  
similar	  to	  the	  Flexner-­‐Jobling	  tumor	  slices	  with	  elevated	  lactate	  production	  [334]	  and	  
similar	  rates	  of	  respiration	  to	  yeast	  and	  muscle	  cells	  [335,	  336].	  	  This	  data	  somewhat	  
modified	  Warburg’s	  hypothesis	  of	  a	  breakdown	  in	  oxidative	  processes	  but	  rather	  
suggested	  that	  there	  was	  no	  defect	  in	  respiration	  and	  that	  lactate	  production	  was	  not	  at	  
the	  cost	  of	  respiration.	  	  Indeed	  Cori	  and	  Cori	  demonstrated	  increased	  lactate	  content	  
was	  coupled	  with	  decreased	  glucose	  content	  in	  venous	  blood	  from	  tumor	  laden	  tissue	  
compared	  to	  normal	  tissue	  [337,	  338].	  	  Similarly,	  Warburg	  measured	  arterial	  and	  venous	  
blood	  in	  healthy	  and	  Jansen’s	  sarcoma	  laden	  tissue	  [339,	  340].	  	  He	  found	  a	  2-­‐17%	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reduction	  in	  glucose	  content	  across	  normal	  tissue	  compared	  to	  a	  40-­‐70%	  reduction	  
across	  the	  tumors.	  	  Healthy	  tissue	  produced	  no	  lactate	  whereas	  the	  tumors	  produced	  
lactate	  on	  average	  with	  66%	  of	  the	  glucose	  consumed.	  	  However,	  these	  lactate	  
measurements	  were	  potentially	  lower	  than	  actual	  lactate	  production	  as	  tumors	  have	  
demonstrated	  the	  ability	  to	  recycle	  the	  lactate	  they	  produce	  under	  aerobic	  conditions	  
[341].	  	  This	  makes	  in	  vitro	  measurements	  more	  indicative	  of	  changes	  in	  glucose	  
metabolism	  at	  a	  cellular	  level	  than	  the	  complex	  microenvironment	  of	  tumors	  at	  a	  
cellular	  level.	  	  	  
Warburg	  found	  that	  the	  Meyerhof	  equation	  (an	  index	  of	  oxygen’s	  ability	  to	  
inhibit	  lactic	  acid	  	  fermentation)	  for	  tumor	  cells	  produced	  an	  index	  similar	  to	  that	  of	  
normal	  cells	  [331].	  	  This	  indicated	  that	  O2	  consumption	  in	  cancer	  cells	  was	  similar	  to	  
that	  in	  normal	  cells	  and	  oxygen	  sensing	  was	  most	  likely	  intact.	  	  However,	  given	  that	  they	  
demonstrate	  increased	  lactate	  production,	  the	  Pasteur	  effect	  was	  not	  supported	  in	  the	  
tumor	  cells.	  	  Warburg	  believed	  this	  had	  to	  be	  some	  defect	  in	  respiration,	  or	  that	  it	  was	  
inadequate	  to	  prevent	  lactate	  production	  [342,	  343],	  and	  that	  higher	  rates	  of	  
respiration,	  if	  possible,	  would	  inhibit	  lactate	  production	  [344].	  	  However,	  contrary	  to	  this	  
hypothesis	  experimental	  data	  has	  shown	  that	  increased	  aerobic	  conditions	  in	  tumors	  
demonstrate	  increased	  lactate	  metabolism	  [341].	  	  	  	  	  	  
More	  recent	  review	  of	  Warburg	  and	  his	  colleagues’	  work	  couple	  with	  more	  
recent	  data	  provides	  a	  better	  understanding	  of	  the	  Warburg	  Effect	  mechanistically.	  	  
Warburg	  and	  his	  colleagues	  demonstrated	  that	  in	  the	  time	  it	  takes	  cancer	  tissue	  under	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normoxic	  consitions	  to	  completely	  metabolize	  one	  molecule	  of	  glucose	  to	  generate	  36	  
molecules	  of	  ATP,	  an	  additional	  20	  molecules	  of	  ATP	  are	  generated	  from	  10	  glucose	  
molecules	  being	  metabolized	  to	  lactate	  [333].	  	  Under	  anoxic	  conditions,	  the	  cancer	  cells	  
produce	  26	  molecules	  of	  ATP	  from	  13	  molecules	  of	  glucose	  over	  the	  same	  time	  period.	  	  
Therefore	  in	  the	  same	  time	  it	  would	  take	  a	  normal	  cell	  exhibiting	  the	  Pasteur	  effect	  and	  
strict	  aerobic	  metabolism	  to	  produce	  36	  ATP	  molecules	  from	  one	  molecule	  of	  glucose,	  
the	  anoxic	  cancer	  cell	  strictly	  relying	  upon	  glycolysis	  produces	  26	  ATP	  from	  13	  molecules	  
of	  glucose,	  and	  the	  cancer	  cell	  exhibiting	  the	  Warburg	  effect	  (running	  both	  glycolytic	  
and	  oxidative	  energy	  production)	  generates	  56	  ATP	  from	  11	  glucose	  molecules	  [282].	  	  
This	  data	  demonstrates	  both	  oxidative	  and	  glycolytic	  metabolism	  production	  working	  
in	  parallel	  in	  the	  Warburg	  effect	  as	  opposed	  to	  one	  inhibiting	  the	  other	  as	  assumed	  in	  
the	  Pasteur	  effect.	  	  Warburg	  and	  colleagues’	  own	  findings	  support	  this,	  their	  data	  
demonstrating	  46	  milligrams	  of	  lactate	  production	  for	  70	  milligrams	  of	  glucose	  removed	  
across	  tumors	  per	  100	  ml	  blood	  measured.	  	  This	  demonstrates	  a	  10%	  increase	  in	  ATP	  
production	  associated	  with	  aerobic	  glycolysis	  compared	  to	  normal	  non-­‐tumor	  burdened	  
tissue	  [339,	  340].	  	  More	  recently	  this	  has	  been	  confirmed	  by	  studies	  in	  LN18	  
glioblastoma	  cells	  which	  demonstrate	  a	  13%	  increase	  in	  ATP	  production	  associated	  with	  
increased	  lactate	  production	  [345].	  	  	  
D.7	  “Benefits”	  of	  Warburg	  Effect	  
Tumor	  cells	  demonstrating	  this	  metabolic	  phenotype	  have	  sufficient	  ATP	  
production	  as	  demonstrated	  by	  high	  ratios	  of	  ATP:ADP	  and	  NADH/NAD+	  [346,	  347].	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However,	  the	  tremendous	  inefficiency	  in	  production	  of	  only	  2	  ATP	  from	  glycolytic	  
metabolism	  compared	  to	  36	  ATP	  from	  oxidative	  metabolism	  of	  one	  glucose	  molecule	  is	  
remarkable.	  	  Why	  would	  the	  Pasteur	  Effect	  in	  which	  oxidative	  metabolism	  is	  proposed	  
to	  dominate	  whenever	  conditions	  are	  permissive,	  not	  be	  the	  case	  for	  all	  cells?	  	  Why	  
would	  this	  change	  for	  tumor	  cells?	  	  There	  are	  a	  number	  of	  reasons	  that	  have	  been	  
proposed	  and	  identified	  using	  tumor	  cells	  as	  a	  model	  for	  study.	  	  	  
This	  process,	  though	  inefficient,	  provides	  beneficial	  effects	  for	  cancer	  cells	  in	  
that	  it	  allows	  for	  biomass	  generation	  through	  the	  utilization	  of	  glycolytic	  intermediates	  
[348,	  349].	  Proliferating	  cells	  require	  the	  ability	  to	  perform	  multiple	  anabolic	  events	  to	  
replicate	  cellular	  contents	  prior	  to	  cytokinesis.	  	  This	  imposes	  a	  large	  need	  for	  lipids,	  
amino	  acids,	  nucleotides,	  etc.	  	  While	  synthesis	  of	  these	  cellular	  components	  requires	  
energy	  (in	  the	  form	  of	  ATP),	  it	  also	  poses	  additional	  requirements	  for	  generating	  
building	  blocks	  for	  the	  synthetic	  pathways.	  	  As	  an	  example,	  generating	  nucleotides	  and	  
amino	  acids	  uses	  more	  building	  block	  units	  (carbon,	  etc)	  than	  energy	  units	  (ATP);	  the	  
yield	  from	  one	  molecule	  of	  glucose	  could	  contribute	  up	  to	  36	  ATP	  in	  energy	  generation	  
or	  up	  to	  6	  carbons	  for	  molecular	  synthesis	  [284].	  	  By	  performing	  aerobic	  glycolysis,	  
glucose	  is	  not	  completely	  catabolized	  to	  CO2,	  instead	  the	  glycolytic	  intermediates	  are	  
more	  available	  to	  be	  siphoned	  off	  for	  macromolecule	  synthesis.	  	  This	  is	  particularly	  
important	  for	  adipocytes	  which	  need	  to	  generate	  three	  carbon	  glycerol	  backbones	  
(glyceroneogenesis)	  for	  esterification	  and	  storage	  of	  fatty	  acids	  as	  triacylglycerol	  (will	  be	  
discussed	  further	  under	  heading	  PDK).	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D.8	  Aerobic	  glycolysis	  summary	  	  	  
The	  Warburg	  Effect	  or	  aerobic	  glycolysis	  is	  a	  unique	  metabolic	  phenotype	  
whereby	  the	  Pasteur	  effect	  is	  not	  observed;	  but	  instead	  aerobic	  conditions	  are	  
accompanied	  by	  increased	  lactate	  production.	  	  As	  described	  in	  tumor	  models,	  there	  is	  
no	  decrease	  in	  oxidative	  processes	  and	  no	  defect	  in	  respiration,	  just	  an	  increase	  in	  
lactate	  production	  (lactic	  acid	  fermentation)	  even	  in	  the	  presence	  of	  oxygen.	  	  Though	  
inefficient	  from	  the	  standpoint	  of	  ATP	  yield	  per	  glucose	  molecule,	  it	  is	  sufficient	  for	  the	  
ATP	  and	  macromolecule	  synthesis	  needs	  of	  rapidly	  dividing	  tumor	  cells.	  	  While	  lactate	  
production	  has	  been	  demonstrated	  in	  human	  adipose	  tissue,	  why	  this	  lactate	  is	  
produced	  at	  a	  cellular	  level	  has	  not	  been	  sufficiently	  explored.	  	  It	  is	  possible	  that	  
adipocytes	  produce	  lactate	  in	  oxygen-­‐replete	  conditions,	  similar	  to	  tumor	  cells.	  	  This	  
dissertation	  identifies	  the	  existence	  of	  a	  Warburg-­‐like	  phenotype	  in	  differentiated	  
human	  adipocytes	  and	  attempts	  to	  determine	  its	  regulation	  and	  purpose	  in	  these	  
cells.	  	  	  
	  
E.	  Metabolic	  ROS	  
E.1	  Introduction	  
Living	  in	  an	  oxygenated	  environment	  and	  depending	  on	  oxygen	  for	  energy-­‐
producing	  respiratory	  processes	  leads	  to	  the	  inevitable	  production	  of	  reactive	  oxygen	  
species	  (ROS).	  	  Endogenous	  production	  of	  oxygen	  radicals	  was	  unheard	  of	  until	  Denham	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Harmon	  introduced	  his	  ‘free	  radical	  theory’	  in	  the	  1950’s	  [350].	  	  This	  stated	  that	  cellular	  
generation	  of	  reactive	  oxygen	  species	  did	  in	  fact	  occur,	  and	  resulted	  in	  cellular	  damage	  
when	  it	  accumulated.	  	  While	  controversial,	  endogenous	  oxygen	  radical	  production	  
gained	  more	  support	  nearly	  a	  decade	  later	  with	  the	  identification	  of	  superoxide	  
dismutase	  (SOD)	  which	  functioned	  in	  aerobic	  organisms	  to	  remove	  superoxide	  anions	  
[351,	  352].	  	  Since	  this	  seminal	  work,	  ROS	  production	  and	  regulation	  has	  been	  intensely	  
studied.	  	  ROS	  can	  be	  both	  beneficial	  and	  detrimental	  to	  normal	  cellular	  processes,	  and	  
dysregulation	  of	  ROS	  homeostasis	  has	  been	  implicated	  in	  multiple	  disease	  states.	  	  
Reviewed	  here	  are	  the	  cellular	  sources	  of	  ROS	  and	  some	  of	  the	  mechanisms	  
counteracting	  ROS	  production,	  some	  of	  the	  benefits	  and	  detriments	  of	  ROS	  production	  
in	  cells,	  and	  its	  role	  in	  adipocytes.	  
E.2	  ROS	  production	  
There	  are	  multiple	  reactive	  oxygen	  species	  which	  can	  be	  generated	  exogenously	  or	  
endogenously.	  	  Common	  examples	  of	  such	  ROS	  include	  hydrogen	  peroxide,	  superoxide	  
anions,	  and	  hydroxyl	  radicals.	  	  	  These	  can	  be	  generated	  in	  the	  cytosol,	  primarily	  by	  
NADPH	  oxidases.	  	  While	  initially	  described	  in	  neutrophils,	  NADPH	  oxidases	  have	  more	  
recently	  demonstrated	  broad	  expression	  in	  multiple	  tissue	  and	  cell	  types	  and	  are	  
involved	  in	  cellular	  transformation	  as	  well	  as	  replicative	  senescence	  [353-­‐358]	  along	  
with	  the	  historically-­‐described	  phagocytic	  activity.	  	  There	  are	  a	  host	  of	  other	  enzymes	  
for	  which	  normal	  function	  can	  result	  in	  ROS	  generation	  including	  but	  not	  limited	  to	  p450	  
enzymes,	  xanthine	  oxidase,	  lipoxygenases,	  and	  cyclooxygenases	  [359].	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The	  bulk	  of	  cellular	  ROS	  is	  generated	  metabolically	  in	  the	  mitochondria.	  	  
Mitochondria-­‐derived	  ROS	  contribution	  to	  cellular	  damage,	  and	  mitochondrial	  ROS-­‐
based	  signaling	  to	  the	  rest	  of	  the	  cell	  have	  been	  well	  documented	  and	  reviewed	  [360,	  
361].	  	  ROS	  production	  by	  the	  respiratory	  chain	  was	  initially	  reported	  in	  1966	  [362]	  
followed	  by	  identification	  of	  H2O2	  production	  in	  isolated	  mitochondria	  [363-­‐365]	  which	  
was	  found	  to	  be	  a	  dismutation	  of	  superoxide	  [366,	  367].	  	  	  Some	  evidence	  exists	  
indicating	  that	  mitochondria	  convert	  between	  1-­‐2%	  of	  consumed	  oxygen	  molecules	  into	  
superoxide	  anions	  [363].	  	  Mitochondrial	  ROS	  production	  is	  mostly	  generated	  by	  two	  
components	  of	  the	  electron	  transport	  chain.	  	  	  
The	  electron	  transport	  chain	  involves	  the	  donation	  of	  electrons	  from	  electron	  
donors	  (NADH,	  FADH2)	  through	  a	  series	  of	  complexes,	  eventually	  reducing	  oxygen	  to	  
form	  water.	  	  Under	  normal	  circumstances	  with	  the	  appropriate	  reduction,	  four	  protons	  
and	  four	  electrons	  are	  transferred	  to	  oxygen	  generating	  water	  in	  a	  harmless	  reaction.	  	  
The	  rapid	  transport	  of	  electrons	  can	  allow	  for	  electron	  leakage	  generating	  superoxide	  
radicals.	  	  While	  this	  can	  occur	  at	  several	  points	  along	  the	  electron	  transport	  chain,	  the	  
two	  points	  that	  are	  especially	  susceptible	  to	  ROS	  generation	  are	  complex	  I	  (NADH	  
dehydrogenase)	  and	  complex	  III	  (ubiquinone-­‐cytochrome	  c	  reductase).	  	  Production	  of	  
ROS	  from	  these	  two	  sites	  is	  thoroughly	  detailed	  by	  Michael	  Murphy	  [368].	  	  Briefly,	  
complex	  I	  demonstrates	  elevated	  superoxide	  production	  in	  two	  basic	  situations.	  	  First,	  a	  
reduced	  state	  of	  flavin	  mononucleotide	  (FMN)	  brought	  on	  by	  a	  high	  ratio	  of	  matrix	  
NADH/NAD+	  (which	  essentially	  increases	  the	  rate	  of	  electron	  transport),	  and	  second,	  a	  
situation	  where	  reverse	  electron	  transport	  occurs	  from	  electron	  transfer	  to	  Coenzyme	  Q	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(CoQ)	  with	  an	  elevated	  proton-­‐motive	  force.	  	  Complex	  III	  can	  generate	  a	  significant	  
amount	  of	  ROS	  as	  it	  funnels	  electrons	  from	  the	  CoQ	  pool	  to	  cytochrome	  c.	  The	  free	  
radical	  semiquinone	  anion	  (a	  component	  for	  regenerating	  coenzyme	  Q)	  readily	  transfers	  
electrons	  to	  oxygen	  forming	  superoxide.	  	  	  This	  site	  is	  considered	  to	  be	  the	  primary	  point	  
of	  reactive	  oxygen	  species	  production	  under	  baseline	  proton	  motive	  force	  [369]	  
whereas	  complex	  I	  is	  considered	  the	  primary	  site	  of	  ROS	  production	  with	  elevated	  
proton	  motive	  force	  [368].	  	  	  
Production	  of	  ROS	  within	  cells	  correlates	  with	  electron	  transport	  and	  therefor	  is	  
heavily	  dependent	  upon	  the	  rate	  of	  oxidative	  phosphorylation	  providing	  the	  necessary	  
NADH	  and	  FADH2	  to	  drive	  electron	  transport.	  	  Essentially,	  the	  processes	  of	  the	  electron	  
transport	  chain	  are	  the	  primary	  source	  of	  metabolic	  ROS.	  	  When	  the	  processes	  that	  
drive	  oxidative	  phosphorylation	  are	  elevated	  (elevated	  rates	  of	  the	  electron	  transport	  
chain	  generating	  a	  high	  proton	  motive	  force),	  more	  ROS	  is	  produced.	  	  	  	  
E.3	  ROS	  Regulatory	  Role	  and	  Stress	  	  	  	  	  
While	  originally	  viewed	  as	  detrimental	  to	  normal	  cellular	  function	  (along	  with	  
phagocytic	  function	  in	  leukocytes)	  a	  critical	  role	  for	  normal	  cell	  signaling	  has	  emerged	  
for	  ROS.	  	  As	  an	  example,	  PDGF	  or	  EGF	  signaling	  stimulate	  a	  burst	  of	  ROS	  production	  
upon	  receptor	  activation	  [370,	  371]	  that	  targets	  associated	  phosphatase	  activities	  to	  
regulating	  receptor	  tyrosine	  kinase	  signal	  transduction	  [372,	  373].	  	  The	  field	  studying	  
ROS	  associated	  signaling	  has	  expanded	  in	  recent	  years	  with	  technologic	  advances	  in	  
broad	  spectrum	  proteomics	  and	  computational	  analysis	  capable	  of	  detecting	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nitrosylation	  and	  glutathionylation	  of	  signaling	  proteins	  as	  a	  result	  of	  ROS	  post-­‐
translational	  modification	  [374,	  375].	  	  While	  ROS	  signaling	  was	  initially	  associated	  with	  
membrane	  and	  cytosolic	  ROS	  generation,	  a	  number	  of	  cellular	  processes	  have	  been	  
identified	  as	  being	  regulated	  by	  mitochondrial-­‐derived	  ROS.	  	  These	  include	  regulating	  
HIF-­‐1α	  in	  hypoxia	  [376-­‐378]	  ,	  response	  to	  metabolic	  excess	  [379],	  regulation	  of	  Atg4	  
dependent	  autophagy	  [380],	  and	  inflammatory	  response	  [381-­‐383].	  	  	  
The	  degree	  of	  cellular	  reactive	  oxygen	  stress	  is	  determined	  by	  the	  amount	  of	  
reactive	  oxygen	  species	  production	  and	  eliminated.	  	  Severe	  stress	  occurs	  when	  
accumulation	  occurs	  either	  by	  excess	  production	  or	  deficiency	  of	  defenses	  against	  
excess	  ROS	  accumulation.	  	  A	  buildup	  of	  ROS	  can	  cause	  damage	  to	  normal	  cellular	  
processes	  including	  DNA	  damage,	  protein	  damage,	  misfolded	  protein	  response,	  and	  
lipid	  peroxidation	  all	  of	  which	  can	  lead	  to	  altered	  normal	  cellular	  function	  and	  even	  
cellular	  necrosis	  or	  apoptosis.	  	  	  	  
E.4	  ROS	  in	  Adipocytes	  
In	  adipocytes,	  ROS	  have	  demonstrated	  a	  regulatory	  effect	  on	  adipocyte	  
differentiation.	  	  Multiple	  signaling	  factors	  sensitive	  to	  ROS	  modulation	  have	  been	  
implicated	  in	  this	  regulation	  including	  CHOP,	  mTORC1,	  FOXO1,	  TNFα,	  and	  Nrf2	  among	  
others	  [384-­‐388].	  	  Under	  normal	  conditions	  ROS	  signaling	  has	  a	  role	  in	  regulation	  of	  
adipogenic	  differentiation	  induction	  and	  also	  in	  directing	  differentiated	  cells	  to	  terminal	  
adipocyte	  differentiation	  [388-­‐390].	  	  However,	  under	  various	  conditions,	  ROS	  role	  in	  
regulating	  adipogenic	  differentiation	  is	  altered.	  	  For	  example,	  in	  elderly	  individuals	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normal	  adipogenic	  differentiation	  is	  suppressed	  [387,	  391,	  392],	  a	  process	  that	  is	  heavily	  
influenced	  by	  ROS	  regulated-­‐CHOP	  signaling	  [387,	  393-­‐395].	  	  	  
Furthermore	  normal	  adipocyte	  function	  is	  altered	  by	  dysregulation	  of	  normal	  
ROS	  production	  resulting	  in	  oxidative	  stress.	  	  Along	  with	  the	  direct	  insults	  of	  reactive	  
oxygen	  stress	  already	  discussed	  (DNA	  and	  protein	  damage,	  apoptosis,	  necrosis,	  etc.)	  a	  
number	  of	  cellular	  alterations	  have	  been	  described	  in	  adipocytes	  in	  response	  to	  
oxidative	  stress	  including	  unfolded	  protein	  response	  (UPR)	  [396],	  alterations	  in	  
adipokine	  production	  [397-­‐403],	  and	  an	  inflammatory	  response	  [396,	  403-­‐406].	  	  
Together,	  these	  alterations	  in	  normal	  cellular	  physiology	  contribute	  to	  disease	  states.	  	  
For	  example,	  oxidative	  stress	  in	  adipocytes	  is	  associated	  with	  the	  metabolic	  syndrome,	  
causes	  insulin	  resistance	  and	  further	  progression	  into	  type	  II	  diabetes	  [398,	  403,	  407-­‐
414].	  	  Other	  less	  studied	  diseases	  associated	  with	  oxidative	  stress	  in	  adipose	  tissue	  
include	  chronic	  kidney	  disease	  [406],	  atherosclerosis	  [400],	  arthritis	  [415],	  and	  sleep	  
apnea	  [416].	  	  These	  disease	  state	  correlations	  demonstrate	  the	  importance	  of	  regulation	  
of	  ROS	  production	  in	  adipocytes	  for	  maintenance	  of	  normal	  whole	  animal/human	  
physiology.	  	  	  
E.5	  Aerobic	  glycolysis	  as	  a	  protection	  against	  damaging	  ROS	  
Tumor	  cells	  demonstrate	  a	  high	  degree	  of	  ROS	  and	  require	  careful	  mechanisms	  
to	  keep	  ROS	  in	  balance	  to	  prevent	  reactive	  oxygen	  stress	  mediated	  damage	  [417].	  	  As	  
for	  most	  cells,	  the	  terminal	  steps	  of	  aerobic	  metabolism	  (the	  electron	  transport	  chain)	  is	  
the	  primary	  source	  of	  metabolically-­‐derived	  ROS	  in	  tumor	  cells.	  	  Many	  tumor	  cells	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reduce	  ROS	  generation	  rates	  by	  increasing	  the	  fraction	  of	  ATP	  generated	  through	  
glycolytic	  metabolism	  in	  the	  cytosol	  as	  opposed	  to	  ROS-­‐producing	  oxidative	  metabolism	  
in	  the	  mitochondria	  [418].	  	  Essentially	  by	  employing	  this	  (Warburg	  effect/aerobic	  
glycolysis),	  they	  limit	  overproduction	  of	  ROS	  reducing	  detrimental	  reactive	  oxygen	  
stress.	  	  This	  has	  been	  validated	  in	  a	  number	  of	  human	  clinical	  trials	  with	  therapeutic	  
mechanisms	  of	  preventing	  tumor	  cell	  aerobic	  glycolysis	  and	  its	  associated	  cytoprotective	  
effects	  against	  ROS	  over-­‐production	  resulting	  in	  tumor	  cell	  death.	  	  A	  number	  of	  
suspected	  regulators	  of	  aerobic	  glycolysis	  have	  been	  targeted	  to	  induce	  this	  ROS	  
mediated	  tumor	  cell	  cytolethality	  including	  PKM2	  [419,	  420],	  LDHA	  [285,	  421,	  422],	  and	  
the	  PDKs	  [423-­‐429].	  	  This	  demonstrates	  that	  purposeful	  alterations	  in	  cellular	  
metabolism	  (upregulation	  of	  aerobic	  glycolysis)	  can	  be	  employed	  by	  cells	  as	  
cytoprotection	  against	  detrimental	  reactive	  oxygen	  stress.	  	  	  
E.6	  Metabolic	  ROS	  summary	  
Reactive	  oxygen	  species	  are	  primarily	  generated	  metabolically	  through	  the	  
terminal	  steps	  oxidative	  phosphorylation	  in	  the	  electron	  transport	  chain.	  	  These	  ROS	  can	  
serve	  a	  beneficial	  signaling	  role	  regulating	  multiple	  cellular	  processes,	  but	  dysregulated	  
overproduction	  of	  ROS	  can	  be	  detrimental	  to	  normal	  cellular	  function	  and	  even	  lead	  to	  
cell	  death.	  	  In	  adipose	  tissue,	  ROS	  have	  demonstrated	  a	  role	  in	  regulating	  cellular	  
function,	  but	  when	  dysregulated,	  reactive	  oxygen	  stress	  contributes	  to	  cellular	  
dysfunction	  and	  multiple	  disease	  states.	  	  This	  suggests	  that	  regulation	  of	  ROS	  (limiting	  
overproduction	  of	  ROS)	  critical	  for	  normal	  adipocyte	  function.	  	  Tumor	  cells	  have	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demonstrated	  the	  ability	  to	  switch	  to	  a	  metabolic	  phenotype	  characterized	  by	  elevated	  
lactate	  production	  from	  the	  Warburg	  Effect	  or	  aerobic	  glycolysis.	  	  In	  these	  cells,	  this	  
regulates	  reactive	  oxygen	  stress	  for	  cytoprotective	  purposes.	  	  Adipose	  tissue	  has	  also	  
demonstrated	  the	  ability	  to	  produce	  lactate,	  	  and	  though	  it	  has	  not	  been	  explored,	  
perhaps	  lactate	  production	  from	  adipocytes	  is	  the	  result	  of	  an	  ability	  to	  alter	  their	  
metabolic	  phenotype	  to	  aerobic	  glycolysis	  as	  a	  protective	  mechanism	  against	  over	  
production	  of	  ROS.	  	  This	  dissertation	  attempts	  to	  demonstrate	  a	  potential	  role	  of	  a	  
Warburg-­‐like	  phenotype	  as	  a	  protective	  mechanism	  regulated	  in	  adipocytes	  against	  
detrimental	  production	  of	  ROS.	  	  	  
	  
F.	  	  PDKs	  
F.1	  Intro	  
The	  PDKs	  (pyruvate	  dehydrogenase	  kinases)	  are	  a	  series	  of	  enzymes	  that	  
regulate	  oxidative	  and	  glycolytic	  metabolism	  with	  tissue	  dependent	  differential	  
expression.	  	  As	  a	  whole	  they	  function	  to	  decrease	  the	  amount	  of	  oxidative	  metabolism	  
by	  reducing	  the	  activity	  of	  the	  pyruvate	  dehydrogenase	  complex.	  	  They	  have	  been	  
extensively	  studied	  in	  terms	  of	  regulation	  with	  some	  roles	  in	  adipose	  tissue	  for	  
macromolecule	  generation.	  	  A	  number	  of	  pharmacologic	  regulators	  have	  been	  identified	  
that	  have	  been	  used	  in	  studies	  with	  tumor	  cells	  identifying	  a	  role	  for	  the	  PDKs	  in	  
regulating	  the	  Warburg	  effect	  in	  these	  models.	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F.2	  Pyruvate	  dehydrogenase	  complex	  and	  PDK	  function	  
The	  “selection”	  between	  executing	  glycolytic	  (glycolysis	  coupled	  with	  lactic	  acid	  
fermentation)	  and	  oxidative	  metabolism	  is	  dependent	  upon	  the	  fate	  of	  pyruvate,	  after	  
pyruvate	  is	  generated	  through	  the	  oxygen-­‐independent	  breakdown	  of	  glucose	  through	  
glycolysis.	  	  Pyruvate	  can	  be	  turned	  into	  lactate	  through	  an	  oxygen-­‐independent	  method	  
(lactic	  acid	  fermentation)	  only	  generating	  energy	  from	  the	  ATP	  generated	  in	  the	  payoff	  
phase	  of	  glycolysis	  or	  it	  can	  be	  further	  oxidized	  (oxidative	  phosphorylation)	  through	  
conversion	  to	  acetyl-­‐Coenzyme	  A	  and	  transport	  into	  the	  mitochondria	  fueling	  the	  TCA	  
cycle	  generating	  energy	  by	  powering	  the	  electron	  transport	  chain	  through	  NADH	  and	  
FADH2	  production.	  	  The	  balance	  of	  how	  much	  glycolytic	  and	  oxidative	  metabolism	  a	  cell	  
runs	  depends	  primarily	  upon	  regulation	  of	  pyruvate’s	  conversion	  to	  acetyl-­‐Coenzyme	  A.	  	  
With	  slower	  conversion	  to	  acetyl-­‐CoA	  even	  in	  normoxic	  conditions,	  pyruvate	  
accumulates	  and	  is	  converted	  to	  lactate	  increasing	  the	  cell’s	  fraction	  of	  energy	  
generation	  from	  glycolytic	  metabolism.	  	  When	  acetyl-­‐CoA	  is	  rapidly	  formed,	  pyruvate	  is	  
less	  likely	  to	  be	  converted	  to	  lactate	  and	  the	  cell’s	  fraction	  of	  energy	  generation	  from	  
oxidative	  metabolism	  increases.	  	  
The	  formation	  of	  acetyl-­‐CoA	  from	  pyruvate	  is	  achieved	  by	  the	  pyruvate	  
dehydrogenase	  complex	  (PDC).	  	  PDC	  regulates	  the	  transformation	  of	  pyruvate	  into	  
acetyl-­‐CoA	  producing	  NADH	  in	  the	  process.	  	  As	  a	  member	  of	  the	  2-­‐oxo	  acid	  
dehydrogenase	  complexes,	  PDC	  is	  a	  multienzyme	  complex	  with	  copies	  of	  three	  
enzymes;	  these	  are	  termed	  E1,	  E2,	  and	  E3.	  	  E1	  is	  considered	  a	  2-­‐oxo	  acid	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dehydrogenase;	  E2	  is	  a	  dihydrolipoamide	  acetyl	  transferase;	  and	  E3	  is	  an	  FAD-­‐containing	  
dihydrolipoamide	  dehydrogenase;	  these	  subunits	  assemble	  in	  the	  mitochondria	  [430-­‐
432].	  	  The	  E1	  complex	  contains	  30	  tetrameric	  pyruvate	  dehydrogenase	  (PDH)	  
components,	  the	  E2	  subunit	  which	  binds	  	  to	  E1	  is	  made	  of	  a	  60-­‐meric	  dihydrolipoamide	  
acetyl	  transferase	  ,	  which	  is	  also	  bound	  to	  the	  E3	  subunit	  containing	  multiple	  copies	  of	  
homodimeric	  dihydrolipoamide	  dehydrogenase	  [430,	  432].	  	  Acetyl	  groups	  from	  the	  E2	  
subunit	  of	  PDC	  are	  transferred	  onto	  oxidatively	  decarboxylated	  pyruvate	  (action	  from	  
the	  E1	  subunit)	  forming	  acetyl-­‐CoA	  [430].	  	  This	  formation	  of	  acetyl-­‐CoA	  is	  irreversible.	  	  	  
PDC	  activity	  is	  regulated	  by	  the	  phosphorylation	  state	  of	  PDH	  demonstrating	  
inactivation	  by	  phosphorylation.	  	  There	  are	  four	  pyruvate	  dehydrogenase	  kinases	  (PDK)	  
that	  actively	  phosphorylate	  PDC	  and	  two	  pyruvate	  dehydrogenase	  phosphatases	  (PDP)	  
dephosphorylating	  PDC	  that	  are	  essentially	  responsible	  for	  regulation	  of	  the	  
phosphorylation	  state	  of	  PDH.	  	  The	  PDH	  PDPs	  are	  phosphoprotein	  phosphatase	  2C	  
family	  members	  [430,	  433,	  434].	  	  Of	  these	  two	  phosphatases,	  PDP1	  is	  primarily	  
expressed	  in	  muscle,	  but	  also	  detected	  in	  heart	  and	  brain;	  while	  PDP2	  is	  primarily	  found	  
in	  adipose	  tissue	  but	  also	  expressed	  in	  kidney,	  brain,	  and	  heart	  [430,	  433,	  435].	  	  	  
This	  section	  will	  focus	  on	  the	  activity	  of	  the	  PDKs.	  	  The	  PDKs	  bind	  to	  lipoyl	  
domains	  of	  E2	  and	  E3	  binding	  protein	  (E3BP)	  to	  gain	  access	  to	  the	  phosphorylation	  sites	  
on	  the	  E1	  α	  component	  where	  they	  regulate	  PDH	  and	  subsequently	  PDC	  by	  site-­‐specific	  
phosphorylation	  [430,	  436,	  437].	  	  There	  are	  three	  sites	  on	  PDH	  that	  are	  phosphorylated:	  	  
Ser264	  (site	  1),	  Ser271	  (site	  2),	  and	  Ser203	  (site	  3).	  	  As	  the	  pyruvate	  dehydrogenase	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(PDH)	  subunit	  of	  PDC	  exists	  as	  a	  heterotetramer	  (α2β2),	  there	  are	  six	  sites	  available	  on	  
PDH	  for	  phosphorylation.	  	  Although	  phosphorylation	  at	  any	  one	  of	  the	  sites	  is	  sufficient	  
suppress	  PDC	  activity	  [438-­‐441],	  the	  mechanism	  of	  inhibition	  is	  different	  at	  each	  site	  
with	  the	  majority	  of	  phosphorylation	  occurring	  at	  site	  1	  compared	  to	  sites	  2	  and	  3	  [442].	  	  	  
F.3	  Differential	  expression	  and	  activities	  of	  PDKs	  
There	  are	  five	  mitochondrial	  protein	  kinases	  encoded	  in	  eukaryotic	  cells.	  	  Four	  of	  
the	  five	  are	  the	  PDKs	  have	  already	  been	  mentioned.	  	  The	  final	  protein	  kinase	  in	  all	  
eukaryotic	  cells	  is	  a	  branched-­‐chain	  α-­‐keto	  acid	  dehydrogenase	  [430,	  443-­‐445].	  	  In	  
mammals,	  the	  four	  PDKs	  demonstrate	  differential	  expression	  in	  different	  tissues	  [430,	  
435,	  446].	  	  PDK1	  is	  present	  in	  the	  heart	  with	  lower	  levels	  in	  pancreas,	  liver	  and	  muscle.	  	  
PDK2	  is	  more	  ubiquitously	  expressed	  being	  found	  in	  many	  tissues.	  	  And	  PDK3	  is	  found	  
mostly	  in	  testis	  and	  to	  a	  lesser	  extent	  in	  the	  kidneys,	  brain,	  and	  lungs,	  and	  PDK4	  is	  highly	  
expressed	  in	  skeletal	  muscle	  and	  heart	  with	  variable	  levels	  in	  lung,	  liver	  and	  kidney.	  	  	  
To	  determine	  the	  activities	  of	  each	  of	  the	  four	  PDKs,	  PDC	  was	  reconstituted	  with	  
specific	  mutagenesis	  at	  two	  of	  the	  three	  phosphorylation	  sites	  (alanine	  substitution)	  to	  
allow	  phosphorylation	  of	  only	  one	  functional	  serine	  (one	  site)	  [447].	  	  These	  studies	  
demonstrated	  that	  all	  four	  PDKs	  can	  phosphorylate	  sites	  one	  and	  two	  (Ser293,	  Ser300),	  
while	  only	  PDK1	  phosphorylates	  site	  three	  of	  PDH	  (Ser232,	  Ser293,	  Ser300).	  	  Differential	  
rates	  of	  phosphorylation	  were	  observed	  for	  sites	  1	  and	  2	  for	  the	  different	  enzymes	  in	  
phosphate	  buffered	  saline.	  	  For	  site	  1:	  	  PDK2	  >	  PDK4,PDK1	  >	  PDK3;	  	  for	  site	  2:	  PDK3	  
>PDK4	  >	  PDK2	  >	  PDK1.	  	  Site	  specific	  alterations	  in	  phosphorylation	  coupled	  with	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differential	  tissue	  expression	  is	  most	  likely	  responsible	  for	  unique	  tissue	  regulation	  of	  
PDC	  activity	  in	  both	  normal	  and	  pathophysiologic	  states	  [430,	  435,	  446,	  447].	  	  	  
F.4	  Regulation	  of	  PDK	  expression	  
PDC	  demonstrates	  both	  short-­‐term	  and	  long-­‐term	  regulation	  by	  
phosphorylation.	  	  Rapid	  alterations	  in	  phosphorylation	  state	  and	  therefore	  activity	  of	  
PDC	  are	  achieved	  by	  pyruvate	  dehydrogenase	  phosphatase	  (PDP1)	  (activated	  by	  Ca2+)	  
and	  PDK	  (activated	  by	  acetyl-­‐CoA	  and	  NADH	  and	  inhibited	  by	  pyruvate)	  [430,	  433].	  	  
From	  rodent	  and	  in	  vitro	  studies,	  more	  long-­‐term	  regulation	  of	  PDC	  has	  been	  proposed	  
to	  be	  achieved	  by	  relative	  expression	  of	  PDKs	  in	  a	  given	  tissue	  under	  various	  physiologic	  
and	  pathophysiologic	  conditions	  [430,	  443,	  448].	  	  	  
In	  vivo	  studies	  in	  rat	  have	  demonstrated	  long	  term	  regulation	  of	  PDC	  activity	  
through	  alterations	  in	  PDK	  expression.	  	  PDKs	  1,2	  and	  4	  are	  expressed	  in	  rat	  heart	  with	  
PDK	  4	  demonstrating	  increased	  expression	  associated	  with	  decreased	  PDC	  activity	  under	  
starvation	  and	  diabetic	  conditions	  [430,	  448-­‐451].	  	  Similarly,	  both	  diabetic	  state	  and	  
starvation	  correlate	  with	  increased	  skeletal	  muscle	  levels	  of	  PDK4	  and	  PDK2	  (smaller	  
increase)	  [430,	  452,	  453].	  	  PDK2	  expression	  increases	  as	  does	  PDK4	  to	  a	  lesser	  extent	  
preserving	  three	  carbon	  sources	  for	  gluconeogenesis	  under	  starvation	  in	  rat	  liver	  [430,	  
453-­‐455].	  	  Glucose	  production	  is	  also	  protected	  in	  the	  kidney	  during	  starvation	  by	  
increased	  expression	  of	  PDK4	  and	  PDK2	  [430,	  453,	  456].	  	  In	  lactating	  rats,	  PDK4	  and	  
PDK2	  are	  increased	  with	  starvation	  most	  likely	  responsible	  for	  the	  inactivation	  of	  
lipogenesis	  necessary	  for	  normal	  milk	  production	  [430,	  457,	  458].	  	  All	  these	  studies	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taken	  together	  demonstrate	  the	  critical	  role	  that	  has	  been	  described	  for	  PDKs	  
(especially	  PDK4	  and	  PDK2)	  in	  regulating	  response	  to	  starvation	  and	  in	  the	  diabetic	  
state.	  	  Contrary	  to	  what	  has	  been	  observed	  in	  the	  above	  tissues,	  starvation	  
demonstrated	  no	  effect	  on	  PDK2	  and	  PDK4	  protein	  expression	  (though	  a	  two	  fold	  
increase	  in	  message	  was	  observed	  in	  PDK4)	  [453]	  with	  no	  increase	  in	  PDC	  activity	  in	  
brain	  [459].	  	  However,	  from	  these	  studies	  it	  is	  difficult	  to	  determine	  in	  minute	  
subpopulations	  of	  neurons	  may	  demonstrate	  response	  to	  starvation.	  	  	  
A	  number	  of	  ligands	  have	  demonstrated	  regulation	  of	  PDK	  expression	  as	  well.	  	  
Treatment	  of	  rats	  with	  the	  stable	  fatty	  acid	  surrogate	  WY-­‐14,643	  elicits	  an	  increase	  in	  
PDK	  activity	  and	  PDK4	  expression	  in	  skeletal	  muscle	  and	  liver	  through	  PPARα	  dependent	  
mechanisms	  [430].	  	  Similar	  findings	  were	  observed	  in	  vitro;	  after	  treating	  7800C1	  
hepatoma	  cells	  with	  WY-­‐14,643,	  PDK4	  message	  significantly	  increased	  [430,	  460].	  	  In	  
this	  cell	  line	  and	  in	  HepG2	  cells,	  dexamethasone	  (glucocorticoid)	  treatment	  results	  in	  
increased	  expression	  of	  PDK4	  through	  a	  Protein	  Kinase	  B-­‐α	  mechanism	  [430,	  461].	  	  
Consistent	  with	  expectation	  based	  on	  effects	  of	  diabetic	  and	  fasted	  states	  (increased	  
PDK),	  insulin	  and	  refeeding	  demonstrate	  reversal	  of	  the	  increased	  PDK4	  expression	  
associated	  with	  those	  metabolic	  and	  disease	  states	  [430,	  451,	  453].	  	  Similarly,	  insulin	  
antagonizes	  the	  dexamethasone	  affect	  reducing	  dexamethasone	  stimulated	  increases	  in	  
PDK4	  and	  effectively	  reduces	  PDK2	  expression	  in	  the	  presence	  of	  both	  WY-­‐14,643	  and	  
dexamethasone	  [430,	  461].	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PDK	  regulation	  of	  PDC	  (and	  associated	  PDP	  regulation)	  are	  thought	  to	  also	  play	  a	  
critical	  role	  in	  regulating	  blood	  glucose,	  this	  has	  been	  reviewed	  by	  Harris	  et	  al	  [462].	  	  In	  
the	  well-­‐fed	  state,	  directing	  carbon	  from	  pyruvate	  to	  the	  citric	  acid	  cycle	  by	  highly	  active	  
PDC	  helps	  to	  reduce	  total	  blood	  glucose.	  	  Similarly,	  in	  low-­‐glucose	  states,	  the	  reduction	  
of	  PDC	  activity	  (by	  PDK	  action)	  conserves	  pyruvate	  for	  gluconeogenic	  activities	  in	  the	  
liver.	  	  These	  hypotheses	  are	  increasing	  the	  interest	  in	  pharmacologic	  regulation	  of	  PDK	  
as	  a	  potential	  target	  for	  diabetic	  care.	  	  Supporting	  the	  therapeutic	  potential	  of	  PDK	  
modulation,	  PDK4	  knockout	  in	  animals	  demonstrated	  lowered	  fasting	  glucose	  [463],	  
improved	  performance	  in	  glucose	  tolerance	  tests	  [464],	  and	  reduced	  negative	  effects	  of	  
long-­‐term	  high	  saturated	  fat	  diet	  [465].	  	  Similarly,	  interest	  has	  grown	  in	  the	  potential	  
association	  of	  PDK4	  polymorphisms	  with	  diabetes,	  though	  further	  studies	  with	  larger	  
cohorts	  are	  most	  likely	  required	  to	  definitively	  identify	  strong	  correlations	  between	  the	  
identified	  single	  nucleotide	  polymorphisms	  (SNPs)	  and	  diabetes	  [466].	  	  	  
F.5	  PDKs	  in	  adipose	  tissue.	  
Studies	  examining	  the	  effects	  of	  starvation	  on	  white	  adipose	  tissue	  
demonstrated	  no	  increase	  in	  PDK2	  or	  PDK4	  protein	  [467].	  	  However,	  four-­‐fold	  increase	  
in	  PDK4	  message	  is	  observed	  in	  white	  adipose	  in	  	  response	  to	  starvation	  [467].	  	  In	  
adipose	  tissue,	  PDP	  plays	  a	  role	  in	  the	  short	  term	  regulation	  of	  PDC	  activity	  in	  an	  insulin	  
dependent	  method	  [468,	  469]which	  may	  be	  sufficient	  for	  response	  to	  starvation	  and	  the	  
decrease	  in	  systemic	  insulin	  levels.	  	  Longer	  term	  starvation	  studies	  have	  not	  been	  
reported	  but	  may	  perhaps	  demonstrate	  significant	  changes	  in	  PDK4	  expression	  in	  white	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adipose	  tissue	  as	  a	  mechanism	  of	  long-­‐term	  regulation.	  	  In	  3T3-­‐L1	  adipocytes	  both	  
prolactin	  and	  growth	  hormone	  treatment	  increased	  PDK4	  expression	  in	  a	  STAT5	  
dependent	  manner	  [470].	  	  In	  parallel	  3T3-­‐L1	  studies,	  the	  elevated	  PDK4	  associated	  with	  
growth	  hormone	  and	  prolactin	  treatment	  decreased	  insulin	  stimulated	  glucose	  uptake	  
[470]	  and	  has	  been	  proposed	  as	  a	  contributor	  to	  	  prolactin-­‐induced	  insulin	  resistance.	  	  	  
In	  white	  adipose	  tissue	  lipolysis	  and	  free	  fatty	  acid	  re-­‐esterification	  to	  glycerol	  
are	  critical	  for	  regulating	  non-­‐esterified	  fatty	  acid	  (NEFA)	  release	  and	  uptake/storage	  
requiring	  glycerol	  as	  a	  substrate	  for	  such	  reactions	  [471,	  472].	  	  This	  requires	  synthesis	  of	  
glycerol-­‐3-­‐phosphate	  (G3P)	  mostly	  generated	  from	  lactate	  and	  pyruvate	  through	  
glyceroneogenesis	  [473,	  474].	  	  As	  this	  pathway	  requires	  lactate	  and/or	  pyruvate	  as	  
substrate,	  PDK	  inhibition	  of	  the	  PDC	  conversion	  of	  pyruvate	  to	  Acetyl-­‐CoA	  (decreasing	  
PDC	  activity)	  benefits	  glyceroneogenesis.	  	  Accordingly,	  human	  white	  adipose	  tissue	  
explants	  and	  3T3-­‐F442A	  adipocytes	  treated	  with	  rosiglitazone	  (PPARγ	  agonist)	  
demonstrated	  increases	  in	  PDK4	  associated	  with	  increased	  rates	  of	  glyceroneogenesis	  
[471].	  	  Inhibition	  of	  PDK	  activity	  with	  pharmacologic	  inhibitors	  leelamine	  and	  
dichloroacetic	  acid	  (DCA)	  altered	  NEFA	  release	  in	  both	  basal	  and	  rosiglitazone	  treated	  
states	  indicating	  PDK4’s	  role	  in	  glyceroneogenesis	  in	  adipocytes.	  	  	  
F.6	  Pharmacologic	  regulation	  of	  PDKs	  
Leelamine	  has	  been	  identified	  as	  a	  relatively	  specific	  small	  molecule	  inhibitor	  of	  
PDKs	  [475].	  	  Treatment	  causes	  PDK	  inhibition	  resulting	  in	  decreased	  glyceroneogenesis	  
in	  adipocytes	  [471]	  and	  lowers	  blood	  glucose	  in	  ob/ob	  mice	  [475].	  	  Thus,	  leelamine	  has	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emerged	  as	  one	  of	  the	  leading	  candidates	  for	  the	  potential	  treatment	  of	  hyperglycemia	  
by	  targeting	  PDKs	  [462]	  and	  as	  a	  tool	  for	  modulating	  PDK	  activity	  in	  vitro	  and	  ex	  vivo	  
[471].	  	  Similarly,	  dichloroacetate	  (DCA)	  has	  demonstrated	  PDK	  inhibition	  and	  lowers	  
blood	  glucose	  [476-­‐478].	  	  2-­‐chloroproprionate	  and	  α-­‐lipoic	  acid	  both	  inhibit	  PDKs	  and	  
have	  demonstrated	  some	  level	  of	  lowering	  blood	  glucose	  [479-­‐481].	  	  Other	  small	  
molecule	  PDK	  inhibitors	  have	  been	  synthesized	  by	  pharmaceutical	  companies	  with	  
various	  potencies	  against	  the	  different	  PDKs	  in	  hopes	  of	  generating	  small	  molecule	  
therapies	  for	  diabetes.	  	  These	  include	  SDZ048-­‐619	  and	  AZD7545-­‐43	  which	  have	  
demonstrated	  decreased	  gluconeogenesis	  in	  liver	  and	  enhanced	  oxidative	  capacity	  in	  
skeletal	  muscle	  [482-­‐485].	  	  	  
F.7	  Cytoprotective	  role	  of	  PDKs	  in	  regulating	  aerobic	  glycolysis	  and	  ROS	  production	  in	  
cancer	  cells	  
As	  previously	  reviewed,	  aerobic	  glycolysis	  or	  an	  increased	  production	  of	  lactate	  
without	  a	  change	  in	  oxygen	  tension	  has	  been	  most	  clearly	  described	  in	  cancer	  cells.	  	  As	  
previously	  discussed,	  this	  confers	  some	  level	  of	  survival	  or	  resistance	  to	  apoptosis	  
through	  reduction	  of	  metabolically	  produced	  ROS.	  	  The	  aerobic	  glycolysis	  phenotype	  has	  
been	  considered	  to	  be	  regulated	  primarily	  by	  HIF-­‐1α	  and	  its	  molecular	  targets.	  	  More	  
recently	  PDKs	  have	  been	  identified	  as	  one	  of	  the	  key	  downstream	  regulators	  of	  the	  
concurrently	  increased	  lactate	  production	  and	  associated	  decreased	  ROS	  in	  tumor	  cells,	  
conferring	  cytoprotection	  [486,	  487].	  	  Multiple	  studies	  in	  cancer	  cells	  have	  confirmed	  
the	  PDK	  regulation	  of	  aerobic	  glycolysis	  in	  cancer	  cells.	  	  Overexpression	  of	  a	  less	  active	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PDK	  leads	  to	  decreased	  lactate	  production,	  increased	  ROS	  production,	  cell	  death,	  and	  
failure	  of	  tumor	  formation	  in	  xenograft	  models	  [488].	  	  Similarly,	  pharmacologic	  
inhibition	  of	  PDK	  in	  multiple	  cancer	  cell	  lines	  A549,	  M059K,	  and	  MCF-­‐7	  resulted	  in	  
decreased	  lactate	  production,	  increased	  ROS	  and	  apoptosis	  [489].	  	  In	  another	  study,	  
pharmacologic	  inhibition	  of	  PDK	  resulted	  in	  a	  reversal	  of	  glycolytic	  phenotype,	  
decreased	  proliferation	  rate,	  increased	  apoptosis,	  and	  reduced	  tumor	  growth	  in	  
multiple	  breast	  cancer	  models	  [490].	  	  In	  head	  and	  neck	  squamous	  cancer	  (HNSCC),	  PDK1	  
was	  found	  to	  be	  elevated	  in	  human	  tumor	  biopsies	  compared	  to	  normal	  tissue	  and	  was	  
more	  predominantly	  expressed	  in	  patients	  who	  demonstrated	  local	  recurrence	  and	  
metastasis	  [491].	  	  Studies	  on	  HNSCC	  lines	  demonstrated	  decreased	  lactate	  production	  
and	  decreased	  proliferation	  rates	  as	  well	  [491].	  	  These	  findings	  have	  led	  to	  PDKs	  as	  an	  
interesting	  target	  for	  tumor	  therapy	  with	  a	  mechanism	  to	  remove	  the	  cytoprotective	  
role	  of	  aerobic	  glycolysis	  in	  cancer	  cells	  [492,	  493].	  	  Altogether	  this	  body	  of	  research	  
demonstrates	  the	  central	  role	  of	  PDKs	  as	  key	  regulators	  of	  aerobic	  glycolysis.	  	  	  
F.8	  PDKs	  	  summary	  
With	  the	  well-­‐defined	  function	  of	  PDKs	  in	  regulating	  oxidative	  and	  glycolytic	  
metabolism	  and	  their	  expression	  in	  adipocytes	  it	  is	  possible	  that	  they	  play	  a	  role	  in	  
regulating	  metabolic	  phenotype	  in	  this	  tissue.	  	  Their	  role	  in	  cancer	  cells	  suggests	  that	  
they	  could	  regulate	  lactate	  production	  in	  adipocytes	  as	  well.	  	  This	  dissertation	  will	  
examine	  these	  possibilities	  using	  expression	  studies	  of	  PDKs	  in	  undifferentiated	  and	  
differentiated	  cells	  in	  which	  metabolic	  phenotype	  shifts	  are	  observed.	  	  Using	  the	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previously	  discovered	  pharmacologic	  inhibitors,	  the	  potential	  regulatory	  role	  of	  PDKs	  in	  
adipocyte	  metabolism	  will	  be	  further	  dissected.	  	  	  
G.	  	  Summary	  of	  Introduction	  and	  Statement	  of	  Hypothesis	  
With	  the	  broad	  pathophysiologies	  and	  co-­‐morbidities	  associated	  with	  obesity	  
and	  its	  epidemic	  proportions,	  a	  better	  understand	  of	  adipose	  tissue	  and	  more	  
importantly	  adipocyte	  biology	  has	  emerged	  as	  a	  critical	  area	  of	  physiologic	  studies.	  	  
While	  lactate	  production	  has	  been	  observed	  in	  adipose	  tissue,	  how	  this	  occurs	  at	  a	  
cellular	  level,	  the	  utility	  of	  lactate	  production	  by	  the	  adipocyte,	  and	  how	  this	  is	  regulated	  
are	  not	  understood.	  	  Our	  central	  hypothesis	  is	  that	  differentiated	  adipocytes	  
demonstrate	  a	  PDK-­‐regulated	  Warburg-­‐like	  effect	  protecting	  against	  detrimental	  
elevation	  of	  ROS.	  	  	  







A.	  	  Adipogenic	  Model	  
To	  understand	  the	  metabolic	  phenotype	  of	  human	  adipocytes	  we	  optimized	  and	  
characterized	  	  a	  model	  of	  human	  adipogenic	  differentiation	  starting	  with	  human	  
adipocyte	  precursors	  (ASCs)	  from	  the	  stromal	  vascular	  fraction	  of	  human	  adipose	  tissue.	  	  
Substantial	  time	  and	  effort	  was	  put	  into	  this	  model	  to	  be	  sure	  we	  had	  appropriate	  
differentiation	  and	  complete	  differentiation	  so	  that	  inferences	  made	  about	  metabolism	  
of	  adipocytes	  (especially	  compared	  to	  their	  preadipocyte	  precursors)	  would	  be	  as	  
reliable	  and	  predictive	  of	  human	  adipocyte	  biology	  as	  possible	  when	  using	  a	  
differentiation	  model	  to	  emulate	  the	  mature	  cells.	  	  	  
A.1	  Isolation	  and	  culture	  of	  human	  preadipocytes	  
To	  study	  adipocyte	  metabolism,	  human	  preadipocytes	  were	  isolated	  from	  the	  
stromal	  vascular	  fraction	  of	  lipoaspirate	  and	  differentiated	  into	  mature	  adipocytes.	  	  
Liposuction	  is	  a	  procedure	  in	  which	  patients	  undergo	  anesthesia	  either	  as	  intravenous	  
sedation	  or	  general	  anesthesia	  followed	  by	  infusion	  into	  the	  adipose	  tissue	  and	  
loosening	  of	  excess	  fat	  using	  a	  cannula	  inserted	  through	  small	  incisions.	  	  The	  dislodged	  
fat	  is	  suctioned	  out	  of	  the	  body	  using	  surgical	  vacuum	  or	  syringe	  attached	  to	  the	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cannula.	  	  	  The	  dislodged	  tissue	  or	  lipoaspirate	  is	  usually	  discarded,	  but	  it	  can	  serve	  	  as	  a	  
large	  source	  of	  ASCs.	  	  Through	  collagenase	  digestion	  the	  unprocessed	  lipoaspirate	  is	  
rendered	  into	  a	  primarily	  single	  cell	  suspension.	  	  Subsequent	  red	  blood	  cell	  lysis	  and	  
centrifugation	  separates	  the	  more	  buoyant	  adipocytes	  from	  the	  stromal	  vascular	  
fraction	  (SVF)	  which	  pellets	  at	  the	  bottom	  of	  the	  tube.	  	  (Fig.	  1a).	  	  	  These	  two	  populations	  
are	  visibly	  separate	  in	  conical	  tubes	  after	  centrifugation	  (Fig.	  1b).	  	  The	  SVF	  after	  plating	  
on	  tissue	  culture	  treated	  plastic	  obtains	  a	  fibroblast	  like	  appearance.	  	  The	  cells	  
proliferate	  rapidly,	  maintaining	  a	  spindle-­‐like	  fibroblast	  morphology	  when	  plated	  in	  




Figure	  1.	  	  Isolation	  of	  ASCs.	  	  Isolation	  of	  ASCs	  from	  lipoaspirate	  or	  minced	  
abdominoplasty	  tissue	  general	  flow	  scheme	  a.	  	  After	  digestion	  and	  centrifugation	  an	  
image	  of	  separated	  adipocytes	  and	  the	  stromal	  vascular	  fraction	  b.	  	  After	  isolation	  and	  









A.2	  Cellular	  homogeneity	  
As	  with	  any	  model	  of	  differentiation	  it	  is	  important	  that	  the	  cellular	  material	  
used	  for	  differentiation	  is	  well-­‐defined,	  that	  is	  an	  understanding	  of	  what	  is	  being	  
differentiated	  is	  critical	  to	  controlling	  the	  experiment.	  	  This	  becomes	  more	  complicated	  
when	  the	  starting	  material	  for	  differentiation	  is	  primary	  isolated	  cells	  from	  tissue.	  	  In	  
modeling	  human	  adipogenic	  differentiation	  to	  obtain	  primary	  differentiated	  adipocytes,	  
the	  beginning	  material	  comes	  from	  the	  previously-­‐described	  SVF.	  	  This	  contains	  
contaminating	  cell	  types	  (non	  adipocyte	  precursors)	  that	  can	  alter	  final	  differentiated	  
populations.	  	  It	  is	  critical	  that	  we	  demonstrate	  the	  potential	  contaminating	  cell	  types	  
associated	  with	  isolation	  of	  the	  adipose	  stromal	  vascular	  fraction	  are	  essentially	  absent	  
from	  our	  differentiation	  model.	  	  By	  doing	  this	  we	  can	  be	  more	  confident	  of	  our	  findings	  
associated	  with	  differentiation	  and	  adipocyte	  metabolism.	  	  	  
Similar	  to	  what	  has	  been	  described	  in	  mice,	  confocal	  microscopy	  of	  isolated	  
human	  subcutaneous	  adipose	  tissue	  demonstrates	  a	  high	  degree	  of	  vasculature	  (Figure	  
2a,	  b).	  	  This	  can	  contribute	  endothelial	  cells	  to	  the	  SVF	  as	  a	  contaminating	  population.	  	  
Similarly,	  it	  is	  well	  documented	  that	  there	  is	  potential	  for	  a	  large	  leukocyte	  population	  
(primarily	  macrophage)	  in	  adipose	  tissue	  that	  can	  also	  contribute	  to	  non-­‐adipocyte	  
precursors	  in	  the	  SVF.	  	  Both	  the	  endothelial	  cells	  and	  leukocytes	  (macrophage)	  along	  
with	  the	  ASCs	  collect	  in	  the	  SVF	  from	  adipose	  tissue	  while	  the	  adipocytes	  remain	  in	  the	  
more	  buoyant	  adipocyte	  fraction	  (Figure	  3)	  generating	  the	  potential	  for	  contaminating	  
populations	  in	  primary	  ASC	  isolation.	  With	  this	  potential	  contamination	  in	  the	  SVF	  we	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examined	  the	  cell	  cultures	  we	  used	  for	  adipocyte	  differentiation	  for	  the	  existence	  of	  
these	  potential	  contaminating	  populations	  by	  flow	  cytometry	  after	  cell	  expansion.	  	  
Analysis	  of	  several	  primary	  isolations	  and	  a	  control	  cell	  line	  showed	  culture-­‐expanded	  
ASC	  populations	  to	  be	  negative	  for	  the	  leukocyte	  marker	  CD45+	  (PTPRC,	  Protein	  
Tyrosine	  Phosphatase,	  Recetpor	  Type,	  C)	  (Fig.	  4a)	  and	  the	  endothelial	  cell	  marker	  CD31+	  
(PECAM-­‐1,	  Platelet/Endothelial	  Cell	  Adhesion	  Molecule)	  (Fig.	  4b).	  	  While	  this	  data	  
indicated	  our	  expanded	  population	  was	  negative	  for	  the	  potential	  contaminating	  
populations,	  we	  further	  determined	  the	  homogeneity	  of	  the	  populations	  using	  a	  marker	  
for	  which	  the	  adipocyte	  precursors	  should	  be	  positive,	  CD140b.	  	  Data	  indicated	  the	  ASCs	  
were	  homogeneously	  positive	  for	  this	  marker	  (Fig.	  4c).	  	  	  Human	  dermal	  Fibroblasts	  
(HDF)	  from	  Lonza	  were	  tested	  in	  parallel	  as	  a	  control	  population.	  	  This	  is	  a	  commercial	  
cell	  line	  that	  is	  devoid	  of	  endothelial	  cells	  and	  leukocytes	  and	  expresses	  the	  same	  
positive	  marker	  as	  ASCs	  (CD140b)	  making	  it	  an	  excellent	  control	  for	  the	  ASCs	  to	  look	  for	  
absence	  of	  contaminating	  populations	  and	  homogeneity	  for	  a	  positive	  marker.	  	  Flow	  
cytometry	  indicated	  the	  ASCs	  appeared	  similar	  to	  HDF	  for	  lack	  of	  leukocyte	  and	  
endothelial	  contamination	  and	  	  cellular	  homogeneity	  for	  the	  positive	  marker	  (Fig.	  4d).	  	  	  
Taken	  together,	  the	  data	  indicate	  that	  our	  isolation	  and	  expansion	  technique	  
results	  in	  a	  homogeneous	  population	  of	  ASCs	  devoid	  of	  potentially	  contaminating	  ECs	  
and	  leukocytes.	  	  Homogeneity	  for	  the	  positive	  marker	  and	  absence	  of	  contaminating	  cell	  
types	  was	  consistent	  across	  multiple	  donors.	  	  	  This	  data	  demonstrates	  the	  isolation/cell	  
source	  is	  usable	  for	  modeling	  differentiation	  within	  a	  single	  donor	  (clear,	  homogeneous	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starting	  material)	  and	  across	  multiple	  donors	  (similar	  starting	  material	  with	  regard	  to	  
cell	  types	  regardless	  of	  isolation).	  	  	  	  	  
	  
Figure	  2.	  	  Cellular	  structure	  of	  human	  adipose	  tissue.	  	  Human	  subcutaneous	  adipose	  
tissue	  was	  obtained	  from	  abdominoplasty.	  	  Small	  pieces	  of	  tissue	  were	  dissected	  away	  
from	  the	  tissue	  and	  stained	  with	  Bodipy	  Red	  (red,	  lipophilic	  fluor),	  isolectin	  IB4-­‐
AlexaFluor	  488	  (green,	  vascular	  binding),	  and	  DAPI	  (blue,	  nuclei).	  	  Multiple	  planar	  
images	  were	  captured	  using	  a	  multipohton	  microscope	  demonstrating	  a	  high	  degree	  of	  
vascularization	  (a).	  Planar	  sections	  were	  rebuilt	  into	  three	  dimensional	  representations	  






Figure	  3.	  	  Primary	  cell	  types	  abundant	  in	  processed	  lipoaspirate.	  	  Image	  of	  unprocessed	  
lipoaspirate,	  upon	  digestion	  and	  single	  cell	  seaparation	  processed	  lipoaspirate	  contains	  
multiple	  primary	  cell	  types	  in	  abundance	  including	  leukocytes,	  endothelial	  cells,	  
adipocytes,	  and	  ASCs.	  	  Such	  cell	  types	  can	  potentially	  contaminate	  preparations	  of	  ASCs.	  	  	  	  	  







Figure	  4.	  	  Cultured	  SVF	  is	  free	  of	  endothelial	  cells	  and	  leukocytes.	  	  Expanded	  stromal	  
vascular	  fractions	  of	  subcutaneous	  adipose	  tissue	  from	  three	  separate	  donors	  	  were	  
expanded	  through	  passage	  3	  and	  subsequently	  analyzed	  by	  flow	  cytometry	  for	  presence	  
of	  potential	  contaminating	  cell	  populations.	  	  In	  each	  histogram	  specific	  stain	  is	  shown	  in	  
green	  with	  non-­‐specific	  IgG	  in	  purple.	  	  Populations	  were	  stained	  as	  described	  in	  
materials	  and	  methods	  for	  CD45	  (a);	  CD31;	  	  and	  CD140b	  (c).	  	  In	  parallel,	  an	  established	  






A.3	  Maintenance	  of	  post-­‐expansion	  plasticity	  
With	  expansion	  of	  any	  primary	  cell	  there	  is	  the	  potential	  loss	  of	  phenotype.	  	  
With	  cells	  that	  demonstrate	  some	  degree	  of	  cellular	  plasticity	  ex	  vivo,	  this	  plasticity	  is	  
often	  one	  of	  the	  lost	  phenotypes.	  	  ASCs	  in	  vivo	  are	  proposed	  to	  have	  two	  potential	  
differentiation	  lineages	  and	  mature	  functions	  or	  a	  bi-­‐potentiality.	  	  The	  first	  and	  most	  
classically	  defined	  lineage	  is	  formation	  of	  new	  adipocytes.	  	  More	  recently	  a	  second	  role	  
(or	  potentially	  a	  second	  differentiation	  lineage)	  is	  associated	  with	  their	  occupying	  a	  
perivascular	  niche	  and	  playing	  a	  pericytic	  role	  (either	  differentiating	  from	  a	  precursor	  
into	  pericytes,	  or	  serving	  as	  pericytes	  prior	  to	  differentiation	  as	  a	  pool	  of	  
undifferentiated	  adipocytes)	  [254,	  494-­‐496].	  	  To	  determine	  whether	  or	  not	  our	  isolation	  
and	  expansion	  caused	  loss	  of	  in	  vivo	  phenotype	  with	  respect	  to	  cellular	  plasticity	  or	  
rather	  bi-­‐potentiality	  we	  tested	  whether	  or	  not	  expanded	  ASCs	  could	  indeed	  
differentiate	  down	  these	  lineages	  after	  the	  amount	  of	  primary	  cell	  expansion	  required	  
to	  support	  our	  differentiation	  studies.	  	  	  
To	  evaluate	  the	  ability	  of	  ASCs	  to	  differentiate	  into	  adipocytes,	  we	  placed	  them	  
under	  adipogenic	  differentiation	  conditions	  and	  stained	  the	  cells	  for	  lipid	  accumulation	  
and	  morphometric	  changes.	  	  The	  cells	  demonstrated	  a	  high	  degree	  of	  adipogenic	  
differentiation	  post-­‐induction	  characterized	  by	  increased	  size	  and	  lipid	  droplet	  
accumulation	  post	  differentiation	  (Fig	  5b)	  as	  compared	  to	  undifferentiated	  ASCs	  (Fig	  5a).	  	  
These	  results	  indicated	  the	  cells	  maintained	  plasticity	  to	  differentiate	  down	  adipogenic	  
lineage	  post	  expansion.	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To	  determine	  whether	  the	  cells	  maintained	  a	  vasculosupportive	  role	  after	  
expansion	  we	  co-­‐cultured	  both	  undifferentiated	  and	  differentiated	  (adipogenic)	  with	  
endothelial	  cells	  (HUVEC)	  to	  look	  for	  cord	  formation	  as	  an	  indication	  of	  fulfilling	  
vasculosupportive	  role.	  	  Co-­‐cultures	  were	  stained	  for	  cords	  (stained	  endothelial	  cells	  for	  
CD31	  to	  identify	  cord	  structures)	  and	  expression	  of	  the	  pericytic	  marker	  smooth	  muscle	  
alpha	  actin.	  	  Cells	  not	  stimulated	  for	  adipogenic	  differentiation	  supported	  cord	  
formation	  of	  the	  endothelial	  cells	  with	  ASCs	  in	  close	  proximity	  to	  the	  ECs	  demonstrating	  
expression	  of	  smooth	  muscle	  alpha	  actin	  (Fig.	  6a).	  	  Smooth	  muscle	  alpha	  actin	  
expression	  appeared	  to	  be	  upregulated	  in	  response	  to	  VEGF	  (Fig.	  6b)	  indicating	  that	  the	  
cells	  contribute	  to	  a	  vascular	  system	  responding	  to	  physiologic	  vascular	  stimulus.	  	  The	  
differentiated	  cells	  did	  support	  endothelial	  cell	  survival	  demonstrated	  by	  existence	  of	  
CD31+	  cells	  but	  did	  not	  support	  cord	  formation	  (Fig.	  6c).	  	  	  The	  differentiated	  co-­‐cultures	  
did	  not	  respond	  to	  VEGF	  (Fig.	  6d).	  	  This	  data	  indicated	  that	  the	  expanded	  cells	  do	  
maintain	  the	  ability	  to	  support	  vasculature	  and	  potentially	  even	  to	  further	  differentiate	  
into	  a	  more	  mature	  pericytic	  cell	  type	  (increased	  SMA	  expression).	  	  	  
Taken	  together	  the	  data	  from	  these	  differentiation	  studies	  indicate	  that	  the	  
isolation	  and	  expansion	  procedure	  used	  for	  our	  studies	  does	  not	  result	  in	  a	  loss	  of	  the	  in	  
vivo	  bi-­‐potentiality	  of	  the	  ASCs.	  	  It	  also	  demonstrates	  that	  the	  cells	  can	  be	  used	  as	  tools	  
to	  model	  both	  adipogenic	  differentiation	  and	  angiogenesis	  (cord	  formation	  support).	  	  	  	  
This	  is	  evidence	  that	  our	  expanded	  cells	  are	  behaving	  physiologically	  with	  respect	  to	  




Figure	  5.	  	  Expanded	  ASCs	  maintain	  adipogenic	  lineage	  differentiation.	  	  ASCs	  at	  passage	  
3	  were	  differentiated	  as	  described	  in	  materials	  and	  methods.	  	  Cells	  were	  stained	  with	  
Syto	  16	  (green,	  nuclear	  stain)	  and	  Nile	  Red	  (lipophilic	  red	  fluor)	  and	  imaged	  using	  






Figure	  6.	  	  Expanded	  ASCs	  maintain	  vasculosupportive	  phenotype.	  	  ASCs	  at	  passage	  3	  
were	  co-­‐cultured	  with	  HUVECs	  for	  3	  days.	  	  After	  co-­‐culture,	  cells	  were	  fixed	  and	  stained	  
for	  CD31	  (green)	  SMA	  (red)	  and	  dapi	  (blue,	  nuclei).	  	  Undifferentiated	  ASCs	  were	  	  
cocultured	  with	  HUVECs	  (a)	  and	  cocultured	  in	  the	  presence	  of	  VEGF	  (b).	  	  Huvecs	  were	  























A.4	  Quantifying	  differentiation	  
As	  mentioned	  previously,	  when	  using	  multiple	  donors	  of	  primary	  cells	  for	  
differentiation	  it	  is	  critical	  that	  extent	  of	  differentiation	  and	  lineage	  commitment	  be	  
quantified	  and	  not	  simply	  observed.	  	  Adipogenic	  differentiation	  is	  often	  identified	  by	  the	  
presence	  of	  lipid	  droplets	  in	  the	  cytosol	  of	  cells.	  	  This	  is	  typically	  visually	  inspected	  using	  
Oil	  Red	  O.	  	  However,	  this	  is	  non-­‐quantitative.	  	  We	  developed	  a	  novel	  quantitative	  
measurement	  of	  lipid	  accumulation	  using	  an	  automated	  fluorescence	  high	  content	  
imaging	  approach	  leveraging	  the	  emerging	  field	  of	  laser	  scanning	  cytometry.	  	  	  
Fluorescence	  staining	  of	  lipids	  is	  achievable	  using	  a	  number	  of	  fluors,	  we	  used	  Nile	  Red	  
for	  our	  studies	  in	  these	  applications.	  	  Our	  initial	  approach	  was	  to	  use	  this	  stain	  in	  
combination	  with	  Syto16	  (green	  nuclear	  stain)	  (Fig.	  5a,	  b).	  	  Fixing	  cells	  at	  various	  time	  
points	  during	  differentiation	  with	  subsequent	  staining	  demonstrated	  an	  observable	  
increase	  in	  lipid	  accumulation	  over	  time	  (Figure	  7).	  	  	  	  By	  imaging	  entire	  populations	  with	  
laser	  scanning	  cytometry	  (Fig.	  8a,	  b)	  and	  subsequent	  quantitation	  of	  total	  lipid	  
fluorescence,	  lipid	  accumulation	  could	  be	  quantified	  (Fig.	  8c).	  	  Applying	  this	  laser	  
scanning	  cytometry	  technique	  with	  inclusion	  of	  nuclear	  identification	  and	  quantitation	  
for	  normalization	  to	  the	  time	  course	  of	  differentiation	  demonstrated	  data	  that	  showed	  a	  
biphasic	  curve	  with	  an	  increase	  in	  lipid	  accumulation	  up	  to	  day	  7	  followed	  by	  a	  decrease	  
in	  lipid	  accumulation	  at	  later	  timepoints	  (figure	  9).	  	  The	  visual	  observation	  and	  imaging	  





Figure	  7.	  Timecourse	  of	  adipogenic	  differentiation.	  	  Expanded	  ASCs	  were	  differentiated	  
over	  a	  10	  day	  period.	  	  Wells	  were	  fixed	  each	  day	  and	  stained	  for	  lipid	  accumulation	  as	  











Figure	  8.	  	  Quantitative	  laser	  scanning	  cytometry	  of	  undifferentiated	  and	  differentiated	  
adipocytes.	  	  Undifferentiated	  and	  differentiated	  cells	  were	  imaged	  and	  subsequently	  
analyzed	  for	  lipid	  accumulation	  using	  laser	  scanning	  cytometry	  (LCM)	  as	  described	  in	  
methods.	  	  Image	  capture	  of	  undifferentiated	  (a)	  differentiated	  (b)	  ASCs,	  and	  subsequent	  



















































Figure	  9.	  Laser	  scanning	  cytometry	  does	  not	  agree	  with	  visual	  inspection	  of	  lipid	  
accumulation.	  	  ASCs	  were	  differentiated	  and	  fixed	  daily	  over	  timecourse	  follwed	  by	  
staining	  as	  described	  in	  Fig	  7.	  	  Fluorescence	  intensity	  from	  Nile	  Red	  was	  normalized	  
against	  nuclear	  count.	  	  	  
	  
Further	  evaluation	  of	  our	  initial	  protocol	  demonstrated	  two	  potential	  reasons	  for	  
the	  disconnect	  between	  visual	  observation	  and	  imaging	  data:	  	  spectral	  overlap	  between	  
fluors	  used	  and	  light	  scattering	  from	  lipid	  accumulation	  in	  differentiated	  adipocytes.	  	  A	  
high	  degree	  of	  spectral	  overlap	  between	  Nile	  Red	  and	  Syto16	  lead	  to	  skewed	  
fluorescence	  intensity	  data	  (Fig.	  10a).	  	  To	  overcome	  this	  we	  switched	  to	  the	  use	  of	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Hoechst	  33342	  which	  has	  a	  very	  little	  spectral	  overlap	  with	  Nile	  Red	  and	  perhaps	  more	  
importantly	  required	  excitation	  using	  a	  different	  laser	  line	  (Fig.	  10b).	  	  This	  separate	  
excitation	  allowed	  separate	  capture	  of	  nuclear	  fluorescence	  (Hoechst)	  and	  lipid	  
fluorescence	  (Nile	  Red).	  	  The	  high	  degree	  of	  lipid	  in	  the	  cells	  posed	  problems	  with	  
imaging	  clear	  nuclei	  due	  the	  refractive	  index	  of	  lipid	  in	  the	  cytosol	  scattering	  fluorescent	  
light	  from	  nuclei	  (Fig.	  10c).	  	  To	  improve	  nuclear	  imaging	  and	  quantitation	  we	  stained	  
and	  imaged	  lipid	  and	  nuclei	  in	  sequence	  with	  a	  lipid	  extraction	  in	  between.	  	  The	  cells	  
were	  initially	  stained	  for	  lipid	  with	  Nile	  Red	  and	  scanned	  to	  quantify	  lipid	  accumulation,	  
then	  lipid	  was	  extracted	  from	  the	  samples	  with	  methanol.	  	  With	  cytosolic	  lipid	  reduced,	  
the	  nuclei	  were	  then	  stained	  with	  Hoechst	  and	  re-­‐imaged	  to	  determine	  nuclear	  
fluorescence	  (Fig.	  10d).	  	  	  The	  resulting	  staining	  generated	  an	  image	  of	  adipocytes	  
consisting	  of	  red	  lipid	  droplets	  and	  blue	  nuclear	  fluorescence	  (Fig.	  10e).	  	  Differentiation	  
along	  a	  timecourse	  	  and	  analyzed	  using	  this	  refined	  staining	  method	  demonstrated	  lipid	  
accumulation	  in	  ASCs	  placed	  under	  adipogenic	  conditions	  and	  compared	  to	  ASCs	  prior	  
to	  differentiation	  (Fig.	  11a,	  b).	  	  	  	  ASCs	  and	  control	  population	  HDF	  cells	  placed	  under	  
differentiation,	  fixed	  in	  an	  undifferentiated	  state,	  at	  6	  days	  and	  12	  days	  post	  induction	  
demonstrated	  different	  morphologies	  when	  stained	  using	  this	  new	  method	  (Fig.	  11c).	  	  
This	  indicated	  the	  cells	  uniquely	  differentiate	  when	  placed	  under	  differentiation	  
conditions	  when	  compared	  against	  a	  fibroblast	  cell	  line	  having	  similar	  cell	  surface	  
marker	  characteristics	  (CD31-­‐,	  CD45-­‐,	  CD140b+)	  (Fig.	  4a-­‐d).	  	  	  	  	  	  	  	  	  
Furthermore,	  we	  found	  that	  using	  laser	  scanning	  cytometry	  we	  could	  set	  a	  
threshold	  for	  lipid	  droplet	  fluorescence	  (using	  peak	  intensity)	  that	  allowed	  us	  to	  collect	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lipid	  fluorescence	  only	  from	  the	  droplets	  and	  not	  background	  fluorescence	  in	  the	  
samples	  (Fig.	  12a-­‐f).	  Normalizing	  lipid	  fluorescence	  accumulation	  against	  nuclear	  
fluorescence	  using	  this	  revised	  staining	  technique	  and	  laser	  scanning	  cytometry	  analysis	  
generated	  data	  that	  agreed	  with	  visual	  inspection	  over	  a	  timecourse	  of	  differentiation	  
using	  ASCs	  and	  HDF	  (negative	  control)	  (Fig	  12g).	  	  	  
This	  method	  provides	  a	  quantitative	  method	  for	  lipid	  accumulation	  far	  superior	  
to	  visual	  inspection	  of	  Red	  Red	  O	  staining.	  	  This	  could	  be	  used	  to	  determine	  extent	  to	  
which	  differentiation	  could	  be	  achieved	  with	  various	  donors	  and	  whether	  or	  not	  various	  







Figure	  10.	  	  Alternative	  staining	  and	  sample	  preparation	  approach	  to	  quantifying	  lipid	  
accumulation.	  	  Excitation/emission	  spectra	  of	  Syto	  16,	  green,	  and	  Nile	  Red,	  yellow	  (a).	  	  
Hoechst,	  blue,	  substituted	  in	  for	  Syto16	  provides	  better	  spectral	  separation	  from	  Nile	  
Red	  and	  allows	  for	  a	  separate	  excitation	  source	  (b).	  	  Schematic	  of	  light	  scatter	  by	  lipid	  
droplets	  in	  differentiated	  cells	  as	  compared	  to	  undifferentiated	  cells	  making	  nuclear	  
fluorescence	  difficult	  to	  quantify	  in	  differentiated	  cells	  (c).	  	  Schematic	  of	  proposed	  
solution	  involving	  lipid	  extraction	  to	  reduce	  nuclear	  light	  diffraction	  (d).	  	  Image	  of	  a	  
single	  differentiated	  adipocyte	  Hoechst/Nile	  Red	  and	  two	  stage	  image	  acquisition	  and	  
overlay,	  lipid	  image	  acquisition	  followed	  by	  lipid	  extraction	  and	  nuclear	  image	  







Figure	  11.	  Imaging	  lipid	  accumulation	  using	  modified	  technique	  over	  adipogenic	  
timecourse	  in	  ASCs	  and	  HDF.	  	  Undifferentiated	  (a)	  and	  differentiated	  (b)	  ASCs	  using	  
modified	  staining	  approach	  Described	  in	  Methods	  and	  Figure	  10.	  	  ASCs	  differentiated	  
and	  fixed	  over	  multiple	  timepoint	  compared	  to	  a	  similarly	  treated	  non-­‐differentiating	  











Figure	  12.	  	  Thresholding	  using	  laser	  scanning	  cytometry	  accurately	  analyzes	  lipid	  
accumulation	  by	  fluorescence.	  	  Thresholding	  on	  object	  peak	  fluorescence	  intensity	  
during	  laser	  scanning	  cytometry	  allows	  identification	  of	  fluorescence	  from	  lipid	  droplets	  
and	  not	  background.	  	  Thresholding	  was	  applied	  in	  analysis	  algorithm	  for	  samples	  fixed	  
and	  stained	  with	  image/lipid	  droplets	  outlined	  in	  blue	  at	  day	  0	  (a,	  d),	  day	  4	  (b,	  e),	  and	  
day	  12	  (c,	  f)	  of	  differentiation.	  Using	  thresholding	  and	  the	  modified	  staining	  method	  
described	  in	  fig	  10	  and	  Methods	  ASCs	  	  and	  non-­‐differentiated	  human	  dermal	  fibroblasts	  









































A.5	  	  Adipogenic	  model:	  	  depot	  specific/method	  specific	  studies	  
Different	  depots	  of	  adipose	  tissue	  demonstrate	  various	  physiologies	  in	  humans.	  	  
Most	  human	  adipocyte	  differentiation	  studies	  use	  primary	  adipocytes	  or	  differentiated	  
preadipocytes	  from	  subcutaneous	  depots.	  	  However,	  as	  phenotype	  and	  contribution	  to	  
metabolic	  syndrome	  are	  different	  between	  different	  adipose	  depots	  [497-­‐499],	  we	  felt	  
that	  if	  differentiation	  of	  preadipocytes	  from	  omental	  depots	  was	  feasible,	  it	  would	  be	  
interesting	  to	  look	  at	  metabolic	  phenotypes	  in	  differentiated	  omental	  adipocytes	  as	  well	  
as	  subcutaneous	  adipocytes.	  	  To	  make	  inquires	  about	  metabolic	  changes	  in	  
differentiated	  adipocytes	  where	  measurements	  are	  made	  on	  whole	  populations,	  a	  high	  
degree	  of	  differentiation	  must	  be	  achieved.	  	  Using	  a	  matched	  pair	  of	  ASCs	  (isolated	  from	  
the	  same	  subject)	  from	  omental	  adipose	  tissue	  and	  subcutaneous	  adipose	  tissue	  we	  
compared	  extent	  of	  differentiation	  between	  these	  two	  depots.	  	  We	  tested	  whether	  the	  
addition	  of	  PPAR	  gamma	  agonist	  would	  aid	  in	  achieving	  a	  more	  complete	  
differentiation.	  	  	  
As	  preadipocytes	  from	  omental	  adipose	  tissue	  historically	  differentiate	  with	  a	  
different	  	  capacity	  compared	  to	  subcutaneous	  preadipocytes	  depending	  on	  the	  
condition	  of	  the	  donor	  [500,	  501],	  we	  tested	  multiple	  differentiation	  techniques	  
employing	  PPARγ	  agonists	  in	  multiple	  formats	  in	  hopes	  of	  identifying	  conditions	  for	  a	  
complete	  differentiation	  of	  the	  omental-­‐derived	  cells.	  	  These	  included	  differentiation	  
without	  PPAR	  gamma	  agonist,	  with	  PPAR	  gamma	  agonist	  for	  the	  “normal”	  amount	  of	  
time	  (first	  half	  of	  differentiation)	  and	  leaving	  the	  PPARγ	  agonist	  throughout	  the	  entire	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differentiation	  to	  determine	  whether	  we	  might	  find	  increased	  differentiation	  with	  
increased	  PPAR	  agonism	  in	  the	  omental	  preadipocytes.	  	  	  	  	  
Subcutaneous	  ASCs	  differentiated	  extensively	  over	  time.	  	  Microscopy	  at	  various	  
time	  points	  throughout	  differentiation	  demonstrated	  similar	  morphometric	  changes	  
between	  the	  two	  groups	  when	  PPAR	  gamma	  agonism	  was	  included	  in	  their	  
differentiation	  procedure.	  	  They	  both	  appear	  to	  dramatically	  increase	  lipid	  vesicle	  
accumulation	  between	  days	  three	  and	  six	  and	  appear	  to	  have	  similar	  fractions	  (near	  
100%)	  of	  the	  total	  population	  differentiated	  by	  the	  end	  of	  the	  time	  course	  (Fig.	  13a).	  	  	  	  In	  
contrast,	  differentiation	  without	  PPAR	  gamma	  agonist	  demonstrated	  a	  delayed	  increase	  
in	  lipid	  accumulation	  in	  the	  subcutaneous	  cells	  on	  days	  nine	  through	  twelve	  and	  a	  
smaller	  fraction	  of	  the	  total	  population	  differentiated	  by	  the	  end	  of	  the	  time	  course	  (Fig.	  
13a).	  	  	  	  
In	  comparison,	  the	  omental	  ASCs	  from	  the	  same	  donor	  differentiated	  using	  the	  
same	  conditions	  demonstrated	  less	  overall	  differentiation	  in	  comparison	  to	  the	  
subcutaneous	  ASCs.	  	  Differentiation	  with	  PPAR	  gamma	  agonist	  (both	  limited	  to	  the	  first	  
half	  and	  throughout	  differentiation)	  demonstrated	  increased	  appearance	  of	  lipid	  
droplets	  over	  time	  with	  the	  majority	  of	  increase	  seen	  between	  days	  nine	  and	  twelve	  
(Fig.	  13b).	  	  Whereas	  the	  subcutaneous	  cells	  appeared	  to	  have	  similar	  amount	  of	  
differentiation	  by	  day	  12	  regardless	  of	  PPAR	  gamma	  agonist	  duration,	  the	  omental	  cells	  
appear	  to	  differentiate	  to	  a	  fuller	  extent	  (larger	  portion	  of	  the	  total	  population)	  with	  the	  
use	  of	  full	  term	  PPAR	  gamma	  agonism	  (Fig.	  13b).	  	  Differentiation	  of	  omental	  ASCs	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without	  addition	  of	  PPAR	  gamma	  agonist	  resulted	  in	  little	  to	  no	  differentiation	  into	  
mature	  adipocytes	  (Fig.	  13b).	  	  	  
Similarly,	  when	  differentiated	  in	  parallel	  and	  fluorescently	  stained	  for	  lipid	  
accumulation	  using	  previously	  described	  method,	  increased	  lipid	  accumulation	  is	  
observed	  in	  subcutaneous	  preadipocytes	  differentiated	  with	  some	  PPAR	  gamma	  agonist	  
present	  (Fig.	  14c,	  d).	  	  Subcutaneous	  ASCs	  differentiated	  without	  addition	  of	  PPAR	  
gamma	  showed	  decreased	  lipid	  staining	  (Fig.	  14b)	  compared	  to	  differentiation	  with	  
PPAR	  gamma	  agonist.	  	  Cells	  maintained	  throughout	  the	  time	  course	  with	  no	  
differentiation	  induction	  at	  all	  demonstrated	  little	  to	  no	  lipid	  staining	  (Fig.	  14a).	  	  
Omental	  cells	  showed	  little	  to	  no	  lipid	  staining	  in	  cells	  maintained	  throughout	  time	  
course	  without	  differentiation	  induction	  and	  with	  differentiation	  induced	  in	  the	  absence	  
of	  PPAR	  gamma	  agonist	  (Fig.	  14e,	  f).	  	  Minimal	  lipid	  staining	  was	  observed	  in	  cells	  
differentiated	  with	  PPAR	  gamma	  agonist	  added	  traditionally	  (Fig.	  14g)	  and	  an	  increased	  
amount	  of	  lipid	  staining	  was	  observed	  in	  omental	  ASCs	  differentiated	  with	  PPAR	  gamma	  
agonist	  addition	  through	  the	  duration	  of	  differentiation	  (Fig.	  14h).	  	  	  
Quantitiation	  of	  staining	  over	  time	  course	  using	  the	  above-­‐described	  laser	  
scanning	  cytometry	  method	  validated	  both	  morphometric	  and	  fluorescence	  staining.	  	  
Subcutaneous	  ASCs	  differentiate	  to	  a	  fuller	  extent	  (by	  lipid	  accumulation	  measurement)	  
with	  some	  PPAR	  gamma	  agonism	  (Fig.	  15a).	  	  Whether	  PPAR	  gamma	  agonist	  is	  added	  
throughout	  differentiation	  or	  more	  traditionally	  during	  the	  first	  half	  of	  differentiation,	  a	  
similar	  amount	  of	  lipid	  accumulation	  is	  quantified	  by	  the	  end	  of	  differentiation.	  	  Without	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PPAR	  gamma	  agonism,	  significantly	  less	  differentiation	  is	  achieved	  and	  lipid	  
accumulation	  appears	  to	  occur	  primarily	  at	  later	  timepoints	  than	  differentiation	  with	  
PPAR	  gamma	  agonist	  included	  (Figure	  15a).	  	  	  Omental	  ASCs	  differentiated	  to	  a	  much	  
lesser	  extent	  and	  achieved	  increased	  lipid	  accumulation	  only	  when	  differentiation	  
included	  addition	  of	  PPAR	  gamma	  agonist.	  	  A	  stark	  increase	  in	  lipid	  accumulation	  was	  
observed	  with	  PPAR	  gamma	  agonist	  addition	  for	  the	  duration	  of	  differentiation	  as	  
compared	  to	  addition	  only	  during	  the	  first	  half	  of	  differentiation	  (Fig.	  15b).	  	  	  
Comparison	  of	  differentiation	  using	  omental	  and	  subcutaneous	  ASCs	  
demonstrated	  a	  substantially	  more	  complete	  differentiation	  using	  subcutaneous	  ASCs.	  	  
Omental	  cells	  demonstrated	  a	  low	  degree	  of	  differentiation	  that	  would	  not	  lend	  itself	  to	  
metabolism	  studies	  in	  differentiated	  adipocytes	  as	  measurements	  post	  differentiation	  
would	  be	  on	  a	  mixed	  population	  of	  adipocytes	  and	  undifferentiated	  cells	  whether	  
differentiation	  is	  stimulated	  with	  PPAR	  gamma	  agonist	  or	  not.	  	  The	  subcutaneous	  cells	  
however	  produce	  a	  very	  homogeneous	  population	  post	  differentiation	  with	  a	  high	  
degree	  of	  differentiation	  when	  PPAR	  gamma	  agonist	  is	  included	  during	  differentiation.	  	  
These	  findings	  however	  demonstrate	  that	  PPAR	  gamma	  agonist	  does	  not	  need	  to	  be	  
used	  throughout	  the	  entire	  differentiation	  as	  similar	  results	  are	  achieved	  using	  PPAR	  
gamma	  agonism	  in	  the	  beginning	  of	  differentiation.	  	  	  While	  omental	  adipose	  is	  an	  
interesting	  adipose	  depot,	  we	  decided	  to	  focus	  my	  research	  on	  the	  metabolic	  
phenotype	  of	  differentiated	  adipocytes	  using	  subcutaneous	  ASCs,	  given	  the	  extent	  to	  
which	  differentiation	  is	  achieved	  is	  in	  	  a	  vast	  majority	  of	  the	  population	  whereas	  only	  a	  





Figure	  13.	  	  Differentiation	  of	  ASCs	  from	  multiple	  depots	  with	  multiple	  conditions.	  	  
ASCs	  from	  both	  subcutaneous	  (a)	  and	  omental	  (b)	  fat	  isolated	  as	  a	  matched	  pair	  form	  a	  
single	  donor	  were	  differentiated	  under	  varying	  conditions	  of	  PPAR	  gamma	  stimulation:	  	  
no	  PPAR	  gamma	  agonist,	  “normal”	  PPAR	  gamma	  agonist	  time	  course	  (first	  half	  of	  
differentiation),	  and	  PPAR	  gamma	  agonism	  throughout	  differentiation.	  	  Cells	  were	  fixed	  













Figure	  14.	  	  Fluorescence	  staining	  of	  differentiating	  ASCs	  from	  multiple	  depots/multiple	  
conditions.	  	  Multiple	  depots/multiple	  methods	  of	  differentiation	  were	  tested	  as	  
described	  in	  Fgure	  13.	  	  Cells	  were	  fixed	  prior	  to	  differentiation	  and	  after	  12	  days	  of	  
differentiation,	  stained	  and	  imaged	  as	  described	  in	  Fig	  5.	  	  Multiple	  magnifications	  are	  
shown	  of	  subcutaneous	  and	  omental	  (a,	  e)	  ASCs	  with	  no	  differentiation	  stimulation;	  
differentiation	  with	  no	  gamma	  agonist	  (b,	  f);	  differentiation	  with	  typical	  PPAR	  gamma	  
agonist	  added	  in	  the	  first	  half	  of	  differentiation	  (c,	  g);	  and	  differentiation	  with	  PPAR	  




Figure	  15.	  Lipid	  accumulation	  in	  differentiating	  ASCs	  from	  multiple	  depots/multiple	  
conditions	  over	  timecourse.	  	  Lipid	  accumulation	  quantitation	  using	  previously	  described	  
laser	  scanning	  cytometry	  method	  (Fig	  12)	  comparing	  subcutaneous(a)	  and	  omental	  (b)	  
derived	  ASCs	  differentiated	  as	  described	  in	  Figures	  14	  at	  multiple	  timepoints.	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A.6	  Consistency	  across	  donors	  
Further	  metabolism	  studies	  in	  differentiated	  adipocytes	  were	  performed	  using	  
differentiated	  ASCs	  from	  multiple	  donors	  to	  rule	  out	  single	  donor	  primary	  culture	  
phenomena.	  	  To	  determine	  donor-­‐to-­‐donor	  consistency	  of	  differentiation,	  multiple	  
donors	  were	  placed	  under	  adipogenic	  differentiation	  conditions.	  	  Extent	  of	  
differentiation	  was	  determined	  using	  the	  quantitative	  lipid	  accumulation	  method	  
previously	  described	  along	  with	  glycerol	  analysis	  as	  an	  additional	  measure	  of	  lipid	  
accumulation	  as	  a	  means	  of	  validating	  our	  novel	  method	  of	  measuring	  lipid	  
accumulation	  by	  automated	  imaging/laser	  scanning	  cytometry.	  	  	  	  	  
Similar	  levels	  of	  lipid	  accumulation	  were	  observed	  across	  multiple	  donors	  at	  
multiple	  timepoints	  with	  similar	  distribution	  of	  differentiated	  (lipid	  laden)	  cells	  across	  
the	  populations	  when	  observing	  images	  capture	  by	  laser	  scanning	  cytometry	  (Fig.	  16a).	  	  
Quantitation	  of	  lipid	  accumulation	  using	  the	  previously	  described	  method	  demonstrated	  
that	  ASCs	  from	  all	  donors	  tested	  (including	  a	  “superlot”	  mix	  of	  all	  donors)	  demonstrated	  
similar	  differentiation	  over	  time.	  	  All	  showed	  an	  increase	  in	  lipid	  accumulation	  primarily	  
between	  days	  three	  and	  six	  and	  achieved	  similar	  levels	  of	  lipid	  staining	  by	  the	  end	  of	  the	  
time	  course	  (Fig.	  16b).	  	  To	  verify	  these	  findings,	  de-­‐esterified	  glycerol	  (fatty	  acids	  
removed)	  was	  assessed	  as	  a	  surrogate	  of	  triacylglycerol	  content	  in	  the	  differentiating	  
populations.	  	  Glycerol	  data	  was	  similar	  to	  lipid	  staining	  approach	  demonstrating	  the	  
largest	  accumulation	  of	  lipid	  between	  days	  three	  and	  six	  of	  differentiation	  and	  similar	  
increases	  in	  glycerol	  were	  achieved	  among	  all	  donors	  tested	  (Fig.	  16c).	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These	  data	  taken	  together	  demonstrate	  similar	  levels	  of	  differentiation	  amongst	  
all	  donors	  tested.	  	  	  This	  is	  critical	  as	  these	  decrease	  the	  probability	  that	  data	  trends	  
could	  be	  from	  variable	  levels	  of	  differentiation	  when	  using	  multiple	  donors.	  	  	  	  
	  
Figure	  16.	  	  Comparison	  of	  adipogenic	  differentiation	  using	  subcutaneous	  ASCs	  from	  
multiple	  donors.	  	  ASCs	  isolated	  from	  eight	  donors	  and	  a	  combined	  superlot	  (SL)	  were	  
differentiated	  as	  described	  in	  Methods	  and	  subsequently	  analyzed	  for	  differentiation	  
using	  method	  described	  in	  Figure	  12.	  	  Represenative	  images	  are	  shown	  of	  each	  of	  the	  
donors	  tested	  over	  a	  9	  day	  period	  (a).	  	  Quantitative	  laser	  scanning	  cytometry	  was	  
perfomed	  on	  samples	  (b).	  	  In	  parallel	  glycerol	  accumulation	  was	  measured	  as	  described	  
in	  methods	  in	  the	  same	  populations	  (c).	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A.7	  Adipokine	  secretion	  
Differentiation	  state	  of	  ASCs	  down	  the	  adipogenic	  lineage	  is	  most	  commonly	  
characterized	  by	  lipid	  accumulation	  as	  we	  have	  already	  demonstrated.	  	  	  However,	  a	  
secondary	  approach	  to	  better	  characterize	  differentiation	  down	  the	  adipogenic	  lineage	  
is	  necessary.	  	  Multiple	  cell	  types	  (hepatocytes,	  macrophage,	  etc.)	  can	  lipid	  load,	  
especially	  in	  culture	  making	  a	  secondary	  non-­‐lipid	  measurement	  valuable	  in	  
demonstrating	  true	  adipogenic	  lineage	  differentiation.	  	  To	  test	  this	  in	  our	  model	  we	  
examined	  secretion	  of	  adipokines	  into	  media	  at	  multiple	  times	  throughout	  
differentiation.	  	  We	  profiled	  both	  adiponectin	  and	  leptin	  secretion	  via	  ELISA	  on	  
conditioned	  media	  which	  are	  only	  secreted	  by	  adipocytes.	  	  Multiple	  donors	  were	  tested	  
at	  days	  0,	  3,	  6,	  9,	  12,	  and	  15	  of	  differentiation.	  	  With	  adipogenic	  differentiation	  we	  
expect	  to	  see	  an	  increase	  in	  secretion	  of	  these	  adipokines	  over	  time	  as	  compared	  to	  
baseline	  (day	  0).	  	  Leptin	  secretion	  increased	  as	  the	  cells	  differentiated	  (Fig.	  17a).	  	  
Similarly	  adiponectin	  increased	  as	  the	  cells	  differentiated	  (Fig.	  17b)	  with	  an	  initial	  
increase	  much	  earlier	  than	  leptin.	  	  The	  data	  are	  another	  indicator	  the	  cells	  are	  




Figure	  17.	  Adipogenic	  differentiation	  of	  multiple	  donors	  demonstrates	  increased	  
production	  of	  both	  leptin	  and	  adiponectin.	  	  ASCs	  isolated	  from	  three	  donors	  were	  
analyzed	  for	  adipokine	  production	  in	  conditioned	  media	  at	  multiple	  times	  throughout	  
adipogenic	  differentiation	  by	  ELISA.	  	  Both	  leptin	  (a)	  and	  adiponectin	  (b)	  production	  were	  
measured.	  	  	  
	  
A.8	  Data	  summary	  	  	  
My	  data	  indicate	  that	  using	  human	  ASCs,	  one	  can	  model	  adipogenic	  
differentiation	  with	  a	  high	  degree	  of	  reproducibility	  across	  multiple	  donors.	  	  A	  novel	  
imaging	  assay	  was	  developed	  enabling	  high	  content	  imaging	  of	  entire	  populations	  of	  
cells	  to	  determine	  lipid	  accumulation	  across	  whole	  populations	  quantitatively	  as	  
opposed	  to	  standard	  oil	  red	  o	  staining.	  	  Omental	  ASCs	  demonstrated	  a	  much	  reduced	  
capacity	  for	  adipogenic	  differentiation	  than	  did	  subcutaneous	  ASCs	  under	  the	  conditions	  
tested.	  	  Both	  adiponectin	  and	  leptin	  secretion	  increase	  with	  differentiation	  with	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adiponectin	  increases	  and	  peaking	  at	  earlier	  timepoints.	  	  The	  consistency	  across	  donors	  
and	  high	  degree	  of	  differentiation	  compare	  favorably	  with	  3T3-­‐L1	  models	  which	  are	  
valued	  for	  their	  reproducibility	  as	  a	  cell	  line	  and	  indicate	  that	  differentiation	  studies	  
using	  multiple	  donors	  of	  ASCs	  are	  indeed	  feasible	  and	  not	  limited	  by	  variability.	  	  	  
	  
B.	  	  	  Aerobic	  Glycolysis	  in	  Differentiated	  Adipocytes	  
To	  test	  whether	  differentiated	  adipocytes	  exhibit	  the	  ability	  to	  perform	  aerobic	  
glycolysis,	  glycolytic	  and	  oxidative	  measurements	  were	  performed	  using	  differentiated	  
adipocytes	  compared	  to	  their	  undifferentiated	  precursors	  (ASCs).	  	  The	  undifferentiated	  
adipocyte	  is	  considerably	  different	  from	  the	  mature	  adipocyte	  yet	  is	  from	  the	  same	  
source	  material	  and	  therefore	  functions	  as	  the	  best	  control	  available.	  	  This	  also	  allows	  us	  
to	  make	  inferences	  as	  to	  metabolic	  changes	  that	  are	  associated	  with	  the	  changing	  role	  
of	  the	  mature	  adipocyte	  compared	  to	  its	  precursor.	  	  	  
B.1	  Preliminary	  findings	  
Using	  our	  model	  of	  differentiation,	  conditioned	  media	  was	  captured	  throughout	  
differentiation	  and	  analyzed	  using	  a	  clinical	  blood	  analyzer	  for	  lactate	  and	  glucose	  
concentrations	  to	  look	  at	  both	  glucose	  consumption	  and	  lactate	  production	  by	  
comparing	  to	  unconditioned	  media	  controls.	  	  Glucose	  consumption	  increased	  with	  
differentiation	  (Fig.	  18a).	  	  The	  mature	  cell	  has	  a	  primary	  role	  of	  energy	  storage	  so	  
increasing	  flux	  of	  high	  energy	  molecules	  such	  as	  glucose	  is	  expected.	  	  However,	  at	  the	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same	  time,	  lactate	  production	  also	  increased	  (Fig.	  18b).	  	  When	  comparing	  the	  molar	  
ratio	  of	  lactate	  produced	  to	  glucose	  consumed,	  the	  data	  indicated	  that	  the	  cells	  in	  an	  
undifferentiated	  state	  had	  a	  low	  ratio	  (little	  lactate	  produced	  per	  glucose	  consumed).	  	  
However,	  as	  the	  cells	  differentiated	  they	  increased	  this	  ratio	  (higher	  amounts	  of	  lactate	  
produced	  per	  glucose	  consumed)	  (Fig.	  18b).	  	  Fibroblasts	  put	  under	  the	  same	  
differentiation	  conditions	  as	  a	  control	  (non-­‐differentiating)	  did	  not	  exhibit	  any	  of	  these	  
findings	  (Fig.	  18c).	  	  	  	  This	  became	  the	  preliminary	  data	  that	  led	  to	  the	  hypothesis	  that	  
during	  differentiation,	  and	  in	  the	  differentiated	  state,	  adipocytes	  exhibit	  an	  increase	  





Figure	  18.	  	  Glucose	  consumption	  and	  lactate	  production	  disproportionately	  increase	  
with	  adipogenic	  differentiation.	  	  Conditioned	  media	  from	  differentiating	  ASCs	  and	  HDF	  
were	  collected	  at	  various	  timepoints	  and	  analyzed	  using	  a	  clinical	  blood	  analyzer	  to	  
determine	  glucose	  consumption	  (a),	  lactate	  production	  (b).	  	  This	  data	  was	  used	  to	  
determine	  lactate	  produced	  per	  glucose	  consumed	  (c),	  only	  for	  the	  differentiating	  




B.2	  Adipose	  depot	  specific	  metabolism	  
As	  previously	  mentioned,	  poor	  amounts	  of	  adipogenic	  differentiation	  are	  
achieved	  using	  omental	  preadpocytes.	  	  However,	  with	  a	  matched	  pair	  (omental	  and	  
subcutaneous	  preadipocytes)	  from	  a	  single	  donor,	  we	  compared	  glucose	  consumption	  
and	  lactate	  production	  rates	  during	  differentiation	  using	  precursors	  from	  both	  depots.	  	  
Glucose	  consumption	  and	  lactate	  production	  accompanying	  differentiation	  in	  both	  
omental	  and	  subcutaneous	  models	  revealed	  similar	  results.	  	  An	  increase	  in	  glucose	  
consumption	  in	  both	  omental	  and	  subcutaneous	  models	  (Fig.	  19a,	  b)	  accompanied	  
adipogenic	  differentiation.	  	  Glucose	  consumption	  was	  higher	  in	  the	  differentiating	  
subcutaneous	  adipocytes	  compared	  to	  omental.	  	  	  Similarly,	  lactate	  production	  increased	  
in	  both	  the	  differentiating	  subcutaneous	  and	  omental	  adipocytes	  (Fig.	  19c,	  d).	  	  However,	  
lactate	  production	  was	  higher	  in	  the	  subcutaneous	  adipocytes	  which	  could	  be	  from	  the	  
increased	  amount	  of	  adipogenic	  differentiation	  in	  subcutaneous	  ASCs	  as	  compared	  to	  
the	  omental	  ASCs.	  	  The	  molar	  ratio	  of	  lactate	  produced	  to	  glucose	  consumed	  
demonstrated	  increases	  similar	  to	  preliminary	  data	  for	  differentiation	  of	  subcutaneous	  
adipocytes	  (Fig.	  19e).	  	  The	  ratio	  went	  above	  2	  in	  some	  points.	  	  This	  would	  indicate	  that	  
lactate	  production	  was	  potentially	  coming	  from	  substrate	  other	  than	  the	  glucose	  
consumed.	  	  Indeed,	  upon	  consideration	  of	  the	  media	  we	  used	  (containing	  L-­‐glutamine	  
and	  pyruvate)	  there	  were	  alternative	  carbon	  sources	  available	  for	  lactate	  production	  
other	  than	  glucose,	  this	  made	  ratios	  of	  lactate	  produced	  to	  glucose	  consumed	  difficult	  
to	  definite	  conclusions	  from.	  	  Accordingly,	  while	  this	  data	  was	  valuable	  for	  preliminary	  
findings,	  subsequent	  studies	  were	  performed	  with	  a	  more	  highly	  controlled	  media.	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Omental	  adipocyte	  differentiation	  did	  not	  demonstrate	  a	  similar	  increase	  lactate	  
produced	  to	  glucose	  consumed	  at	  later	  timepoints	  (Fig.	  19f).	  	  
	  
Figure	  19.	  	  Lactate	  production	  increases	  vs.	  glucose	  consumption	  in	  both	  
subcutaneous	  and	  omental	  adipogenic	  differentiation.	  	  Conditioned	  media	  from	  
ometal	  and	  subcutaneous	  matched	  donor	  ASCs	  was	  collected	  and	  analyzed	  as	  described	  
in	  Figure	  18.	  Increases	  in	  glucose	  consumption	  (-­‐Δ	  glucose)	  were	  observed	  with	  
differentiation	  of	  both	  subcutaneous	  and	  omental	  (a,	  b)	  ASCs.	  	  Similar	  increases	  in	  
lactate	  production	  (+Δ	  lactate)	  were	  observed	  (c,	  d).	  	  An	  increase	  in	  ratio	  of	  lactate	  
produced	  to	  glucose	  consumed	  was	  observed	  compared	  to	  undifferentiated	  or	  day	  0	  
cells	  (e,	  f).	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B.3	  Lactate	  measurements	  using	  multiple	  donors	  in	  various	  conditions	  
To	  better	  understand	  lactate	  production	  rates	  associated	  with	  adipocytes	  
compared	  to	  their	  precursors,	  ASCs	  from	  several	  donors	  were	  obtained	  and	  
differentiated	  using	  methods	  previously	  described.	  	  Lactate	  measurements	  were	  
performed	  on	  media	  (controlled	  for	  glucose	  and	  devoid	  of	  glutamine	  and	  pyruvate)	  
after	  conditioning	  by	  the	  cells	  in	  both	  differentiated	  and	  undifferentiated	  states.	  	  Each	  
of	  the	  donors	  showed	  marked	  increases	  in	  lactate	  production	  after	  differentiation	  into	  
mature	  adipocytes	  (Figure	  20).	  	  	  
Studies	  up	  to	  this	  point	  had	  been	  performed	  euglycemic	  conditions	  (100	  mg/dL	  
glucose),	  Further	  studies	  were	  performed	  using	  multiple	  glucose	  concentrations	  and	  
insulin	  stimulation.	  	  Insulin	  had	  little	  to	  no	  effect	  on	  lactate	  production	  in	  the	  
differentiated	  adipocytes	  across	  all	  donors	  whereas	  increasing	  glucose	  seemed	  to	  
increase	  lactate	  production	  at	  500	  and	  1000	  mg/dL	  glucose	  comapared	  to	  euglycemic	  
conditions	  at	  100	  mg/dL	  (Figure	  21b,	  d,	  f).	  	  In	  the	  undifferentiated	  cells,	  insulin	  had	  a	  
larger	  effect	  than	  glycemic	  conditions.	  	  Insulin	  appeared	  to	  increase	  lactate	  production	  
(Fig.	  21a,	  c,	  e).	  	  Data	  was	  consistent	  across	  all	  donors	  indicating	  an	  increase	  in	  lactate	  
production	  or	  glycolytic	  metabolism	  accompanies	  differentiation.	  	  The	  increased	  lactate	  
production	  with	  increased	  glucose	  concentration	  suggests	  that	  excess	  glucose	  flux	  into	  
the	  cell	  above	  some	  threshold	  amount	  might	  be	  funneled	  into	  glycolytic	  processes.	  	  To	  
better	  determine	  this,	  the	  lactate	  data	  would	  have	  to	  be	  compared	  against	  oxidative	  




Figure	  20.	  	  Lactate	  production	  is	  higher	  in	  differentiated	  adipocytes	  than	  
undifferentiated	  ASCs	  in	  multiple	  donors.	  	  Three	  separate	  donors	  were	  tested	  in	  both	  
undifferentiated	  and	  differentiated	  states	  for	  lactate	  production	  by	  colorimetric	  lactate	  

























Figure	  21.	  Insulin	  and	  glucose	  effects	  on	  lactate	  production	  in	  differentiated	  and	  
undifferentiated	  ASCs.	  	  Lactate	  production	  was	  measured	  in	  conditioned	  media	  as	  
previously	  described	  on	  undifferentiated	  (a,	  c,	  e)	  and	  differentiated	  ASCs(b,	  d,	  f)	  from	  
three	  donors	  in	  various	  hyperglycemic	  conditions	  and	  with	  and	  without	  addition	  of	  100	  




B.4	  Oxygen	  consumption	  measurements	  using	  multiple	  donors	  
Oxidative	  measurements	  using	  Seahorse	  Bioscience	  FX	  analyzer	  allow	  for	  real-­‐
time	  oxygen	  consumption	  measurements	  by	  creating	  a	  low	  volume	  space	  around	  the	  
cells	  and	  making	  oxygen	  tension	  measurements	  over	  time	  to	  determine	  oxygen	  
consumption	  rates.	  	  To	  understand	  the	  oxidative	  state	  of	  the	  cells	  we	  employed	  the	  use	  
of	  mitochondrial	  toxins	  that	  would	  allow	  us	  to	  measure	  basal	  oxygen	  consumption	  rates	  
(not	  treatment),	  maximal	  oxygen	  consumption	  rates	  (uncoupling	  with	  DNP),	  and	  
minimum	  oxygen	  consumption	  rates	  (inhibiting	  site	  one	  of	  electron	  transport	  with	  
rotenone).	  	  To	  observe	  whether	  oxidative	  metabolism	  changes	  with	  differentiation,	  
oxygen	  consumption	  rates	  were	  measured	  in	  undifferentiated	  day	  0	  (Fig.	  22a),	  
differentiating	  day	  6	  (Fig.	  22b),	  and	  differentiated	  cells	  day	  12	  populations	  (Fig.	  22c).	  	  
Treatment	  with	  rotenone	  decreased	  oxygen	  consumption	  rates	  in	  undifferentiated,	  day	  
6	  and	  day	  12	  adipocytes	  as	  a	  result	  of	  site	  one	  inhibition	  of	  electron	  transport	  chain.	  	  
DNP	  increased	  oxygen	  consumption	  rates	  at	  each	  time	  point	  tested	  as	  a	  result	  of	  
mitochondrial	  uncoupling	  with	  larger	  responses	  (increasing)	  observed	  in	  the	  day	  six	  and	  
day	  12	  differentiated	  adipocytes	  compared	  to	  day	  0	  undifferentiated	  preadipocytes.	  	  	  	  
DNP	  treatment	  allows	  for	  free	  proton	  movement	  across	  the	  mitochondrial	  
membrane	  destroying	  the	  proton	  gradient	  and	  the	  proton	  motive	  force	  necessary	  for	  
ATP	  synthase	  activity.	  	  The	  cell	  increases	  oxidative	  phosphorylation	  up	  to	  maximal	  rates	  
to	  restore	  this.	  	  Rotenone	  inhibits	  site	  one	  of	  electron	  transport.	  	  Using	  these	  
mitochondrial	  toxins	  we	  are	  able	  to	  determine	  basal	  oxidative	  activity	  (untreated	  O2	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consumption	  rate),	  maximal	  oxidative	  rate	  (DNP	  treated	  O2	  consumption	  rate),	  
minimum	  oxidative	  rate	  (rotenone	  treated	  O2	  consumption	  rate).	  	  Using	  these	  
measurements	  we	  could	  determine	  total	  oxidative	  capacity	  (max	  –	  min	  or	  DNP	  –	  
Rotenone	  elicited	  O2	  consumption	  rates)	  (Fig	  23).	  	  As	  a	  fraction	  of	  this	  total	  oxidative	  
capacity	  we	  could	  observe	  where	  the	  cells	  function	  in	  a	  basal	  state	  (unstimulated),	  we	  
termed	  this	  fractional	  oxidative	  state.	  	  	  	  	  
Basal	  oxidative	  rates	  increased	  with	  adipogenic	  differentiation	  of	  ASCs	  (Fig.	  24a)	  
indicating	  an	  increase	  in	  oxidative	  processes	  accompanying	  differentiation.	  	  	  However,	  
total	  oxidative	  capacity	  also	  increased	  substantially	  with	  differentiation	  (Fig.	  24b).	  	  As	  a	  
function	  of	  this	  increase	  in	  total	  oxidative	  capacity	  the	  fractional	  oxidative	  state	  actually	  
decreases	  as	  the	  cells	  differentiate	  (Fig.	  24c).	  	  This	  indicates	  that	  the	  cell’s	  oxidative	  
process	  is	  not	  rate	  limited.	  	  One	  concern	  we	  had	  with	  our	  data	  demonstrating	  an	  
increase	  in	  lactate	  production	  was	  that	  the	  increase	  in	  glycolytic	  activity	  was	  simply	  
because	  oxidative	  capacity	  was	  saturated	  and	  any	  further	  metabolism	  would	  be	  forced	  
through	  glycolytic	  process.	  	  This	  data	  actually	  shows	  the	  opposite;	  the	  differentiated	  
adipocytes	  demonstrate	  a	  much	  larger	  excess	  capacity	  above	  basal	  state	  to	  perform	  




Figure	  22.	  	  Oxygen	  consumption	  in	  differentiating	  adipocytes	  using	  mitochondrial	  
toxins.	  	  Oxygen	  consumption	  was	  measured	  using	  Seahorse	  Bioscience	  XF	  analyzer	  on	  
differentiating	  adipocytes.	  	  Data	  shown	  is	  from	  a	  single	  donor.	  	  Traces	  from	  Seahorse	  
analyzer	  before	  and	  after	  rotenone,	  DNP,	  or	  media	  (control)	  injection	  from	  days	  0,	  6,	  12	  




Figure	  23.	  	  Oxidative	  capacity	  and	  fractional	  oxidative	  capacity	  calculations.	  	  Sample	  
data	  demonstrating	  calculations	  for	  oxidative	  capacity	  and	  fractional	  oxidative	  capacity.	  	  
Rotenone	  is	  used	  to	  inhibit	  mitochondrial	  oxygen	  consumption,	  DNP	  maximizes	  




Figure	  24.	  	  Changes	  in	  basal,	  capacity,	  and	  fractional	  oxidative	  values	  in	  differentiating	  
adipocytes.	  	  Oxidative	  data	  in	  a	  single	  donor	  of	  differentiating	  adipocytes	  was	  obtained	  
as	  described	  in	  Fig	  22,	  23.	  	  Basal	  oxygen	  consumption	  (a),	  total	  oxidative	  capacity	  (b),	  
and	  fractional	  oxidative	  capacity	  (c)	  changes	  associated	  with	  adipogenic	  differentiation	  
are	  shown.	  
B.5	  Comparison	  against	  another	  differentiation	  model	  	  
To	  determine	  whether	  this	  observed	  increase	  in	  capacity	  and	  decrease	  in	  
fractional	  oxidative	  state	  is	  primarily	  a	  function	  of	  differentiation	  in	  vitro,	  or	  was	  a	  
particular	  characteristic	  of	  differentiated	  adipocytes,	  similar	  experiments	  were	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performed	  on	  differentiated	  myotubes.	  	  This	  is	  a	  good	  control	  model	  considering	  we	  
differentiate	  human	  myogenic	  precursors	  into	  mature	  myotubes	  similar	  to	  
differentiation	  of	  human	  adipocyte	  precursors	  into	  mature	  adipocytes.	  	  	  Similar	  to	  
adipogenic	  differentiation	  we	  wanted	  to	  be	  sure	  our	  differentiation	  of	  primary	  human	  
myoblasts	  was	  characterized.	  	  Differentiation	  demonstrated	  a	  high	  degree	  of	  staining	  for	  
polymerized	  actin	  in	  multinucleated	  tubes	  (Fig.	  25a)	  and	  a	  marked	  increase	  in	  
expression	  of	  myogenic	  markers	  including	  desmin	  (Fig.	  25b),	  myoD	  (Fig.	  25c),	  and	  
myosin	  heavy	  chain	  (Fig.	  	  25d).	  	  When	  measuring	  these	  markers	  over	  time	  using	  
fluorescence	  staining	  and	  laser	  scanning	  cytometry	  we	  found	  that	  the	  differentiation	  at	  
least	  with	  respect	  to	  these	  markers	  plateaued	  around	  day	  eight	  post	  induction	  of	  
differentiation	  and	  was	  maintained	  through	  at	  least	  day	  thirteen	  (Fig.	  25e).	  	  	  	  
Oxygen	  consumption	  studies	  were	  performed	  on	  undifferentiated	  myoblasts	  and	  
day	  10	  differentiated	  myotubes.	  	  Differentiation	  resulted	  in	  decreased	  basal	  oxidative	  
rate	  (Fig.	  26a,	  b),	  decreased	  total	  oxidative	  capacity	  (Fig.	  26c),	  and	  increased	  fractional	  
oxidative	  state	  (Fig.	  26d).	  	  This	  data	  was	  different	  than	  the	  observations	  in	  adipocytes	  
previously	  described	  indicating	  that	  the	  changes	  observed	  in	  our	  adipogenic	  model	  are	  




Figure	  25.	  	  Myoblast	  to	  myotube	  differentiation	  as	  a	  control	  differentiation	  system.	  	  In	  
vitro	  differentiated	  human	  myotubes	  stained	  for	  polymerized	  actin	  using	  phalloidin-­‐
AlexaFluor	  488,	  green,	  and	  multinucleation	  using	  Hoechst	  33342,	  blue	  (a),	  and	  costained	  
with	  antibodies	  against	  myogenic	  markers	  conjugated	  to	  red	  fluor	  for	  desmin	  (b),	  myoD	  
(c),	  and	  myosin	  heavy	  chain	  (d).	  	  Image	  analysis	  of	  fluorescence	  intensity	  normalized	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Figure	  26.	  	  Changes	  in	  basal,	  capacity,	  and	  fractional	  oxidative	  values	  in	  differentiating	  
myotubes.	  	  Oxidative	  data	  in	  a	  single	  donor	  of	  differentiating	  myotubes	  was	  obtained	  as	  
described	  in	  Fig	  22,	  23.	  	  Comparison	  of	  undifferentiated	  and	  differentiated	  myotubes:	  	  
Rotenone	  and	  DNP	  effects	  compared	  to	  basal	  oxygen	  consumption	  rates	  (a,b),	  




B.6	  Oxidative	  measurements	  associated	  with	  differentiation.	  	  	  
	  	   To	  determine	  the	  amount	  of	  oxidative	  metabolism	  occurring	  in	  the	  adipocytes,	  
we	  measured	  oxygen	  consumption	  rates	  in	  undifferentiated	  ASCs	  and	  differentiated	  
adipocytes	  using	  the	  same	  donors	  under	  the	  same	  conditions	  as	  the	  lactate	  
measurements	  were	  made.	  	  Data	  indicated	  a	  small	  but	  consistent	  increase	  in	  basal	  
oxygen	  consumption	  across	  each	  of	  the	  donors	  tested	  (Fig.	  27a).	  	  To	  determine	  whether	  
the	  basal	  rates	  observed	  were	  near	  saturating	  the	  oxidative	  capacity	  of	  the	  cells,	  basal	  
rates	  were	  compared	  against	  uncoupled	  rates	  (DNP	  treated)	  as	  previously	  described.	  	  
Each	  of	  the	  donors	  demonstrated	  excess	  oxidative	  capacity	  above	  basal	  oxidation	  (Fig.	  
27b)	  and	  again	  showed	  a	  larger	  excess	  oxidative	  capacity	  in	  the	  differentiated	  state	  than	  
the	  undifferentiated	  state	  (Fig.	  27b).	  	  This	  again	  confirmed	  that	  in	  each	  of	  the	  donors	  
tested,	  the	  increase	  in	  lactate	  production	  did	  not	  occur	  because	  the	  ability	  to	  perform	  
oxidative	  metabolism	  was	  saturated	  in	  the	  differentiated	  adipocytes.	  	  	  
Similar	  to	  lactate	  measurements,	  insulin	  had	  little	  to	  no	  effect	  on	  oxygen	  
consumption	  rates	  in	  the	  undifferentiated	  (Fig.	  28a,	  c,	  e)	  or	  the	  differentiated	  
adipocytes	  (Fig.	  28b,	  d,	  e).	  	  However,	  contrary	  to	  lactate	  data,	  increasing	  glucose	  
concentration	  did	  not	  demonstrate	  an	  increase	  in	  oxidative	  rate	  in	  both	  the	  
undifferentiated	  and	  differentiated	  adipocytes	  (Fig.	  28a-­‐e)	  whereas	  it	  increased	  lactate	  
production	  only	  in	  the	  differentiated	  adipocytes.	  	  In	  all	  conditions	  tested,	  DNP	  
stimulation	  identified	  significant	  excess	  oxidative	  capacity,	  indicating	  the	  cells	  are	  not	  
being	  “forced”	  to	  perform	  glycolytic	  metabolism	  because	  oxidative	  processes	  are	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saturated.	  	  Also,	  the	  increase	  in	  lactate	  production	  in	  differentiated	  adipocytes	  in	  
response	  to	  increased	  glucose	  without	  an	  increase	  in	  oxidative	  rate	  suggests	  that	  excess	  
glucose	  above	  some	  threshold	  is	  more	  likely	  to	  be	  metabolized	  with	  glycolytic	  process	  







Figure	  27.	  	  Small	  increase	  in	  basal	  oxidation	  rates	  with	  differentiation	  but	  not	  near	  
saturating	  capacity.	  	  Oxygen	  consumption	  rates	  were	  measured	  using	  Seahorse	  as	  
previously	  described.	  	  Basal	  oxygen	  consumption	  rates	  are	  shown	  for	  ASCs	  both	  
undifferentiated	  and	  differentiated	  into	  adipocytes	  from	  three	  donors	  (a).	  	  DNP	  was	  
used	  to	  compare	  basal	  and	  saturated	  (uncoupled)	  oxygen	  consumption	  rates	  in	  











































































Figure	  28.	  Insulin	  and	  glucose	  effects	  on	  oxygen	  consumption	  rates	  in	  differentiated	  
and	  undifferentiated	  ASCs.	  	  Basal	  (B)	  and	  uncoupled	  (U)	  oxygen	  consumption	  rates	  
were	  measured	  in	  conditioned	  media	  as	  previously	  described	  on	  undifferentiated	  (a,	  c,	  
e)	  and	  differentiated	  ASCs(b,	  d,	  f)	  from	  three	  donors	  in	  various	  hyperglycemic	  




B.7	  Oxidative/glycolytic	  ratios	  
To	  better	  understand	  changes	  in	  oxidative	  relative	  to	  glycolytic	  ratios,	  data	  from	  
all	  donors	  was	  combined	  demonstrating	  a	  5.2	  fold	  increase	  in	  lactate	  production	  (Fig.	  
29a).	  	  At	  the	  same	  time,	  differentiated	  adipocytes	  demonstrated	  a	  1.2	  fold	  increase	  in	  
oxygen	  consumption	  rate	  (Fig.	  29b).	  	  To	  determine	  how	  these	  changes	  compared	  to	  one	  
another,	  ATP	  production	  associated	  with	  each	  of	  these	  processes	  was	  determined	  
assuming	  6.3	  ATP	  generated	  per	  O2	  consumed	  (oxidative	  equation:	  	  C6H12O6	  +	  6O2	  →	  
6CO2	  +	  6H2O	  +	  38	  ATP)	  and	  1	  ATP	  generated	  per	  lactate	  produced	  (glycolytic	  equation:	  	  
C6H12O6	  →	  2CH3CHOHCOOH	  +	  NAD	  +	  2	  ATP).	  	  There	  was	  a	  small	  and	  non-­‐signifcant	  
1.37	  fold	  increase	  in	  total	  ATP	  production	  from	  these	  processes	  combined	  comparing	  
differentiated	  verses	  undifferentiated	  adipocytes	  (Fig.	  29c).	  	  However,	  determining	  what	  
percentage	  of	  total	  ATP	  was	  from	  glycolytic	  and	  oxidative	  processes	  demonstrated	  a	  
significant	  decrease	  in	  percentage	  of	  ATP	  from	  oxidative	  process	  (1.14	  fold,	  SEM	  0.03)	  
and	  a	  significant	  increase	  in	  percentage	  of	  ATP	  from	  glycolytic	  process	  (3.8	  fold,	  SEM	  
0.6)	  (Fig.	  29d).	  	  This	  indicates	  the	  cells	  exhibit	  a	  Warburg-­‐like	  effect	  whereby	  the	  cells	  
are	  increasing	  the	  fraction	  of	  substrate	  metabolized	  in	  glycolytic	  process	  compared	  to	  





Figure	  29.	  	  Lactate	  production	  compared	  with	  oxygen	  consumption	  rates	  and	  effects	  
on	  ATP	  production	  in	  undifferentiated	  and	  differentiated	  adipocytes.	  	  Lactate	  data	  
from	  all	  donors	  tested	  is	  combined	  (a)	  as	  well	  as	  oxygen	  consumption	  rates	  from	  all	  
donors	  tested	  combined	  (b).	  	  Total	  ATP	  production	  from	  these	  two	  processes	  is	  
determines	  as	  described	  in	  methods	  and	  shown	  for	  undifferentiated	  and	  differentiated	  
ASCs	  for	  all	  donors	  tested	  (c).	  	  Percentage	  of	  the	  total	  ATP	  from	  oxidative	  process	  and	  

















































































B.8	  Aerobic	  glycolysis	  summary:	  	  	  
Differentiated	  adipocytes	  demonstrate	  a	  Warburg-­‐like	  phenotype	  (aerobic	  
glycolysis)	  characterized	  by	  elevated	  lactate	  production	  and	  increased	  oxidative	  capacity	  
but	  minimal	  increase	  in	  oxygen	  consumption	  rates	  compared	  to	  undifferentiated	  control	  
populations.	  	  
	  
C.	  	  PDK	  Regulation	  of	  Aerobic	  Glycolysis	  in	  Differentiated	  Adipocytes	  
With	  an	  increase	  in	  glycolytic	  metabolism	  relative	  to	  oxidative	  in	  differentiated	  
verses	  undifferentiated	  adipocytes	  the	  opportunity	  exists	  to	  test	  candidate	  regulators	  of	  
the	  change	  in	  metabolic	  phenotype.	  	  The	  same	  cells	  display	  different	  phenotype	  
depending	  on	  differentiation	  state.	  	  A	  change	  in	  expression	  of	  candidate	  proteins	  in	  
differentiated	  and	  undifferentiated	  states	  potentially	  identifies	  regulators.	  	  	  
Pyruvate	  is	  decarboxylated	  to	  acetyl-­‐CoA	  for	  oxidative	  purposes	  or	  reduced	  to	  
lactate	  for	  glycolytic	  purposes.	  	  The	  regulation	  of	  pyruvates	  fate	  is	  therefore	  a	  large	  
regulator	  of	  balance	  between	  glycolytic	  and	  oxidative	  metabolism.	  	  PDKs	  phosphorylate	  
PDH	  thereby	  inhibiting	  acetyl-­‐CoA	  formation	  and	  increasing	  lactic	  acid	  fermentation	  and	  
increasing	  the	  cells’	  reliance	  on	  glycolytic	  energy	  production.	  	  PDKs	  are	  therefore	  a	  





C.1	  PDK	  expression	  
RNA	  prepped	  from	  undifferentiated	  ASCs	  and	  from	  differentiated	  adipocytes	  was	  
probed	  for	  transcript	  levels	  of	  PDK	  isoforms	  1-­‐4.	  	  The	  same	  three	  donors	  used	  in	  
oxidative	  and	  glycolytic	  studies	  were	  all	  examined	  for	  expression	  changes	  in	  
differentiated	  adipocyte	  state	  versus	  undifferentiated	  ASCs.	  	  Indeed,	  transcript	  profiling	  
of	  the	  four	  PDK	  isoforms	  demonstrated	  an	  increase	  in	  PDK1	  and	  PDK4	  mRNA	  (Fig.	  30).	  	  	  
To	  further	  explore	  expression,	  protein	  lysates	  were	  generated	  on	  differentiated	  
adipocytes	  and	  undifferentiated	  ASCs.	  	  Special	  care	  was	  taken	  to	  remove	  lipid	  from	  the	  
samples	  by	  rounds	  of	  centrifugation	  and	  incubation	  on	  ice	  (Fig.	  31a).	  	  The	  resulting	  
samples	  appear	  to	  have	  removed	  their	  lipid	  content	  which	  makes	  protein	  determination	  
and	  even	  loading	  difficult	  (Fig.	  31b-­‐d).	  	  Western	  blotting	  with	  antibodies	  for	  PDK	  
isoforms	  1-­‐4	  demonstrated	  a	  visible	  increase	  in	  PDK1	  and	  PDK4	  protein	  expression	  in	  
differentiated	  adipocytes	  compared	  to	  their	  undifferentatiated	  ASCs	  (Fig.	  32a).	  	  Indeed,	  
Band	  intensity	  profiling	  indicated	  a	  six	  fold	  increase	  in	  PDK1	  and	  around	  a	  1.8	  fold	  
increase	  in	  PDK4.	  	  PDK2	  and	  PDK3	  demonstrated	  no	  significant	  increase	  in	  western	  blot	  
analysis	  (Fig.	  32b).	  	  	  The	  increase	  in	  expression	  of	  enzymes	  that	  increase	  glycolytic	  
metabolism	  correlated	  with	  the	  increase	  in	  glycolytic	  metabolism	  in	  the	  differentiated	  
adipocytes	  indicating	  that	  PDKs	  1	  and	  4	  most	  likely	  play	  a	  role	  in	  regulating	  the	  




Figure	  30.	  	  Increased	  PDK	  transcript	  associated	  with	  adipocyte	  differentiation.	  	  RNA	  
was	  generated	  from	  undifferentiated	  and	  differentiated	  adipocytes	  from	  three	  donors	  
and	  assessed	  for	  PDKs	  1-­‐4	  by	  Taqman.	  	  Data	  is	  average	  of	  all	  three	  donors	  for	  specific	  
PDK	  isoform	  relative	  to	  18s.	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Figure	  31.	  	  Lipid	  removal	  and	  protein	  preparation	  from	  adipocyte	  lysates.	  	  Schematic	  
of	  protein	  sample	  preparation	  to	  remove	  excess	  lipid	  from	  samples	  (a).	  	  Images	  were	  
taken	  of	  lysates	  showing	  undifferentiated	  lysate	  on	  the	  left	  and	  differentiated	  adipocyte	  
lysate	  on	  the	  right	  showing	  initial	  lysis	  in	  RIPA	  buffer	  (b),	  after	  initial	  centrifugation	  (c),	  






Figure	  32.	  Increased	  PDK	  protein	  with	  adipogenic	  differentiation.	  	  Lysates	  of	  
undifferentiated	  and	  differentiated	  adipocytes	  from	  three	  donors	  were	  prepped	  as	  
previously	  described	  and	  were	  analyzed	  by	  western	  blot	  for	  PDKs	  1-­‐4,	  blot	  images	  (a)	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C.2	  Pharmacologic	  inhibition	  
To	  test	  whether	  the	  PDKs	  play	  a	  regulatory	  role	  in	  the	  Warburg	  like	  effect	  
observed	  in	  the	  differentiated	  adipocytes,	  we	  employed	  the	  use	  of	  the	  PDK	  inhibitor	  
leelamine.	  	  Leelamine	  treatment	  should	  reduce	  lactate	  production	  if	  the	  PDKs	  play	  a	  
regulatory	  role	  in	  the	  increased	  glycolytic	  phenotype	  observed	  in	  differentiated	  
adipocytes.	  	  Indeed,	  treatment	  with	  leelamine	  dose	  responsively	  decreased	  lactate	  
production	  when	  tested	  on	  differentiated	  adipocytes	  from	  each	  of	  the	  donors	  
previously	  used	  for	  both	  metabolism	  and	  PDK	  expression	  studies	  (Fig.	  33).	  	  	  Inhibition	  of	  
PDK	  resulting	  in	  a	  reduction	  of	  the	  glycolytic	  phenotype	  in	  differentiated	  adipocytes	  
indicates	  that	  the	  PDKs	  for	  which	  expression	  is	  increased	  in	  differentiated	  adipocytes	  do	  





Figure	  33.	  	  PDK	  inhibition	  decreases	  lactate	  production	  from	  differentiated	  adipocytes.	  	  
Differentiated	  adipocytes	  from	  three	  separate	  donors	  were	  treated	  with	  multiple	  
concetnrations	  of	  PDK	  inhibitor	  leelamine	  for	  12	  hours,	  subsequent	  lactate	  analysis	  on	  
samples	  was	  performed	  as	  previously	  described	  to	  determine	  lactate	  produciton	  rates.	  	  	  	  	  
	  
D.	  	  Aerobic	  Glycolysis	  Protection	  Against	  ROS	  in	  Differentiated	  Adipocytes	  
Increasing	  glycolytic	  metabolism	  in	  conditions	  that	  are	  permissive	  for	  oxidative	  
metabolism	  is	  inefficient.	  	  As	  previously	  described	  in	  cancer	  cells,	  aerobic	  glycolysis	  or	  
the	  Warburg	  effect	  confers	  protection	  against	  detrimental	  metabolic	  ROS	  production.	  	  
To	  determine	  whether	  similar	  protection	  against	  ROS	  is	  conferred	  in	  differentiated	  
Lac Production























adipocytes	  by	  increasing	  metabolism	  via	  aerobic	  glycolysis,	  ROS	  measurements	  were	  
performed.	  	  
D.1	  Measuring	  ROS	  in	  differentiated	  adipocytes	  
As	  one	  of	  two	  key	  glucose	  depots	  in	  humans	  (along	  with	  skeletal	  muscle)	  
increased	  glucose	  consumption	  in	  adipocytes	  can	  lead	  to	  increased	  metabolic	  ROS	  
production.	  	  	  To	  determine	  if	  ROS	  production	  is	  regulated	  by	  the	  increase	  in	  glycolytic	  
metabolism,	  differentiated	  adipocytes	  were	  loaded	  with	  ROS	  sensitive	  dye	  (Fig.	  34a)	  and	  
subsequently	  analyzed	  for	  fluorescent	  intensity	  measurements.	  	  Indeed,	  differentiated	  
adipocytes	  demonstrated	  an	  increased	  amount	  of	  ROS	  accumulation	  compared	  to	  
undifferentiated	  ASCs	  as	  seen	  by	  image	  and	  even	  by	  fluorescence	  intensity	  
measurements	  (Fig.	  34b).	  	  This	  increase	  in	  ROS	  leads	  to	  an	  increased	  need	  for	  regulation	  




Figure	  34.	  ROS	  accumulation	  in	  differentiated	  adipocytes.	  	  ASCs	  were	  differentiated	  as	  
previously	  described	  and	  loaded	  with	  ROS	  sensitive	  dye	  as	  described	  in	  Methods.	  	  
Sample	  image	  of	  differentiated	  adipocyte	  loaded	  with	  dye	  (green)	  and	  counterstained	  
with	  Nile	  Red	  (red)	  and	  Hoechst	  33342	  (blue)	  (a).	  	  ROS	  dye	  accumulation	  analyzed	  by	  

























D.2	  PDK	  inhibition	  and	  ROS	  accumulation	  
It	  is	  possible	  that	  the	  PDK	  regulated	  increase	  in	  glycolytic	  phenotype	  is	  a	  method	  
the	  differentiated	  adipocytes	  employ	  to	  reduce	  metabolic	  ROS	  accumulation.	  	  To	  
determine	  if	  this	  is	  the	  case,	  differentiated	  adipocytes	  were	  loaded	  with	  ROS	  sensitive	  
dye	  and	  treated	  with	  PDK	  inhibitor	  (which	  has	  already	  demonstrated	  the	  ability	  to	  
inhibit	  the	  glycolytic	  phenotype)	  and	  subsequent	  intensity	  measurements	  were	  
performed.	  	  	  	  Treatment	  with	  varying	  concentrations	  of	  leelamine	  dose	  responsively	  
increased	  ROS	  accumulation	  in	  the	  cells	  both	  dose	  dependently	  and	  over	  time	  continued	  
accumulation	  for	  each	  of	  the	  donors	  tested	  (Fig.	  35).	  	  The	  data	  indicated	  that	  PDK	  
inhibition	  which	  we	  have	  already	  demonstrated	  decreases	  the	  glycolytic	  phenotype	  also	  
results	  in	  increased	  ROS	  accumulation	  supporting	  the	  hypothesis	  that	  the	  increase	  in	  
glycolysis	  resulting	  from	  limitation	  of	  oxidative	  metabolism	  is	  to	  keep	  ROS	  accumulation	  






Figure	  35.	  	  PDK	  inhibition	  results	  in	  increased	  ROS	  accumulation	  in	  differentiated	  
adipocytes.	  	  	  	  Differentiated	  adipocytes	  from	  three	  separate	  donors	  were	  loaded	  with	  
ROS	  sensitive	  dye	  as	  previously	  descried	  and	  then	  treated	  with	  DMSO	  (control),	  	  10	  uM,	  
or	  100	  uM	  Leelamine	  and	  subsequently	  analyzed	  for	  ROS	  dye	  after	  4	  hours	  of	  treatment.	  	  
Data	  from	  all	  three	  donors	  is	  combined.	  	  	  
	  
D.3	  Cytotoxicity	  and	  PDK	  inhibition	  
In	  cancer	  cells,	  the	  reduction	  of	  ROS	  accumulation	  achieved	  through	  aerobic	  















glycolytic	  phenotype	  that	  reduces	  ROS	  accumulation	  serves	  a	  cytoprotective	  role	  in	  
differentiated	  adipocytes,	  cytolethality	  experiments	  were	  performed.	  	  Indeed,	  PDK	  
inhibition	  resulted	  in	  an	  increase	  in	  LDH	  release	  into	  media	  (Fig.	  36a,b).	  	  LDH	  release	  
indicates	  a	  loss	  of	  membrane	  integrity	  and	  is	  a	  surrogate	  of	  cytolethality.	  	  The	  data	  
indicate	  that	  loss	  of	  the	  PDK	  regulated	  phenotype	  results	  in	  a	  loss	  of	  some	  





Figure	  36.	  	  PDK	  inhibition	  leads	  to	  cytotoxicity	  in	  differentiated	  adipocytes.	  
Differentiated	  adipocytes	  from	  three	  separate	  donors	  were	  treated	  with	  Leelamine	  at	  
control,	  10,	  50,	  and	  100	  uM	  for	  36	  hours.	  	  After	  treatment,	  	  media	  was	  collected	  and	  
analyzed	  for	  LDH	  release	  by	  fluorescence	  LDH	  assay.	  	  Data	  is	  shown	  from	  individual	  



























D.4	  PDK	  inhibited	  cytolethality	  is	  ROS	  mediated	  
PDK	  inhibition	  resulted	  in	  an	  increase	  in	  ROS	  accumulation	  of	  the	  cells.	  	  It	  also	  
lead	  led	  to	  increased	  cytolethality.	  	  To	  determine	  if	  these	  two	  were	  connected,	  
cytolethality	  experiments	  were	  performed	  with	  ROS	  scavengers.	  	  If	  the	  cytolethality	  was	  
due	  to	  increased	  accumulation	  of	  ROS	  in	  the	  differentiated	  adipocytes,	  treatment	  with	  
antioxidant	  should	  rescue	  the	  effect.	  	  When	  the	  differentiated	  adipocytes	  were	  treated	  
with	  both	  PDK	  inhibitor	  leelamine	  and	  antioxidant	  Tempol	  concurrently,	  LDH	  release	  
from	  the	  cells	  was	  decreased	  (Fig.	  37a,b).	  	  With	  rescue	  of	  cytolethality	  with	  antioxidant	  
treatment	  it	  can	  be	  inferred	  that	  some	  or	  all	  of	  the	  cytolethality	  from	  leelamine	  
treatement	  indeed	  was	  from	  ROS	  accumulation.	  	  This	  demonstrates	  that	  the	  PDK	  




Figure	  37.	  	  ROS	  scavenger	  treatement	  reduces	  PDK	  stimulated	  cytolethality	  in	  
differentiated	  adipocytes.	  	  Differentiated	  adipocytes	  from	  three	  donors	  were	  treated	  
with	  Leelamine	  at	  control,	  100	  uM	  Leelamine,	  and	  10	  uM	  Leelamine	  +	  10	  mM	  Tempol	  
for	  36	  hours.	  	  After	  treatment,	  	  media	  was	  collected	  and	  analyzed	  for	  LDH	  release	  by	  
fluorescence	  LDH	  assay.	  	  Data	  is	  shown	  from	  individual	  donors	  (a)	  and	  from	  all	  donors	  












































Many	  adipocyte	  studies	  are	  done	  using	  the	  well	  established	  3T3-­‐L1	  model	  of	  
adipogenesis.	  	  However,	  this	  model	  is	  not	  a	  human	  model,	  rather	  the	  3T3-­‐L1	  cells	  come	  
from	  mouse.	  	  Beyond	  this,	  3T3-­‐L1	  cells	  do	  not	  come	  from	  adipose	  depots	  or	  function	  in	  
vivo	  as	  mouse	  preadipocytes	  for	  which	  the	  physiologic	  role	  would	  be	  to	  differentiate	  
into	  adipocytes.	  	  Instead,	  3T3-­‐L1	  are	  a	  sub-­‐clone	  of	  the	  spontaneously	  immortalized	  3T3	  
line	  established	  after	  20-­‐30	  passages	  of	  mouse	  embryonic	  fibroblasts.	  	  With	  the	  goal	  of	  
this	  thesis	  research	  focusing	  on	  human	  adipocyte	  metabolism	  in	  a	  context	  where	  some	  
comparisons	  could	  be	  made	  to	  their	  precursor	  as	  a	  control,	  3T3-­‐L1	  are	  a	  poor	  choice.	  	  It	  
is	  much	  more	  relevant	  to	  use	  human	  cells	  that	  are	  the	  reservoir	  for	  formation	  of	  new	  
adipocytes.	  	  For	  this	  reason,	  we	  used	  the	  adipocyte	  precursors	  (adipose	  stem	  cells	  or	  
ASCs)	  isolated	  from	  human	  adipose	  tissue	  stromal	  vascular	  fraction.	  	  	  
Literature	  has	  demonstrated	  the	  isolation	  of	  these	  human	  adipocyte	  precursors	  
(ASCs)	  and	  subsequent	  differentiation	  into	  mature	  adipocytes.	  To	  perform	  our	  planned	  
experiments	  enabling	  the	  study	  of	  the	  glycolytic	  and	  oxidative	  phenotypes	  of	  
differentiated	  adipocytes	  as	  compared	  to	  their	  precursors,	  ASCs	  from	  multiple	  donors	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would	  need	  to	  be	  expanded	  and	  differentiated.	  	  Expansion	  of	  enough	  cells	  ex	  vivo	  for	  
planned	  experiments	  can	  lead	  to	  a	  loss	  of	  in	  vivo	  phenotype.	  	  Considering	  that	  planned	  
experiments	  depend	  on	  successful	  differentiation	  of	  ASCs	  from	  multiple	  donors	  it	  is	  
important	  that	  the	  extent	  and	  lineage	  of	  differentiation	  is	  explored	  and	  understood	  
using	  quantitative	  methods.	  	  	  	  
Populations	  used	  for	  differentiation	  studies	  are	  homogeneous	  
When	  setting	  up	  a	  differentiation	  model	  it	  is	  important	  that	  the	  starting	  source	  
of	  cells	  for	  differentiation	  are	  relatively	  homogeneous	  and	  devoid	  of	  contaminate	  cell	  
populations.	  	  This	  builds	  confidence	  in	  statements	  made	  concerning	  the	  phenotype	  of	  
the	  differentiated	  cells	  compared	  to	  the	  undifferentiated	  cells.	  	  The	  major	  cell	  types	  of	  
the	  SVF	  from	  adipose	  tissue	  that	  could	  be	  mixed	  in	  with	  ASCs	  are	  endothelial	  cells	  and	  
leukocytes	  as	  adipose	  tissue	  is	  highly	  vascularized	  and	  has	  demonstrated	  accumulation	  
of	  macrophage	  and	  other	  leukocytes.	  	  The	  data	  in	  section	  2.1.2	  clearly	  demonstrate	  our	  
starting	  material	  for	  adipogenic	  differentiation	  to	  be	  homogeneous	  and	  devoid	  of	  such	  
contaminant	  populations.	  	  To	  show	  this,	  after	  isolation	  and	  expansion,	  we	  performed	  
flow	  cytometry	  experiments	  showing	  no	  leukocytes	  (CD45+	  cells)	  or	  endothelial	  cells	  
(CD31+	  cells)	  mixed	  in	  with	  the	  ASCs.	  	  	  Similarly,	  we	  demonstrated	  the	  cells	  were	  also	  
homogeneously	  positive	  for	  an	  ASC	  marker	  (CD140b).	  	  The	  populations	  were	  
homogeneously	  positive	  for	  this	  marker	  and	  negative	  for	  the	  potential	  contaminants	  
from	  isolated	  and	  cultured	  stromal	  vascular	  fraction	  of	  adipose	  tissue.	  	  This	  was	  
expected.	  	  Endothelial	  cells	  should	  not	  attach	  very	  well	  (if	  at	  all)	  to	  the	  uncoated	  tissue	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culture	  treated	  plates	  we	  use	  for	  culture	  of	  the	  SVF.	  	  The	  leukocytes	  (primarily	  
macrophage)	  that	  could	  attach	  to	  the	  plastic	  do	  not	  generally	  maintain	  the	  ability	  to	  
proliferate.	  	  So	  the	  several	  rounds	  of	  expansion	  required	  to	  have	  enough	  cells	  for	  our	  
studies	  would	  be	  expected	  to	  result	  in	  dilution	  and	  essentially	  total	  loss	  of	  the	  leukocytic	  
population	  through	  trypsinization	  and	  splitting	  the	  cells	  several	  times	  with	  multiple	  
doublings	  between	  these	  steps.	  	  	  While	  a	  homogeneous	  population	  was	  expected	  for	  
these	  reasons,	  it	  was	  critical	  for	  us	  to	  perform	  these	  studies	  with	  our	  isolated/expanded	  
cells	  to	  make	  confident	  whole	  population	  measurements	  and	  assertions	  about	  
differentiated	  and	  undifferentiated	  cells.	  	  	  
Populations	  used	  for	  differentiation	  maintain	  in	  vivo	  bi-­‐potentiality	  
Differentiation	  of	  adipocyte	  precursors	  into	  mature	  adipocytes	  is	  best	  achieved	  
using	  high	  density	  seeding.	  	  With	  a	  large	  number	  of	  studies	  planned	  to	  assess	  adipogenic	  
differentiation	  lineage	  commitment	  and	  capacity,	  metabolic	  phenotype	  of	  differentiated	  
adipocytes	  and	  their	  precursors,	  transcript	  and	  protein	  expression	  studies,	  
pharmacologic	  pathway	  interrogation	  studies,	  ROS	  generation	  studies,	  and	  viability	  
studies	  all	  under	  multiple	  conditions,	  expansion	  of	  isolated	  SVF	  had	  to	  be	  performed.	  	  	  
With	  expansion,	  primary	  cells	  often	  lose	  their	  in	  vivo	  phenotype.	  	  	  In	  particular,	  
precursor	  and	  stem	  cells	  often	  lose	  their	  plasticity.	  	  
It	  is	  important	  to	  demonstrate	  this	  plasticity	  is	  maintained	  in	  differentiation	  
models.	  	  As	  with	  all	  cell	  based	  modeling,	  the	  ultimate	  goal	  is	  to	  make	  assertions	  about	  
physiology,	  that	  is,	  the	  model	  developed	  should	  mimic	  in	  vivo	  physiology	  as	  best	  as	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possible.	  	  For	  differentiation	  studies,	  it	  is	  therefore	  critical	  that	  the	  cells	  being	  used	  to	  
mimic	  physiologic	  differentiation	  demonstrate	  physiologic	  plasticity	  as	  best	  as	  possible	  
post	  isolation	  and	  expansion.	  	  ASCs	  have	  demonstrated	  a	  bi-­‐potential	  role	  in	  vivo	  
(discussed	  in	  the	  Introduction)	  that	  includes	  the	  formation	  of	  new	  adipocytes	  and	  
support	  of	  local	  vasculature.	  	  The	  first	  is	  a	  clear	  differentiation	  event	  from	  ASC	  into	  
adipocyte,	  the	  second	  potentially	  involves	  some	  differentiation	  into	  a	  more	  mature	  
vasculosupportive	  cell,	  though	  in	  vivo,	  the	  ASC	  may	  be	  performing	  this	  role	  even	  in	  an	  
undifferentiated	  state.	  	  	  The	  data	  in	  section	  2.1.3	  demonstrate	  maintenance	  of	  this	  
bipotentiality	  in	  vitro	  after	  expansion	  and	  are	  further	  discussed	  below.	  	  	  
When	  we	  placed	  the	  expanded	  ASCs	  under	  adipogenic	  conditions	  after	  
expansion,	  the	  isolated	  and	  expanded	  ASCs	  clearly	  demonstrated	  maintenance	  of	  
plasticity	  for	  differentiation	  down	  this	  lineage	  as	  seen	  by	  lipid	  accumulation	  and	  
morphologic	  changes.	  	  	  The	  undifferentiated	  ASCs	  also	  demonstrated	  the	  ability	  to	  
support	  vascular	  networks	  as	  demonstrated	  by	  cord	  formation	  of	  HUVECs	  when	  co-­‐
cultured	  with	  the	  ASCs.	  	  In	  co-­‐culture,	  the	  ASCs	  that	  were	  juxtaposed	  to	  the	  forming	  
cords	  and	  in	  immediate	  contact	  with	  the	  endothelium	  demonstrated	  enhanced	  
expression	  of	  SMA	  further	  indicating	  the	  vasculosupportive	  role	  of	  the	  ASCs	  was	  
maintained	  even	  after	  expansion.	  	  An	  increase	  in	  SMA	  was	  even	  observed	  in	  VEGF-­‐
treated	  populations.	  	  This	  further	  speaks	  to	  the	  concept	  that	  ASCs	  do	  have	  some	  
maturation	  into	  an	  even	  more	  vasculosupportive	  cell	  type	  when	  directly	  contacting	  
newly	  forming	  vessels	  or	  at	  the	  very	  least	  contacting	  naked	  endothelium.	  	  The	  ASCs	  lack	  
KDR	  (VEGF	  receptor)	  and	  therefore	  must	  have	  some	  cross-­‐talk	  with	  the	  endothelium	  to	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increase	  SMA	  expression	  in	  response	  to	  VEGF.	  	  Though	  not	  the	  focus	  of	  this	  particular	  
thesis,	  our	  lab	  has	  made	  and	  continues	  to	  make	  significant	  progress	  investigating	  this	  
angiogenic	  event,	  the	  role	  of	  ASCs	  in	  this	  process	  in	  vitro	  and	  in	  vivo,	  and	  how	  this	  can	  
potentially	  benefit	  cell	  therapy.	  	  It	  does	  however	  clearly	  demonstrate	  the	  maintenance	  
of	  vasculosupportive	  plasticity	  post	  expansion.	  	  These	  studies	  further	  build	  confidence	  in	  
the	  maintenance	  of	  normal	  physiologic	  phenotype	  with	  respect	  to	  differentiation	  
capacity	  of	  the	  populations	  we	  use	  to	  model	  adiopogenesis	  and	  therefore	  makes	  us	  
more	  confident	  in	  our	  adipogenic	  model	  with	  respect	  to	  maintenance	  of	  normal	  
physiology	  ex	  vivo.	  	  	  	  
Quantitative	  method	  development	  for	  adipogenesis	  
Differentiation	  and	  lineage	  tracing	  is	  often	  assessed	  at	  checkpoints	  using	  
markers	  that	  attempt	  to	  demonstrate	  cells	  are	  changing	  from	  some	  stem	  cell	  or	  
precursor	  into	  a	  different	  or	  more	  mature	  cell	  type.	  	  The	  cues	  (growth	  
factors/metabolites/ligands/etc)	  provided	  to	  direct	  cells	  down	  a	  specific	  differentiation	  
lineage	  attempt	  to	  focus	  the	  plasticity	  of	  the	  starting	  cells	  to	  progress	  a	  specific	  way,	  
however,	  it	  is	  possible	  that	  the	  cells	  will	  not	  follow	  this	  path.	  	  Therefore,	  when	  setting	  
up	  a	  differentiation	  model	  it	  is	  critical	  to	  demonstrate	  that	  differentiation	  is	  indeed	  
occurring	  and	  it	  is	  progressing	  down	  the	  appropriate/desired	  lineage.	  	  
	  	   For	  long	  term	  differentiations	  or	  for	  complex	  transdifferentiations,	  this	  very	  
often	  involves	  many	  steps	  and	  multiple	  checkpoints	  can	  be	  assessed.	  	  This	  is	  commonly	  
done	  with	  maturation	  of	  embryonic	  or	  induced	  pluripotent	  stem	  (IPS)	  cells	  as	  multiple	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steps	  of	  maturation	  often	  must	  be	  achieved	  systematically	  mimicking	  embryologic	  
and/or	  neonatal	  differentiation.	  	  For	  progenitor	  or	  precursor	  maturation	  this	  is	  often	  
much	  more	  simple	  as	  the	  final	  step	  of	  differentiation	  is	  occurring.	  	  This	  is	  the	  case	  for	  
adipogenic	  differentiation	  of	  human	  ASCs.	  	  The	  cells	  have	  already	  progressed	  from	  
embryonic	  differentiation	  through	  mesenchymal	  lineage	  commitment	  all	  the	  way	  to	  
formation	  of	  the	  adipocyte	  precursor	  in	  vivo.	  	  We	  believe	  this	  is	  a	  benefit	  of	  using	  
primary-­‐sourced	  precursors.	  	  Mimicking	  differentiation	  ex	  vivo	  will	  never	  perfectly	  
mimic	  differentiation	  in	  vivo	  as	  each	  step	  of	  differentiation	  introduces	  potential	  
derivation	  from	  normal	  cellular	  development.	  	  For	  this	  reason	  working	  with	  precursors	  
who	  have	  undergone	  most	  of	  their	  development/differentiation	  in	  vivo	  and	  only	  
requiring	  final	  steps	  of	  differentiation	  ex	  vivo	  is	  beneficial.	  	  Differentiation	  of	  ASCs	  into	  
adipocytes	  is	  a	  terminal	  step	  of	  differentiation	  that	  we	  perform	  ex	  vivo.	  	  While	  there	  are	  
not	  a	  large	  number	  of	  milestone	  checkpoints	  to	  achieve	  in	  this	  terminal	  differentiation,	  
the	  cells	  do	  demonstrate	  the	  ability	  to	  differentiate	  down	  alternative	  lineages	  other	  
than	  adipocytes	  (as	  mentioned	  in	  the	  Introduction)	  and	  therefore	  it	  is	  important	  that	  we	  
have	  a	  method	  of	  tracing	  differentiation	  into	  adipocytes.	  	  	  
For	  adipogenic	  differentiation,	  the	  most	  common	  method	  of	  demonstrating	  
successful	  differentiation	  is	  based	  upon	  lipid	  accumulation	  in	  the	  cells.	  	  The	  mature	  
adipocytes	  demonstrate	  a	  lipid	  laden	  morphology	  compared	  to	  their	  undifferentiated	  
precursors.	  	  Therefore,	  most	  models	  of	  differentiation	  identify	  this	  lipid	  accumulation	  by	  
staining	  lipids	  within	  the	  cell	  a	  red	  color	  using	  Oil	  Red	  O	  and	  subsequent	  microscopy.	  	  
This	  is	  however	  poorly	  quantitative	  if	  quantitation	  is	  applied	  to	  this	  at	  all.	  	  As	  we	  are	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using	  multiple	  donors	  to	  look	  at	  metabolic	  changes	  in	  mature	  adipocytes	  and	  we	  are	  
using	  their	  undifferentiated	  precursors	  as	  controls,	  it	  is	  important	  that	  we	  have	  a	  
quantitative	  method	  for	  assessing	  adipocyte	  differentiation	  across	  these	  donors	  to	  
account	  for	  potential	  variability	  in	  differentiation	  from	  donor	  to	  donor.	  	  Standard	  Oil-­‐
Red-­‐O	  staining	  is	  not	  quantitative	  enough	  for	  such	  an	  assessment.	  	  To	  do	  so	  we	  
developed	  our	  own	  quantitative	  method	  for	  assessing	  lipid	  accumulation	  in	  whole	  
populations	  of	  cells	  as	  they	  differentiated.	  	  	  
The	  method	  we	  developed	  is	  a	  quantitative	  imaging	  based	  approach	  whereby	  
lipids	  are	  stained	  with	  a	  lipophilic	  fluor	  with	  subsequent	  fluorescence	  intensity	  
determined	  using	  laser	  scanning	  cytometry	  to	  assess	  total	  lipid	  accumulation	  in	  the	  cells	  
specifically	  within	  the	  lipid	  droplets.	  	  Following	  this,	  lipid	  is	  extracted,	  and	  nuclei	  are	  
labeled	  and	  intensity	  assessed	  using	  a	  nuclear	  dye.	  	  Detailed	  methods	  development	  and	  
optimization	  for	  this	  is	  described	  in	  section	  2.1.4.	  	  Laser	  scanning	  cytometry	  enables	  
rapid	  image	  capture	  and	  analysis	  of	  whole	  populations	  as	  opposed	  to	  representative	  
individual	  scan	  areas	  commonly	  used	  by	  microscopy	  and	  standard	  automated	  imaging.	  	  
This	  allowed	  quantitation	  of	  lipid	  accumulation	  and	  normalization	  to	  nuclei	  for	  whole	  
population	  analysis	  as	  opposed	  to	  fractions	  of	  the	  population	  that	  could	  be	  obtained	  by	  
standard	  fluorescence	  imaging.	  	  It	  also	  enables	  segmentation	  and	  subsequent	  lipid	  
quantitation	  only	  from	  lipid	  droplets	  eliminating	  non-­‐specific	  fluorescence	  which	  can’t	  
be	  achieved	  with	  fluorescence	  plate	  readers	  attempting	  to	  make	  whole	  population	  
analysis.	  	  This	  method	  enabled	  fixation	  and	  analysis	  of	  samples	  throughout	  time	  course	  
of	  differentiation	  to	  assess	  donor	  to	  donor	  variability	  and	  the	  effects	  of	  changing	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protocol	  on	  progression	  through	  differentiation.	  	  This	  method	  can	  be	  employed	  in	  other	  
areas	  of	  biology	  to	  quantify	  lipid	  accumulation	  and	  can	  be	  altered	  to	  look	  at	  lipid	  
accumulation	  in	  other	  cell	  types.	  	  For	  example,	  lipid	  accumulation	  in	  hepatocytes	  can	  be	  
quantified	  using	  this	  technique	  to	  model	  steatosis.	  	  Similarly,	  monocytes	  turning	  into	  
foam	  cells	  are	  characterized	  by	  lipid	  accumulation	  in	  their	  cytosol.	  	  Development	  of	  this	  
technique	  has	  been	  applied	  to	  such	  studies	  as	  well.	  	  	  
Assessing	  subcutaneous	  and	  omental	  adipogenic	  differentiation	  	  
Employing	  the	  quantitative	  method	  in	  our	  studies	  of	  adipogenic	  differentiation	  
demonstrated	  a	  clear	  and	  complete	  differentiation	  of	  adipocytes	  using	  lipid	  
accumulation	  as	  a	  surrogate.	  	  Time-­‐course	  data	  in	  section	  2.1.5	  demonstrate	  a	  plateau	  
of	  differentiation	  using	  this	  approach	  around	  day	  9	  and	  extending	  through	  days	  12-­‐15	  of	  
differentiation.	  	  The	  cells	  from	  this	  point	  on	  continue	  to	  coalesce	  lipid	  droplets	  however,	  
cells	  appear	  to	  be	  lost	  past	  this	  point.	  	  We	  believe	  the	  cells	  become	  buoyant,	  lift	  off	  the	  
surface	  of	  the	  culture	  plate	  or	  stretch	  and	  strain	  the	  membrane	  too	  far	  in	  2-­‐dimensional	  
culture	  and	  die	  (observations	  under	  microscope).	  	  	  When	  comparing	  differentiation	  of	  
omental	  preadipocytes	  to	  subcutaneous	  preadipocytes,	  we	  saw	  reduced	  levels	  of	  
differentiation	  in	  the	  omental	  cells.	  	  This	  was	  expected	  based	  on	  previous	  work	  in	  the	  
field,	  however,	  limited	  numbers	  of	  omental	  versus	  subcutaneous	  preadipocyte	  
differentiation	  studies	  have	  been	  performed	  in	  the	  past	  (none	  with	  a	  quantitative	  
method	  such	  as	  ours)	  and	  thus	  we	  were	  compelled	  to	  use	  our	  quantitative	  approach	  to	  
study	  this	  with	  a	  single	  donor,	  matched-­‐pair	  of	  omental	  and	  subcutaneous	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preadipcoytes	  from	  the	  same	  donor.	  	  Using	  matched	  donor	  adipocyte	  precursors	  from	  
separate	  adipose	  depots	  reduce	  any	  genetic	  or	  epigenetic	  variation	  that	  could	  
contribute	  to	  similar	  studies	  comparing	  omental	  and	  subcutaneous	  ASC	  differentiation	  
when	  the	  separate	  donors	  are	  used	  to	  source	  cells	  from	  the	  different	  depots.	  	  	  
As	  expected,	  PPAR	  gamma	  agonist	  improved	  	  differentiation	  in	  subcutaneous	  
and	  omental	  adipogenic	  differentiation.	  	  However,	  even	  with	  PPAR	  gamma	  agonism	  
throughout	  the	  time	  course	  of	  differentiation,	  sufficient	  differentiation	  was	  not	  
achieved	  using	  omental	  derived	  ASCs	  to	  model	  adipogenesis	  and	  make	  assertions	  about	  
metabolic	  phenotype	  in	  differentiated	  adipocytes	  vs	  undifferentiated	  precursors	  when	  
whole	  populations	  measurements	  	  would	  be	  made.	  	  The	  differnetiated	  population	  was	  
too	  heterogeneous	  of	  a	  mix	  of	  undifferentiated	  and	  differentiated	  adipocytes.	  	  As	  a	  
result,	  our	  continued	  studies	  primarily	  focused	  on	  differentiation	  of	  subcutaneous	  
adipocytes.	  	  	  
Donor	  to	  donor	  variability	  	  
In	  sections	  2.1.6-­‐7	  we	  demonstrate	  consistency	  across	  multiple	  donors.	  	  As	  
previously	  discussed,	  to	  better	  assess	  human	  adipocyte	  metabolic	  phenotype,	  we	  used	  
primary	  cells	  from	  human	  adipose	  tissue	  (ASCs).	  	  Single	  donor/single	  source	  studies	  
provide	  valuable	  information;	  however,	  there	  is	  the	  potential	  that	  observations	  made	  
from	  such	  studies	  are	  due	  to	  some	  unforeseen	  genetic	  or	  epigenetic	  predisposition	  of	  
the	  particular	  donor	  being	  used.	  	  Pooled	  lots	  of	  undifferentiated	  cells	  can	  be	  used,	  
however,	  often	  one	  particular	  component	  donor	  of	  the	  pooled	  lot	  may	  predominate	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over	  the	  others	  depending	  on	  the	  function	  being	  tested	  or	  phenotype/genotype	  being	  
studied.	  	  To	  account	  for	  this,	  we	  tested	  multiple	  donors	  for	  critical	  measurements	  being	  
made	  throughout	  this	  thesis.	  	  	  
In	  assessing	  variability	  in	  differentiation	  capacity,	  our	  data	  demonstrated	  a	  very	  
consistent	  differentiation	  across	  8	  separate	  donors	  (plus	  superlot)	  when	  tested	  for	  lipid	  
accumulation	  over	  time.	  	  Indeed,	  the	  majority	  of	  lipid	  accumulation/morphologic	  
change	  was	  observed	  in	  nearly	  all	  donors	  tested	  between	  days	  3-­‐6	  of	  differentiation.	  	  	  
As	  this	  method	  was	  newly	  developed	  in	  our	  lab,	  alternatively	  we	  confirmed	  these	  results	  
measuring	  intracellular	  glycerol	  accumulation	  as	  a	  more	  standard	  surrogate	  of	  
triglyceride	  accumulation,	  the	  preferred	  method	  of	  lipid	  storage	  in	  adipocytes.	  	  This	  
helped	  confirm	  the	  more	  high	  content	  novel	  approach	  we	  developed	  and	  further	  
demonstrated	  through	  a	  separate	  measure	  that	  the	  cells	  were	  differentiating	  with	  little	  
variability	  across	  donors.	  	  	  
While	  lipid	  accumulation	  is	  often	  used	  to	  demonstrate	  adipogenic	  differentiation	  
we	  demonstrated	  a	  second	  non-­‐lipid	  measurement	  to	  show	  adipogenic	  lineage	  
differentiation.	  	  This	  was	  achieved	  by	  measuring	  adipokine	  production	  from	  the	  cells	  
throughout	  differentiation.	  	  	  This	  is	  important	  as	  multiple	  cell	  types	  can	  lipid	  load	  
(hepatocytes,	  macrophage,	  skeletal	  muscle,	  etc)	  but	  will	  not	  produce	  these	  adipokines.	  	  
Our	  data	  demonstrated	  a	  minimal	  variation	  amongst	  multiple	  donors	  tested	  for	  
production	  of	  leptin	  and	  adiponectin.	  	  Production	  of	  both	  adipokines	  increased	  
throughout	  differentiation.	  	  Interestingly,	  adiponectin	  precedes	  leptin	  accumulation	  in	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the	  media.	  	  Adiponectin	  is	  perhaps	  more	  sensitive	  to	  the	  PPAR	  gamma	  agonist	  that	  is	  
added	  during	  the	  early	  stages	  of	  differentiation.	  	  	  This	  is	  consistent	  with	  literature	  which	  
identifies	  adiponectin	  as	  a	  biomarker	  of	  PPAR	  gamma	  agonist	  treatment	  in	  vivo.	  	  This	  
data	  (adipokine	  production)	  further	  validates	  appropriate	  adipogenic	  differentiation	  and	  
demonstrates	  (as	  does	  lipid	  accumulation	  analysis)	  that	  donor	  to	  donor	  variability	  is	  
very	  low	  in	  our	  model.	  	  And	  it	  makes	  us	  confident	  that	  metabolic	  measurements	  from	  
multiple	  human	  donors	  would	  not	  be	  skewed	  by	  variability	  in	  differentiation	  between	  
donors.	  	  	  	  
Lactate	  production	  and	  aerobic	  glycolysis	  in	  differentiated	  adipocytes	  
As	  discussed	  in	  the	  Introduction	  it	  has	  been	  shown	  that	  adipose	  tissue	  generates	  
lactate.	  	  But	  how	  this	  lactate	  is	  generated,	  and	  what	  is	  regulating	  its	  production	  is	  still	  
unknown.	  	  Using	  our	  differentiation	  model,	  we	  were	  able	  to	  demonstrate	  similar	  lactate	  
production	  from	  the	  mature/differentiated	  adipocytes	  and	  not	  in	  their	  precursors.	  	  This	  
identified	  the	  precursors	  as	  an	  ideal	  control	  to	  study	  regulation	  of	  this	  lactate	  
production	  in	  the	  differentiated	  adipocytes.	  	  	  	  	  
Initial	  metabolism	  studies	  on	  multiple	  depots	  shown	  in	  section	  3.2	  identified	  
increased	  glucose	  consumption	  coupled	  with	  an	  increase	  in	  lactate	  production.	  	  This	  was	  
our	  initial	  data	  suggesting	  there	  may	  be	  a	  Warburg-­‐like	  effect	  occurring	  in	  differentiated	  
adipocytes	  compared	  to	  their	  precursors.	  	  As	  previously	  introduced,	  the	  Warburg	  effect	  
or	  aerobic	  glycolysis	  is	  an	  increase	  in	  lactate	  production	  in	  normal	  oxygen	  tensions.	  	  The	  
cells	  in	  our	  human	  adipocyte	  model	  are	  maintained	  in	  atmospheric	  oxygen	  throughout	  
130	  
	  
differentiation	  (21%).	  	  The	  increase	  in	  glucose	  consumption	  was	  expected	  as	  the	  cells	  
increase	  expression	  of	  Glut1	  during	  adipogenic	  differentiation,	  Glut4	  is	  also	  increased,	  
however	  it	  is	  primarily	  only	  active	  with	  insulin	  stimulation	  and	  resulting	  insertion	  into	  
the	  membrane.	  	  The	  increase	  in	  glucose	  consumption	  helps	  the	  differentiating	  cells	  
store	  fatty	  acids	  by	  providing	  substrate	  for	  glycerol	  production	  (glyceroneogenesis	  as	  
described	  in	  introduction).	  	  It	  also	  is	  part	  of	  the	  new	  energy	  storage/glucose	  clearance	  
role	  the	  differentiated	  cells	  have	  compared	  to	  their	  undifferentiated	  precursors.	  	  The	  
elevation	  of	  lactate	  production	  indicates	  that	  some	  portion	  of	  the	  glucose	  was	  being	  
metabolized	  through	  lactic	  acid	  fermentation.	  	  Again,	  at	  normal	  oxygen	  tensions,	  this	  
was	  indicative	  of	  aerobic	  glycolysis	  occurring	  in	  these	  cells.	  	  It	  also	  points	  towards	  the	  
production	  of	  lactate	  in	  adipose	  tissue	  may	  not	  be	  due	  to	  hypoxia	  in	  the	  tissue	  or	  
intermittent	  hypoxia	  in	  the	  tissue	  but	  because	  of	  the	  metabolic	  phenotype	  of	  the	  
adipocytes.	  	  Further	  studies	  in	  human	  would	  need	  to	  be	  performed	  to	  better	  correlate	  
realtime	  lactate	  production	  with	  oxygen	  tension	  measurements	  in	  the	  tissue.	  	  	  
While	  the	  same	  trends	  (increased	  glucose	  consumption	  coupled	  with	  increased	  
lactate	  production)	  were	  seen	  in	  both	  the	  subcutaneous	  and	  omental	  differentiation	  
models,	  we	  are	  more	  confident	  in	  statements	  about	  the	  subcutaneous	  model	  as	  
previously	  discussed	  due	  to	  the	  heterogeneity	  of	  the	  omental	  cells	  by	  the	  end	  of	  
differentiation.	  	  Seeing	  the	  similar	  trend	  indicates	  however,	  that	  the	  cells	  that	  are	  
differentiating	  in	  that	  particular	  model	  are	  most	  likely	  demonstrating	  similar	  metabolic	  
changes	  and	  may	  indicate	  similar	  progression	  into	  aerobic	  glycolysis	  in	  both	  omental	  
and	  subcutatneous	  adipocytes.	  	  However,	  further	  studies	  for	  this	  thesis	  research	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focused	  on	  subcutaneous	  adiopocytes	  where	  differentiation	  produced	  a	  more	  
homogeneous	  population	  of	  differentiated	  adipocytes	  as	  previously	  discussed.	  	  	  
The	  preliminary	  data	  were	  confirmed	  when	  tested	  on	  multiple	  donors.	  	  Lactate	  
production	  increased	  an	  average	  of	  5.2	  fold	  across	  donors	  in	  differentiated	  adipocytes	  
compared	  to	  their	  undifferentiated	  precursors	  (with	  each	  donor	  significantly	  increasing	  
lactate	  production	  in	  differentiated	  state).	  	  Again,	  this	  increase	  in	  glycolytic	  metabolism	  
was	  observed	  in	  normoxic	  conditions	  demonstrating	  aerobic	  glycolysis	  for	  all	  donors	  
tested.	  	  	  This	  metabolic	  phenotype	  was	  held	  up	  under	  all	  conditions	  tested	  (increased	  
glucose	  concentration	  and	  stimulation	  with	  insulin).	  	  Differentiated	  cells	  even	  
demonstrated	  an	  increase	  in	  lactate	  production	  when	  glucose	  concentration	  was	  
increased.	  	  We	  believe	  this	  indicates	  that	  increased	  glucose	  was	  being	  glycolytically	  
metabolized.	  	  This	  demonstrates	  that	  the	  model	  was	  behaving	  similar	  to	  clinical	  studies	  
of	  human	  adipose	  tissue	  mentioned	  in	  introduction	  where	  adipose	  lactate	  production	  
increased	  after	  feeding	  and	  may	  suggest	  excess	  glucose	  beyond	  some	  concentration	  
may	  be	  preferentially	  metabolized	  glycolytically	  (discussed	  further	  later).	  	  	  
Taken	  together,	  the	  lactate	  data	  indicate	  that	  in	  all	  donors	  tested	  a	  Warburg-­‐like	  
effect	  was	  occurring	  in	  the	  differentiated	  adipocytes	  compared	  to	  their	  precursors	  
characterized	  by	  increased	  lactate	  production	  at	  normoxic	  conditions.	  	  This	  also	  
confirmed	  the	  differentiated	  adipocytes	  were	  metabolically	  similar	  to	  what	  has	  been	  
observed	  in	  clinical	  studies	  of	  human	  adipose	  tissue	  where	  lactate	  production	  occurs	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and	  suggests	  that	  this	  production	  of	  lactate	  is	  potentially	  part	  of	  normal	  adipocyte	  
metabolism.	  
Oxidative	  metabolism	  and	  aerobic	  glycolysis	  in	  differentiated	  adipocytes	  	  
To	  better	  understand	  metabolic	  changes	  and	  characterize	  aerobic	  glycolysis,	  we	  
performed	  oxidative	  metabolism	  measurements	  (data	  in	  section	  2.2.4).	  	  Oxygen	  
consumption	  rate	  (OCR)	  measurements	  were	  taken	  as	  a	  surrogate	  of	  oxidative	  activity	  in	  
the	  cells.	  	  Oxygen	  consumed	  is	  primarily	  being	  used	  in	  the	  electron	  transport	  chain	  and	  
therefore	  its	  rate	  of	  consumption	  is	  directly	  related	  to	  oxidative	  metabolism.	  	  This	  was	  
confirmed	  by	  inhibition	  of	  site	  1	  of	  electron	  transport	  with	  rotenone	  and	  a	  resulting	  
decrease	  of	  OCR	  to	  near	  non-­‐existent	  levels.	  	  Comparing	  differentiated	  to	  
undifferentiated	  adipocytes	  demonstrated	  only	  a	  very	  small	  increase	  in	  oxidative	  
metabolism	  in	  the	  differentiated	  cells.	  	  	  
This	  small	  increase	  in	  oxidative	  metabolism	  is	  interesting	  as	  we	  saw	  large	  
increases	  in	  lactate	  production	  (glycolytic	  metabolism).	  	  Such	  data	  further	  confirms	  the	  
existence	  of	  an	  aerobic	  glycolysis	  phenotype	  in	  the	  differentiated	  cells	  compared	  to	  
their	  precursors.	  	  This	  data	  is	  similar	  to	  what	  Otto	  Warburg	  initially	  found	  in	  tumor	  
models.	  	  Cells	  displaying	  the	  Warburg	  effect	  do	  not	  demonstrate	  decreased	  oxidative	  
metabolism,	  rather	  they	  demonstrate	  increased	  lactate	  metabolism,	  in	  effect	  increasing	  
the	  amount	  of	  ATP	  generated	  from	  glycolytic	  processes	  compared	  to	  oxidative	  
processes	  even	  though	  measurements	  are	  being	  made	  in	  normoxic	  conditions.	  	  Our	  data	  
certainly	  supported	  this	  when	  theoretical	  ATP	  yields	  were	  calculated	  from	  glycolytic	  and	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oxidative	  measurements	  (Section	  2.2.6).	  	  These	  demonstrated	  that	  with	  differentiation,	  
overall	  ATP	  production	  increases.	  	  Both	  oxidative	  and	  glycolytic	  metabolism	  show	  an	  
increase	  in	  ATP	  production,	  however,	  as	  a	  percentage	  of	  contribution	  to	  total	  
theoretical	  ATP	  production,	  glycolytic	  metabolism	  increases	  whereas	  oxidative	  
metabolism	  decreases.	  	  Again,	  these	  calculations	  clearly	  demonstrate	  existence	  of	  the	  
Warburg	  effect	  or	  an	  aerobic	  glycolysis	  phenotype	  in	  the	  differentiated	  adipocytes.	  	  	  
It	  is	  also	  important	  to	  note	  that	  there	  were	  no	  increases	  in	  oxidative	  metabolism	  
in	  the	  same	  glucose	  and	  insulin	  conditions	  previously	  discussed	  for	  lactate	  
measurements.	  	  That	  is,	  increasing	  glucose	  did	  not	  result	  in	  increased	  OCR.	  	  This	  is	  
particularly	  interesting	  as	  lactate	  production	  did	  increase	  with	  glucose	  concentration	  in	  
the	  differentiated	  adipocytes.	  	  This	  is	  perhaps	  indicating	  that	  there	  is	  some	  threshold	  
level	  of	  glucose	  flux	  and	  metabolism	  above	  which	  excess	  glucose	  is	  increasingly	  
glycolytically	  metabolized	  though	  further	  studies	  with	  more	  glucose	  concentrations	  for	  
lactate	  production	  and	  OCR	  measurements	  would	  need	  to	  be	  performed	  to	  confirm	  this.	  	  	  	  
Oxidation	  in	  mitochondria	  is	  not	  rate	  limiting.	  
Using	  mitochondrial	  toxins	  we	  were	  able	  to	  measure	  maximum	  and	  minimum	  
OCRs	  with	  respect	  to	  mitochondrial	  metabolism.	  	  By	  doing	  so,	  we	  were	  able	  to	  
determine	  total	  oxidative	  capacity	  (TOC)	  and	  fraction	  of	  oxidative	  capacity	  or	  a	  measure	  
of	  how	  much	  of	  the	  oxidative	  the	  capacity	  the	  cells	  were	  using.	  	  These	  calculations	  are	  
described	  in	  results.	  	  Briefly,	  minimum	  oxygen	  consumption	  was	  determined	  by	  
treatment	  with	  rotenone	  which	  inhibits	  site	  one	  of	  electron	  transport,	  inhibiting	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oxidation	  in	  the	  mitochondria;	  maximal	  oxygen	  consumption	  was	  determined	  by	  
allowing	  proton	  movement	  across	  mitochondrial	  membrane	  using	  the	  proton	  ionophore	  
DNP	  resulting	  in	  maximal	  oxidation	  in	  an	  attempt	  by	  the	  mitochondria	  to	  restore	  the	  
proton	  motive	  force.	  	  Interestingly,	  though	  there	  was	  only	  a	  modest	  increase	  in	  basal	  
oxidative	  metabolism	  in	  the	  differentiated	  cells	  compared	  to	  their	  precursors,	  their	  TOC	  
increased	  robustly	  (section	  2.2.4).	  	  As	  a	  result,	  even	  though	  there	  was	  a	  small	  increase	  in	  
basal	  oxidative	  rate,	  as	  a	  function	  of	  what	  the	  cells	  were	  capable	  of	  the	  fraction	  of	  
oxidative	  capacity	  decreased	  with	  differentiation.	  	  In	  other	  words,	  the	  ability	  to	  perform	  
oxidative	  metabolism	  increases	  considerably	  with	  adipogenic	  differentiation;	  however,	  
the	  increase	  in	  oxidative	  capacity	  far	  exceeds	  that	  actual	  amount	  of	  oxidation	  occurring.	  	  
As	  we	  demonstrated	  in	  section	  2.2.5,	  performing	  similar	  oxidative	  measurements	  in	  
differentiated	  human	  myotubes	  compared	  to	  their	  undifferentiated	  precursor	  
myoblasts	  as	  a	  model	  of	  myogenesis	  does	  not	  demonstrate	  the	  large	  increase	  in	  
oxidative	  capacity	  that	  accompanies	  adipogenic	  differentiation.	  	  This	  indicates	  that	  the	  
observed	  changes	  in	  oxidative	  capacity	  and	  percentage	  of	  that	  capacity	  being	  used	  in	  
the	  adipocytes	  is	  not	  some	  event	  common	  to	  differentiation	  models	  in	  vitro.	  
Measuring	  oxidative	  capacity	  and	  especially	  observing	  DNP	  stimulated	  maximal	  
OCR	  was	  important	  to	  demonstrate	  that	  increases	  in	  lactate	  production	  were	  not	  due	  to	  
saturation	  of	  oxidative	  processes	  thereby	  causing	  a	  build-­‐up	  of	  pyruvate	  enhancing	  
lactate	  dehydrogenase	  action.	  	  In	  other	  words,	  this	  data	  indicates	  that	  the	  cells	  are	  
capable	  of	  oxidizing	  more	  or	  their	  pyruvate,	  they	  are	  instead	  performing	  lactatic	  acid	  
fermentation,	  not	  simply	  because	  they	  are	  “forced”	  to	  do	  so	  by	  limited	  oxidative	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capacity.	  	  This	  points	  towards	  the	  concept	  that	  the	  cells	  are	  purposefully	  increasing	  their	  
glycolytic	  metabolism	  via	  a	  controlled	  mechanism	  in	  the	  differentiated	  adipocytes	  and	  
not	  in	  the	  undifferentiated	  cells	  (where	  aerobic	  glycolysis	  is	  not	  observed).	  	  	  
PDK	  regulation	  of	  aerobic	  glycolysis	  in	  differentiated	  adipocytes	  
With	  the	  increase	  in	  glycolytic	  metabolism	  observed	  in	  differentiated	  adipocytes	  
and	  not	  in	  their	  undifferentiated	  precursor	  state,	  we	  were	  able	  to	  test	  for	  changes	  in	  
expression	  of	  candidate	  regulators	  of	  glycolytic	  vs	  oxidative	  metabolism.	  	  The	  PDKs,	  as	  
already	  introduced,	  are	  an	  interesting	  class	  of	  these	  regulators.	  	  	  They	  are	  targeted	  in	  
tumor	  cells	  to	  inhibit	  aerobic	  glycolysis	  and	  have	  demonstrated	  a	  role	  in	  regulating	  
glyceroneogeneis	  in	  adipocytes	  so	  there	  is	  precedence	  that	  these	  are	  expressed	  in	  
adipocytes	  and	  are	  potentially	  involved	  in	  regulation	  of	  aerobic	  glycolysis	  in	  our	  model.	  	  
Data	  in	  section	  2.3.1	  demonstrated	  increased	  expression	  of	  PDK1	  (and	  to	  a	  lesser	  extent	  
PDK4)	  in	  the	  differentiated	  cells	  compared	  to	  undifferentiated	  precursors	  indicating	  
correlation	  of	  increased	  expression	  where	  aerobic	  glycolysis	  is	  occurring.	  	  Indeed,	  PDK	  
activity	  would	  induce	  a	  build-­‐up	  of	  pyruvate	  by	  diminishing	  its	  conversion	  to	  acetyl-­‐CoA	  
by	  PDH	  slowing	  down	  PDC	  activity	  by	  phosphorylation.	  	  The	  increase	  in	  expression	  of	  
PDKs	  in	  the	  differentiated	  state	  point	  to	  the	  concept	  that	  differentiated	  adipocytes	  are	  
programmed	  to	  run	  a	  more	  glycolytic	  metabolism	  in	  their	  differentiated	  state.	  	  More	  
simply	  put,	  the	  data	  suggest	  that	  part	  of	  adipocyte	  maturation	  is	  an	  alteration	  of	  
metabolic	  phenotype	  that	  enhances	  the	  ability	  to	  perform	  aerobic	  glycolysis.	  	  This	  
agrees	  with	  our	  previous	  data	  indicating	  the	  cells	  are	  not	  forced	  to	  increase	  lactic	  acid	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fermentation	  due	  to	  a	  rate-­‐limit	  in	  oxidative	  metabolism.	  	  Increased	  expression	  of	  PDKs	  
correlated	  with	  increased	  aerobic	  glycolysis	  in	  differentiated	  adipocytes	  further	  
supports	  that	  the	  ability	  to	  demonstrate	  the	  Warburg	  effect	  is	  associated	  with	  normal	  
adipocyte	  maturation.	  	  	  	  	  
Pharmacologic	  inhibition	  of	  PDKs	  in	  our	  model	  better	  demonstrated	  their	  role	  in	  
regulating	  the	  increase	  in	  glycolytic	  metabolism.	  	  Inhibition	  with	  Leelamine	  has	  
demonstrated	  PDK	  inhibition	  in	  adipocyte	  models	  to	  study	  regulation	  of	  
glyceroneogenesis.	  	  Leelamine	  inhibition	  of	  PDK	  in	  our	  model	  demonstrated	  dose-­‐
dependent	  reduction	  in	  lactate	  production.	  	  In	  effect,	  inhibiting	  PDK	  resulted	  in	  loss	  of	  
the	  glycolytic	  phenotype	  (as	  characterized	  by	  decreased	  lactate	  production	  with	  
Leelamine).	  	  This	  data	  further	  supported	  the	  role	  of	  PDKs	  in	  regulation	  of	  aerobic	  
glycolysis	  in	  differentiated	  adipocytes.	  	  	  
The	  correlation	  of	  increased	  PDK	  expression	  with	  the	  aerobic	  glycolysis	  
phenotype	  and	  loss	  of	  that	  phenotype	  with	  pharmacologic	  inhibition	  of	  PDK	  
demonstrate	  a	  regulatory	  role	  for	  PDK	  	  controlling	  the	  observed	  aerobic	  glycolysis	  in	  
differentiated	  adipocytes.	  	  While	  adipose	  tissue	  has	  demonstrated	  lactate	  production	  in	  
clinical	  studies,	  how	  this	  is	  regulated	  at	  a	  cellular	  level	  has	  been	  poorly	  understood,	  we	  
believe	  our	  data	  experimentally	  demonstrates	  such	  a	  regulatory	  role	  for	  PDKs	  in	  





Aerobic	  glycolysis	  and	  ROS	  production	  in	  differentiated	  adipocytes	  
As	  previously	  mentioned	  in	  the	  Introduction,	  ROS	  regulation	  in	  adipocytes	  is	  
critical	  for	  maintaining	  normal	  adipocyte	  function	  and	  viability.	  	  As	  previously	  discussed	  
in	  introduction,	  tumor	  cells	  are	  susceptible	  to	  ROS	  damage	  and	  demonstrate	  aerobic	  
glycolysis	  to	  reduce	  oxidative	  stress.	  	  The	  proposed	  mechanism	  is	  that	  by	  switching	  
some	  glucose	  metabolism	  to	  lactic	  acid	  fermentation,	  the	  amount	  of	  oxidative	  
metabolism	  that	  would	  be	  occurring	  is	  reduced,	  and	  with	  this	  reduction	  in	  oxidative	  
metabolism,	  mitochondrial	  ROS	  production	  is	  decreased.	  	  Our	  data	  indicates	  a	  similar	  
purpose	  for	  aerobic	  glycolysis	  in	  differentiated	  adipocytes	  to	  reduce	  or	  regulate	  ROS	  
production.	  	  
We	  have	  already	  demonstrated	  the	  existence	  of	  a	  metabolic	  phenotype	  in	  
differentiated	  adipocytes	  characterized	  by	  an	  increase	  in	  aerobic	  glycolysis.	  	  This	  can	  be	  
inhibited	  when	  treated	  with	  PDK	  inhibitor	  Leelamine.	  	  When	  we	  treat	  with	  Leelamine	  
and	  inhibit	  aerobic	  glycolysis	  in	  the	  differentiated	  adipocytes,	  we	  also	  observe	  an	  
increase	  in	  ROS	  accumulation	  in	  the	  cells.	  	  Similar	  effects	  are	  observed	  in	  tumor	  cells	  
when	  inhibiting	  PDKs.	  	  The	  elevated	  ROS	  production	  is	  most	  likely	  mitochondrial	  sourced	  
as	  PDK	  inhibition	  allows	  more	  pyruvate	  conversion	  to	  acetyl-­‐CoA	  and	  subsequent	  
oxidative	  phosphorylation.	  Our	  data	  point	  towards	  the	  potential	  role	  of	  a	  PDK	  regulated	  
Warburg	  effect	  in	  differentiated	  adipocytes	  	  to	  help	  control	  ROS	  production.	  	  To	  be	  
more	  definitive	  with	  this,	  oxidative	  metabolism	  studies	  need	  to	  be	  performed	  
demonstrating	  increased	  OCR	  with	  PDK	  inhibition	  need	  to	  be	  performed	  that	  correlate	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with	  the	  increase	  in	  ROS	  production	  and	  reduction	  of	  lactate	  production.	  	  	  However,	  
from	  our	  data,	  it	  is	  clear	  that	  inhibition	  of	  the	  aerobic	  glycolysis	  increases	  ROS	  
production	  in	  differentiated	  adipocytes.	  	  	  
Aerbobic	  glycolysis	  and	  cell	  health	  in	  differentiated	  adipocytes	  
As	  mentioned	  previously,	  tumor	  cells	  perform	  aerobic	  glycolysis	  as	  a	  
cytoprotective	  mechanism	  against	  the	  detrimental	  effects	  of	  ROS.	  	  Indeed,	  PDK	  
inhibition	  resulting	  in	  loss	  of	  the	  Warburg	  effect	  in	  tumor	  cells	  has	  demonstrated	  
cytotoxicity.	  	  Our	  data	  demonstrates	  that	  a	  similar	  role	  is	  most	  likely	  occurring	  in	  
differentiated	  adipocytes.	  	  When	  we	  inhibit	  aerobic	  glycolysis	  in	  the	  differentiated	  
adipocytes,	  we	  see	  an	  increase	  in	  ROS	  accumulation	  over	  the	  first	  several	  hours;	  
however,	  the	  cells	  appear	  healthy	  and	  viable	  morphologically.	  	  When	  we	  inhibit	  aerobic	  
glycolysis	  for	  a	  longer	  term	  treatment	  (36	  hours),	  the	  cells	  begin	  to	  “look”	  unhealthy.	  	  
Measurements	  indicate	  that	  inhibiting	  Warburg	  for	  these	  longer	  periods	  of	  time	  results	  
in	  LDH	  accumulation	  in	  the	  media.	  	  This	  enzyme	  accumulation	  in	  the	  media	  may	  be	  used	  
as	  a	  surrogate	  for	  cytotoxicity,	  as	  LDH	  is	  not	  released	  from	  cells	  unless	  the	  membrane	  
has	  been	  severely	  compromised.	  	  It	  is	  often	  used	  as	  this	  can	  indicate	  general	  cell	  death,	  
whether	  by	  apoptosis	  or	  necrosis	  and	  all	  means	  of	  cell	  death	  in	  vitro	  eventually	  result	  in	  
membrane	  compromise	  or	  rupture.	  	  	  
While	  it	  appears	  that	  there	  is	  a	  loss	  in	  cell	  viability	  that	  coincides	  with	  PDK	  
inhibition,	  loss	  of	  aerobic	  glycolysis,	  and	  an	  increase	  in	  ROS,	  our	  data	  also	  demonstrates	  
that	  the	  decrease	  in	  cell	  health	  is	  indeed	  ROS	  mediated.	  	  Treating	  the	  cells	  with	  the	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reactive	  oxygen	  scavenger	  (Tempol)	  and	  a	  PDK	  inhibitor	  at	  the	  same	  time	  results	  in	  a	  
rescue	  of	  cell	  viability.	  	  The	  Tempol	  alleviates	  reactive	  oxygen	  stress,	  scavenging	  ROS	  as	  
it	  is	  produced	  in	  response	  to	  inhibition	  of	  aerobic	  glycolysis	  with	  Leelamine.	  	  This	  
indicates	  the	  cell	  death	  is	  most	  likely	  due	  to	  build-­‐up	  of	  ROS	  and	  resulting	  oxidative	  
stress	  in	  the	  cells.	  	  	  
Taken	  together,	  our	  data	  indicate	  that	  inhibition	  of	  PDK	  results	  in	  a	  loss	  of	  the	  
Warburg	  effect,	  an	  increase	  in	  ROS	  that	  results	  in	  loss	  of	  cell	  viability	  in	  differentiated	  
adipocytes.	  	  This	  indicates	  a	  specific	  role	  for	  Warburg	  effect	  that	  is	  cytoprotective	  in	  
adipocytes	  against	  ROS	  damage.	  	  This	  also	  mimics	  what	  is	  observed	  in	  tumor	  cells.	  	  As	  
differentiated	  adipocytes	  handle	  large	  amounts	  of	  high	  energy	  molecules	  (fatty	  acids,	  
glucose,	  etc)	  that	  readily	  contribute	  to	  ROS	  production	  when	  metabolized,	  	  it	  is	  
beneficial	  for	  them	  to	  have	  a	  greater	  ability	  to	  regulate	  ROS	  production	  than	  their	  
precursors	  which	  do	  not	  accumulate	  lipids	  and	  demonstrate	  a	  much	  lower	  flux	  of	  
glucose.	  
Overall	  conclusions	  
Our	  data	  indicate	  that	  differentiated	  human	  adipocytes	  indeed	  produce	  lactate	  
as	  part	  of	  aerobic	  glycolysis	  or	  the	  Warburg	  effect.	  	  This	  metabolic	  phenotype	  is	  not	  
observed	  in	  the	  adipocyte	  precursors.	  	  This	  phenotype	  appears	  to	  be	  regulated	  by	  PDKs	  
1	  and	  4,	  for	  which	  the	  expression	  increases	  in	  correlation	  with	  the	  observed	  aerobic	  
glycolysis	  and	  inhibition	  results	  in	  loss	  of	  the	  metabolic	  phenotype.	  	  This	  PDK-­‐regulated	  
Warburg	  effect	  is	  cytoprotective	  via	  regulation	  of	  ROS	  production	  in	  the	  differentiated	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adipocyte.	  	  Thus,	  taken	  together,	  the	  data	  support	  our	  hypothesis	  that	  differentiated	  
adipocytes	  demonstrate	  a	  PDK	  regulated	  Warburg-­‐like	  effect	  protecting	  against	  
detrimental	  elevation	  of	  ROS.	  
Impact	  
This	  body	  of	  work	  provides	  a	  better	  metabolic	  understanding	  of	  how	  and	  why	  
human	  adipose	  tissue	  lactate	  production	  is	  regulated	  as	  observed	  in	  clinical	  studies	  at	  a	  
cellular	  level.	  	  While	  it	  indicates	  another	  role	  for	  the	  PDKs	  in	  adipose	  tissue	  in	  addition	  
to	  its	  role	  regulating	  glyceroneogenesis,	  it	  also	  further	  bolsters	  PDKs	  as	  a	  target	  for	  
cancer	  therapy	  as	  a	  similar	  cytoprotective	  role	  for	  aerobic	  glycolysis	  is	  observed	  in	  
tumor	  cells.	  	  The	  development	  of	  a	  high	  content	  quantitative	  approach	  to	  measure	  lipid	  
accumulation	  has	  generated	  a	  better	  understanding	  of	  donor	  to	  donor	  variability	  in	  
human	  adipogenic	  differentiation	  and	  the	  comparative	  effects	  of	  PPAR	  gamma	  agonism	  
on	  modeling	  adipogenesis	  from	  multiple	  adipose	  depots.	  	  The	  quantitative	  method	  has	  
also	  been	  applied	  to	  other	  cell	  based	  physiologic	  and	  pathophysiologic	  models.	  	  	  	  
Future	  work	  
Further	  work	  elucidating	  the	  regulation	  of	  PDK	  expression	  and	  thus	  control	  of	  
aerobic	  glycolysis	  in	  differentiated	  adipocytes	  would	  be	  interesting.	  	  Data	  we	  have	  
generated	  but	  not	  shown	  in	  this	  thesis	  indicates	  HIF1α	  may	  indeed	  be	  playing	  a	  role	  in	  
this.	  	  Protein	  expression	  studies	  focused	  on	  nuclear	  localization	  would	  be	  interesting	  to	  
determine	  if	  HIF1α	  accumulation	  in	  the	  nucleus	  occurs	  with	  adipogenic	  differentiation	  
and	  correlates	  with	  the	  aerobic	  glycolytic	  phenotype	  and	  elevated	  PDK	  expression.	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Chromatin	  immunoprecipitation	  studies	  with	  HIF1α	  would	  also	  be	  interesting	  to	  
determine	  whether	  PDK	  is	  indeed	  under	  HIF	  control	  	  in	  the	  differentiated	  adipocytes.	  	  	  
As	  differentiated	  adipocytes	  demonstrate	  a	  metabolic	  phenotype	  somewhat	  
similar	  to	  tumor	  cells,	  it	  would	  be	  interesting	  to	  further	  investigate	  other	  similarities	  
between	  newly	  formed	  adipocytes	  and	  tumor	  cells.	  	  We	  have	  generated	  data	  
demonstrating	  potential	  differential	  paracrine	  regulation	  of	  local	  vasculature	  between	  
differentiated	  adipocytes	  and	  their	  precursors	  that	  appears	  somewhat	  similar	  to	  tumor	  
regulation	  of	  angiogenesis	  based	  on	  preliminary	  studies.	  	  It	  would	  be	  interesting	  to	  look	  
more	  deeply	  for	  similarities	  between	  adipocytes	  in	  expanding	  fat	  mass	  and	  cancer	  cells	  
in	  the	  expanding	  tumor.	  	  It	  would	  also	  be	  particularly	  interesting	  to	  determine	  if	  
similarities	  exist	  between	  these	  cells	  with	  their	  ability	  to	  switch	  between	  oxidative	  
metabolism,	  glycolytic	  metabolism,	  and	  aerobic	  glycolysis	  depending	  on	  the	  hypoxic	  
state	  of	  the	  tumor	  and	  the	  hypoxic	  or	  intermittent	  hypoxic	  state	  observed	  in	  adipose	  
tissue.	  	  	  







ASC	  isolation	  and	  maintenance.	  	  Adipose	  stem	  cells	  (ASCs)	  were	  isolated	  using	  
methods	  previously	  described	  by	  our	  lab	  [254].	  	  Briefly,	  lipoaspirate	  (or	  minced	  
subcutaneous	  adipose	  tissue	  from	  abdminoplasty)	  is	  subjected	  to	  collagenase	  digest	  and	  
incubated	  with	  shaking.	  	  Post	  digest,	  red	  blood	  cell	  lysis	  is	  performed	  on	  samples	  with	  
increased	  red	  blood	  cell	  content.	  	  Adipocytes	  are	  then	  separated	  form	  stromal	  vascular	  
fraction	  (SVF)	  by	  centrifugation.	  	  The	  pelleted	  SVF	  is	  resuspended	  and	  passed	  through	  a	  
cell	  strainer	  to	  remove	  excess/undigested	  tissue.	  	  The	  strained	  SVF	  is	  washed	  several	  
times	  and	  plated	  on	  standard	  tissue	  culture	  plastic	  in	  EGM2-­‐MV	  (Lonza)	  media.	  	  Cells	  are	  
expanded	  and	  through	  subculture	  when	  density	  reaches	  approximately	  75%.	  	  For	  our	  
research,	  cells	  underwent	  two	  passages	  and	  were	  used	  for	  indicated	  studies	  at	  passage	  
three.	  	  All	  metabolic,	  ROS,	  and	  LDH	  measurements	  were	  obtained	  with	  cells	  
cultured/treated	  in	  DMEM	  (without	  glucose/sodium	  pyruvate/L-­‐glutamine)	  
supplemented	  with	  100	  mg/dL	  glucose	  unless	  otherwise	  noted.	  	  	  
Adipogenic	  Differentiation.	  	  For	  differentiation,	  ASCs	  were	  seeded	  down	  into	  
appropriate	  plates/dishes	  per	  experiment	  at	  150000	  cells/cm2	  in	  EGM2-­‐MV(day	  -­‐2).	  	  
The	  following	  day	  media	  was	  switched	  to	  DMEM/F12	  containing	  10%	  FBS	  (day	  -­‐1).	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Following	  24	  hour	  incubation,	  media	  was	  switched	  to	  DM-­‐2	  media	  from	  Zen-­‐Bio	  (day	  0)	  
and	  replaced	  after	  three	  days	  (day	  3).	  	  Following	  an	  additional	  three	  days	  media	  was	  
switched	  to	  AM-­‐1	  media	  from	  Zen-­‐Bio	  (day	  6)	  and	  changed	  every	  three	  days	  until	  use	  in	  
experiments.	  	  Cells	  obtain	  an	  adipocyte	  phenotype	  beginning	  around	  day	  9	  and	  can	  be	  
used	  through	  day	  15	  though	  most	  of	  our	  measurements	  were	  made	  on	  day	  12.	  	  
Omental	  and	  Subcutaneous	  ASC	  matched	  pair	  culture	  and	  differentiation.	  	  
Omental	  and	  subcutaneous	  ASCs	  from	  the	  same	  donor	  were	  purchased	  from	  Zen	  Bio	  as	  
a	  matched	  pair	  of	  ASCs	  from	  different	  depots.	  	  Cells	  were	  cultured	  and	  expanded	  as	  
described	  for	  isolated	  ASCs.	  	  Differentiation	  was	  performed	  as	  described	  for	  isolated	  
ASCs	  with	  the	  addition	  of	  PPARγ	  agonist	  (from	  Zen	  Bio)	  applied	  for	  different	  durations	  of	  
differentiation	  as	  noted	  in	  results.	  	  	  
Myoblast	  culture	  and	  differentiation	  into	  myotubes.	  	  Human	  primary	  myoblasts	  
were	  purchased	  from	  Invitrogen	  and	  cultured/expanded	  per	  vendor	  recommendation	  in	  
vendor	  supplied	  media.	  	  For	  differentiation	  or	  maturation	  into	  myotubes,	  cells	  were	  
harvested	  and	  seeded	  at	  high	  density	  (150000	  cells/cm2).	  	  The	  following	  day,	  confluent	  
cells	  were	  switched	  to	  DMEM	  with	  5%	  horse	  serum.	  	  Media	  was	  changed	  every	  other	  
day	  for	  two	  weeks	  for	  myogenic	  differentiation.	  	  	  
Flow	  cytometry.	  	  Cells	  were	  harvested,	  pellets	  were	  resuspended	  in	  4%	  
formaldehyde	  underwent	  fixation	  for	  10	  minutes	  at	  37°C.	  	  Following	  fixation	  cells	  were	  
blocked	  in	  1%	  BSA.	  	  Fixed/blocked	  cell	  suspension	  (1	  million	  cells	  in	  100	  ul)	  was	  
transferred	  to	  tubes	  with	  appropriate	  FITC	  conjugated	  antibodies	  and	  left	  to	  incubate	  at	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room	  temperature	  in	  the	  dark	  for	  1	  hour.	  	  Cells	  were	  pelleted	  and	  resuspended	  in	  1	  ml	  
PBS	  and	  analzed	  for	  fluorescence	  intensity	  by	  flow	  cytometry.	  	  	  
Human	  live	  adipose	  tissue	  imaging.	  	  Subcutaneous	  human	  adipose	  tissue	  was	  
obtained	  from	  abdominoplasty.	  	  Tissue	  was	  cut	  into	  small	  pieces	  and	  stained	  for	  20	  
minutes	  in	  a	  mixture	  of	  isolectin	  IB4	  conjugated	  to	  AlexaFlour	  488,	  Nile	  Red,	  and	  
Hoechst	  33342.	  	  After	  incubation,	  tissue	  pieces	  were	  washed	  and	  immersed	  in	  PBS	  
under	  a	  coverslip.	  	  Imaging	  was	  performed	  using	  an	  Olympus	  FV1000-­‐MPE	  
Confocal/Multiphoton	  Microscope	  with	  dipping	  objectives	  to	  obtain	  confocal-­‐planar	  and	  
three-­‐dimensional	  images	  of	  the	  tissue.	  
ROS	  measurement.	  	  	  CMH2DCFDA	  ROS	  dye	  was	  loaded	  into	  cells.	  	  Briefly,	  cells	  
were	  incubated	  in	  media	  containing	  CMH2DCFDA	  (10	  µM)	  for	  20	  minutes	  at	  37°C.	  	  After	  
loading,	  the	  cells	  were	  incubated	  with	  Nile	  Red	  (10nM)	  and	  Hoechst	  33342	  (1:1000)	  for	  
20	  minutes	  at	  37°C	  and	  treated	  with	  compounds	  where	  appropriate.	  	  Live	  stained	  cells	  
were	  then	  imaged	  using	  Leica	  DMI2000	  widefield	  fluorescence	  microscope.	  	  	  ROS	  
accumulation	  was	  measured	  as	  increased	  CMH2DCFDA	  fluorescence	  using	  a	  plate	  based	  
fluorometer	  at	  multiple	  time	  points	  post	  compound	  addition.	  	  	  	  
Lipid	  accumulation.	  	  Cells	  were	  fixed	  using	  the	  Prefer	  fixative	  method	  previously	  
described.	  	  Fixed	  cells	  were	  then	  stained	  with	  Nile	  Red	  (PBS	  with	  10	  nM	  Nile	  Red)	  for	  30	  
minutes	  at	  room	  temperature	  and	  then	  analyzed	  by	  laser	  scanning	  cytometry	  (Acumen	  
Explorer)	  for	  total	  lipid	  fluorescence	  intensity.	  	  Subsequently,	  samples	  were	  
permeabilized	  with	  0.5%	  Triton	  X-­‐100	  in	  PBS	  for	  10	  minutes	  at	  room	  temperature,	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washed,	  and	  then	  incubated	  with	  methanol	  and	  gentle	  shaking	  followed	  by	  wash	  with	  
PBS	  for	  several	  iterations	  of	  20	  minutes	  to	  reduce	  lipid	  in	  the	  samples.	  	  After	  lipid	  
extraction	  and	  washing,	  samples	  were	  incubated	  with	  Hoechst	  33342	  (1:1000	  in	  PBS	  
with	  RNAse	  I)	  for	  1	  hour	  at	  room	  temperature.	  	  Following	  Hoechst	  stain,	  samples	  were	  
analyzed	  again	  by	  laser	  scanning	  cytometry	  (Acumen	  Explorer)	  to	  obtain	  total	  nuclear	  
fluorescence.	  	  Total	  lipid	  fluorescence	  was	  normalized	  to	  total	  nuclear	  fluorescence	  for	  
each	  population.	  	  To	  image	  lipid	  accumulation,	  undifferentiated	  and	  differentiated	  ASCs	  
were	  fixed	  by	  removal	  of	  media	  and	  addition	  of	  Prefer	  Fixative	  for	  20	  minutes	  at	  room	  
temperature	  followed	  by	  two	  PBS	  washes.	  	  After	  washing,	  cells	  were	  incubated	  with	  Nile	  
Red/Syto16	  solution	  (10	  nM	  Nile	  Red,	  1:1000	  Syto16	  in	  PBS)	  for	  30	  minutes	  at	  room	  
temperature.	  	  Cells	  were	  washed	  twice	  and	  imaged	  using	  LEICA	  DMI2002	  widefield	  
fluorescence	  microscope.	  
Imaging	  myogenic	  differentiation.	  	  Cells	  were	  fixed	  at	  various	  time	  points	  
throughout	  differentiation	  by	  removal	  of	  media	  and	  addition	  of	  Prefer	  Fixative	  for	  20	  
minutes	  at	  room	  temperature	  followed	  by	  two	  PBS	  washes.	  	  Fixed	  cells	  were	  then	  
permeabilized	  with	  0.1%	  Triton	  X-­‐100	  for	  10	  minutes	  at	  room	  temperature,	  followed	  by	  
two	  PBS	  washes	  and	  1	  hour	  of	  blocking	  with	  1.0%	  BSA	  at	  room	  temperature.	  	  Primary	  
antibodies	  were	  added	  and	  incubated	  at	  4°C	  overnight.	  	  The	  following	  day,	  cells	  were	  
washed	  twice	  with	  PBS	  followed	  by	  incubation	  with	  a	  mixture	  of	  appropriate	  secondary	  
antibodies	  conjugated	  to	  R-­‐phycoerytherin,	  Phalloidin-­‐Alexa	  Fluor	  488,	  and	  Hoechst	  
33342	  for	  2	  hours	  at	  room	  temperature.	  	  Stained	  cells	  were	  washed	  twice	  and	  imaged	  
using	  LEICA	  DMI2002	  widefield	  fluorescence	  microscope.	  	  Flurescence	  intensity	  
146	  
	  
measurements	  were	  obtained	  laser	  scanning	  cytometry	  as	  previously	  described	  for	  lipid	  
accumulation	  measurements.	  	  	  
Adipokine	  secretion.	  	  Conditioned	  media	  was	  collected	  at	  multiple	  time	  points	  
throughout	  differentiation	  at	  72	  hour	  intervals.	  	  Conditioned	  media	  was	  subsequently	  
analyzed	  by	  bead	  based	  ELISA	  (Millipore)	  to	  determine	  concentration	  of	  adipokines	  
leptin	  and	  adiponectin	  per	  vendor	  protocol.	  	  	  
Lactate	  measurement.	  	  Both	  undifferentiated	  and	  differentiated	  cells	  were	  
incubated	  in	  reduced	  serum	  (0.1%)	  	  DMEM	  for	  4	  hours	  and	  then	  incubated	  in	  DMEM	  
(without	  glucose/sodium	  pyruvate/L-­‐glutamine)	  supplemented	  with	  100,	  500,	  or	  1000	  
mg/dL	  glucose	  for	  12	  hours	  with	  or	  without	  the	  addition	  of	  100	  nM	  insulin.	  	  Conditioned	  
media	  was	  then	  collected	  and	  analyzed	  for	  lactate	  content	  using	  a	  colorimetric	  assay	  
(Sigma	  Aldrich).	  	  Conditioned	  media	  samples	  were	  compared	  against	  non-­‐conditioned	  
control	  media	  and	  Δ	  lactate	  was	  determined.	  	  Values	  were	  normalized	  by	  time	  to	  
achieve	  a	  lactate	  production	  rate	  per	  whole	  population	  (well).	  	  	  	  	  
Oxygen	  consumption	  measurements.	  	  Both	  undifferentiated	  and	  differentiated	  
cells	  were	  incubated	  in	  reduced	  serum	  (0.1%)	  	  DMEM	  for	  4	  hours	  and	  then	  incubated	  in	  
DMEM	  (without	  glucose/sodium	  pyruvate/L-­‐glutamine)	  supplemented	  with	  100,	  500,	  or	  
1000	  mg/dL	  glucose	  with	  or	  without	  the	  addition	  of	  100	  nM	  insulin	  and	  subsequently	  
analyzed	  using	  Seahorse	  XF	  flux	  analyzer	  to	  determine	  oxygen	  consumption	  rates	  (OCR).	  	  
For	  undifferentiated	  and	  differentiated	  myotubes,	  similar	  measurements	  were	  made	  
but	  only	  in	  DMEM	  (without	  glucose/sodium	  pyruvate/L-­‐glutamine)	  supplemented	  with	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100	  mg/dL	  glucose.	  	  Mitochondrial	  toxins	  were	  injected	  at	  various	  times	  during	  OCR	  
measurements	  as	  described	  in	  results	  to	  characterize	  mitochondrial	  oxidative	  capacity.	  
Transcript	  analysis.	  	  Unidfferentiated	  and	  differentiated	  adipocytes	  were	  
harvested	  for	  transcript	  analysis	  with	  Trizol.	  	  RNA	  concentrations	  were	  measured	  with	  
Qubit®	  Fluorometer	  (invitrogen).	  Reverse	  transcription	  of	  200ng	  RNA	  to	  total	  cDNA	  for	  
each	  sample	  was	  carried	  out	  using	  TaqMan®Reverse	  Transcription	  Reagents	  (Applied	  
Biosystems).	  Quantitative	  PCR	  (qPCR)	  was	  performed	  with	  gene-­‐specific	  primers	  
(Applied	  Biosystems)	  and	  TaqMan	  Universal	  PCR	  Master	  Mix	  (Applied	  Biosystems),	  using	  
the	  Applied	  Biosystems	  HT7900	  PCR	  system.	  
Western	  blotting.	  	  Undifferentiated	  and	  differentiated	  adipocytes	  were	  
harvested	  for	  western	  blotting	  using	  1X	  RIPA	  buffer	  with	  protease	  and	  phosphatase	  
inhibitor	  cocktails.	  	  Lysed	  samples	  were	  flash	  frozen	  using	  liquid	  nitrogen.	  	  Samples	  were	  
thawed	  and	  all	  subsequent	  steps	  were	  performed	  on	  ice.	  	  Samples	  were	  centrifuged	  5	  
minutes.	  	  After	  centrifugation,	  lipid	  layer	  is	  discarded	  (top	  layer)	  and	  samples	  sit	  on	  ice	  
for	  20	  minutes	  followed	  by	  centrifugation	  and	  removal	  of	  lipid	  layer.	  	  This	  is	  repeated	  
until	  samples	  are	  clear.	  	  Protein	  was	  determined	  using	  BCA	  assay.	  	  20	  ug	  of	  protein	  was	  
separated	  by	  electrophoresis	  in	  4-­‐20%	  tris	  glycine	  gels	  (in	  reduced	  conditions)	  then	  
transferred	  to	  PVDV	  using	  iBlot	  quick	  transfer	  (invitrogen).	  	  Membranes	  were	  blocked	  
with	  LiCor	  blocking	  buffer	  for	  1	  hour.	  	  Membranse	  were	  then	  incubated	  in	  blocking	  
solution	  containing	  primary	  antibodies	  overnight	  at	  4°C.	  	  Membranes	  were	  washed	  5	  
times	  for	  20	  minutes	  in	  PBST	  (tween)	  and	  then	  incubated	  in	  blocking	  buffer	  with	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appropriate	  secondary	  LiCor	  antibodies	  (IR	  dye-­‐conjugated).	  	  Membranes	  were	  again	  
washed	  5	  times	  for	  20	  minutes	  in	  PBST	  and	  finally	  in	  PBS	  w/o	  calcium	  and	  magnesium.	  	  
Blots	  were	  imaged	  in	  LiCor	  Odyssey.	  	  	  	  Band	  intensities	  were	  determined	  using	  LiCor	  
analysis	  software	  and	  compared	  against	  actin	  bands.	  	  	  
Cell	  viability.	  	  Cell	  viability	  was	  measured	  using	  fluorescence	  CytoTox-­‐One	  LDH	  
release	  assay	  (Promega).	  	  	  Differentiated	  adipocytes	  were	  incubated	  in	  various	  
treatments	  as	  noted	  in	  Results.	  	  After	  36	  hour	  incubation	  at	  37°C,	  media	  was	  collected.	  	  
Media	  was	  then	  analyzed	  for	  LDH	  accumulation	  per	  vendor	  protocol.	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Research	  Experience	   	  
Cell	  Culture:	  	  Primary	  isolation	  and	  culture	  of	  multiple	  
cell	  types	  (human/rodent	  adipocytes	  and	  adipose	  
stromal	  vascular	  cells,	  human/rodent	  skeletal	  muscle	  
myoblasts,	  human/rodent/simian	  hepatocytes,	  
human/rodent	  PBMCs,	  rodent	  cortical	  neurons,	  
human/rodent/simian	  spleenocytes);	  human	  Induced	  
Pluripotent	  Cell	  (IPS)	  and	  differentiated	  human	  IPS	  cell	  
models	  (parent	  lines,	  hepatocytes,	  cortical	  neurons,	  
skeletal	  muscle	  cells,	  cardiomyocytes,	  differentiated	  
intestinal	  organoid	  culture);	  cell	  lines	  (HepG2,	  Hep3b,	  
H42E,	  SKnMC,	  CHO,	  HEK293,	  L6,	  C2C12,	  C3H10T.5,	  
3T3L1,	  NHDF,	  HuVEC,	  HMVEC)	  
Preparation	  and	  analysis	  of	  Protein:	  
SDS-­‐PAGE,	  Western	  blot	  analysis,	  whole-­‐cell	  
immunofluorescence,	  immunoprecipitation,	  
fluorescent,confocal	  microscopy,	  and	  laser	  scanning	  
cytometry	  in	  cultured	  cells	  and	  intact	  tissue,	  subcellular	  
fractionation	  
Preparation	  and	  analysis	  of	  DNA	  and	  RNA:	  
PCR,	  RT-­‐PCR,	  qRT-­‐PCR,	  sequencing,	  agarose	  and	  
acrylamide	  gel	  electrophoresis,	  plasmid	  isolation,	  
restriction	  digest,	  ligation,	  vector	  construction,	  isolation	  
of	  genomic	  DNA	  from	  various	  tissues	  
Modeling	  Human/Rodent	  Cellular	  
Differentiation:Hepatic,	  cardiac,	  adipocyte,	  skeletal	  
muscle,	  neural	  
	  
